Surgical treatments compared with early structured physiotherapy in secondary care for adults with primary frozen shoulder: the UK FROST three-arm RCT by Brealey, Stephen et al.
Article
Surgical treatments compared with early 
structured physiotherapy in secondary care for 
adults with primary frozen shoulder: the UK 
FROST three-arm RCT
Brealey, Stephen, Northgraves, Matthew, Kottam, Lucksy, Keding, 
Ada, Corbacho, Belen, Goodchild, Lorna, Srikesavan, Cynthia, Rex, 
Saleema, Charalambous, Charalambos P., Hanchard, Nigel, 
Armstrong, Alison, Brooksbank, Andrew, Carr, Andrew, Cooper, 
Cushla, Dias, Joseph, Donnelly, Iona, Hewitt, Catherine, Lamb, 
Sarah E, McDaid, Catriona, Richardson, Gerry, Rodgers, Sara, 
Sharp, Emma, Spencer, Sally, Torgerson, David, Toye, Francine and 
Rangan, Amar
Available at http://clok.uclan.ac.uk/36082/
Brealey, Stephen, Northgraves, Matthew, Kottam, Lucksy, Keding, Ada, Corbacho, Belen,  
Goodchild, Lorna, Srikesavan, Cynthia, Rex, Saleema, Charalambous, Charalambos P. 
et al (2020) Surgical treatments compared with early structured physiotherapy in 
secondary care for adults with primary frozen shoulder: the UK FROST three-arm RCT. 
Health Technology Assessment, 24 (71). pp. 1-162. ISSN 1366-5278  
It is advisable to refer to the publisher’s version if you intend to cite from the work.
http://dx.doi.org/10.3310/hta24710
For more information about UCLan’s research in this area go to 
http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.
For information about Research generally at UCLan please go to 
http://www.uclan.ac.uk/research/ 
All outputs in CLoK are protected by Intellectual Property Rights law, including
Copyright law.  Copyright, IPR and Moral Rights for the works on this site are retained 
by the individual authors and/or other copyright owners. Terms and conditions for use 
of this material are defined in the http://clok.uclan.ac.uk/policies/
CLoK
Central Lancashire online Knowledge
www.clok.uclan.ac.uk
CLoK
Central Lancashire online Knowledge
www.clok.uclan.ac.uk
Journals Library
DOI 10.3310/hta24710
Surgical treatments compared with early 
structured physiotherapy in secondary 
care for adults with primary frozen 
shoulder: the UK FROST three-arm RCT 
Stephen Brealey, Matthew Northgraves, Lucksy Kottam, Ada Keding, Belen Corbacho, 
Lorna Goodchild, Cynthia Srikesavan, Saleema Rex, Charalambos P Charalambous,  
Nigel Hanchard, Alison Armstrong, Andrew Brooksbank, Andrew Carr, Cushla Cooper, 
Joseph Dias, Iona Donnelly, Catherine Hewitt, Sarah E Lamb, Catriona McDaid,  
Gerry Richardson, Sara Rodgers, Emma Sharp, Sally Spencer, David Torgerson,  
Francine Toye and Amar Rangan
Health Technology Assessment
Volume 24 • Issue 71 • December 2020
ISSN 1366-5278

Surgical treatments compared with early
structured physiotherapy in secondary care
for adults with primary frozen shoulder:
the UK FROST three-arm RCT
Stephen Brealey ,1 Matthew Northgraves ,1
Lucksy Kottam ,2 Ada Keding ,1 Belen Corbacho ,1
Lorna Goodchild ,3 Cynthia Srikesavan ,4 Saleema Rex ,1
Charalambos P Charalambous ,5,6 Nigel Hanchard ,7
Alison Armstrong ,8 Andrew Brooksbank ,9
Andrew Carr ,4 Cushla Cooper ,4 Joseph Dias ,8
Iona Donnelly ,9 Catherine Hewitt ,1 Sarah E Lamb ,4
Catriona McDaid ,1 Gerry Richardson ,10 Sara Rodgers ,1
Emma Sharp ,9 Sally Spencer ,11 David Torgerson ,1
Francine Toye 12 and Amar Rangan 1,2,4*
1York Trials Unit, Department of Health Sciences, University of York, York, UK
2The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust,
Middlesbrough, UK
3The Physiotherapy Practice, South Shields, UK
4Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
Botnar Research Centre, University of Oxford, Oxford, UK
5Department of Orthopaedics, Blackpool Victoria Hospital, Blackpool, UK
6School of Medicine, University of Central Lancashire, Preston, UK
7School of Health & Life Sciences, Teesside University, Middlesbrough, UK
8University Hospitals of Leicester NHS Trust, Leicester, UK
9Glasgow Royal Infirmary, Glasgow, UK
10Centre for Health Economics, University of York, York, UK
11Postgraduate Medical Institute, Edge Hill University, Ormskirk, UK
12Physiotherapy Research Unit, Oxford University Hospitals NHS Foundation Trust,
Oxford, UK
*Corresponding author
Declared competing interests of authors: Lucksy Kottam reports grants from the National Institute
for Health Research (NIHR) Health Technology Assessment (HTA) programme for other work during
the conduct of this study. South Tees Hospitals NHS Foundation Trust receives an educational grant
to the Department of Trauma and Orthopaedic Surgery from DePuy Synthes (Warsaw, IN, USA; part
of the Johnson & Johnson Medical Devices group). It also receives payment from DePuy Synthes for
Lucksy Kottam as a study co-ordinator for the GLOBAL ICON Stemless Shoulder System Post Market

Clinical Follow Up Study: CT 1401. These payments are outside and unrelated to the submitted work.
Catherine Hewitt is a member of the NIHR HTA Commissioning Board. Catriona McDaid receives
funding from the British Orthopaedic Association (2014 to present). She is a member of the NIHR
HTA and Efficacy and Mechanism Evaluation Editorial Board (2017 to present). Sarah E Lamb reports
membership of the following boards: HTA Additional Capacity Funding Board 2012–15, HTA Clinical
Trials Board 2010–15, HTA End of Life Care and Add on Studies Board 2015, HTA Funding Boards
Policy Group (formerly Clinical Studies Group) 2010–15, HTA Maternal, Neonatal and Child Health
Methods Group 2013–15, HTA Post-board funding teleconference 2010–15, HTA Primary Care
Themed Call Board 2013–14, HTA Prioritisation Group 2010–15 and the NIHR Clinical Trials Unit
Standing Advisory Committee 2012–16. Amar Rangan reports other grants from the NIHR HTA
programme, Orthopaedic Research UK (London, UK) and Horizon 2020 during the conduct of the
study. South Tees Hospitals NHS Foundation Trust receives an educational grant to the department
from DePuy Synthes. The institution also receives payment from DePuy Synthes for Amar Rangan as
the co-ordinating investigator for the GLOBAL ICON Stemless Shoulder System Post Market Clinical
Follow Up Study: CT 1401. These are outside and unrelated to the submitted work. Joseph Dias
reports grants from NIHR during the conduct of the study, outside the submitted work.
Published December 2020
DOI: 10.3310/hta24710
This report should be referenced as follows:
Brealey S, Northgraves M, Kottam L, Keding A, Corbacho B, Goodchild L, et al. Surgical treatments
compared with early structured physiotherapy in secondary care for adults with primary frozen
shoulder: the UK FROST three-arm RCT. Health Technol Assess 2020;24(71).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA/HTA TAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 3.370
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics
Science Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE)
(www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be
purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme,
and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis
methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can
be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate
any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that
have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote
health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include
any intervention used in the treatment, prevention or diagnosis of disease.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform
National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for
National Screening Committee (NSC) policy decisions.
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 13/26/01. The
contractual start date was in October 2014. The draft report began editorial review in October 2019 and was accepted for
publication in June 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for
writing up their work. This report has been published following a shortened production process and, therefore, did not undergo
the usual number of proof stages and opportunities for correction. The HTA editors and publisher have tried to ensure the
accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document.
However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions
expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR,
NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this
publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect
those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Brealey et al. under the terms of a commissioning
contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of
private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation,
Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library
Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK
NIHR Journals Library Editors
Professor John Powell Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals.
Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of 
Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK 
Professor Andrée Le May
Professor Matthias Beck
Dr Tessa Crilly
Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK
Dr Peter Davidson
Ms Tara Lamont
Dr Catriona McDaid
Professor William McGuire
Professor Geoffrey Meads Emeritus Professor of Wellbeing Research, University of Winchester, UK 
Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK
Professor James Raftery
Dr Rob Riemsma
Professor Helen Roberts
Professor Jonathan Ross
Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK
Professor Jim Thornton
Professor Martin Underwood
Please visit the website for a list of editors: 
Editorial contact:  
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Surgical treatments compared with early structured
physiotherapy in secondary care for adults with primary
frozen shoulder: the UK FROST three-arm RCT
Stephen Brealey ,1 Matthew Northgraves ,1 Lucksy Kottam ,2
Ada Keding ,1 Belen Corbacho ,1 Lorna Goodchild ,3
Cynthia Srikesavan ,4 Saleema Rex ,1 Charalambos P Charalambous ,5,6
Nigel Hanchard ,7 Alison Armstrong ,8 Andrew Brooksbank ,9
Andrew Carr ,4 Cushla Cooper ,4 Joseph Dias ,8 Iona Donnelly ,9
Catherine Hewitt ,1 Sarah E Lamb ,4 Catriona McDaid ,1
Gerry Richardson ,10 Sara Rodgers ,1 Emma Sharp ,9 Sally Spencer ,11
David Torgerson ,1 Francine Toye 12 and Amar Rangan 1,2,4*
1York Trials Unit, Department of Health Sciences, University of York, York, UK
2The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK
3The Physiotherapy Practice, South Shields, UK
4Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research
Centre, University of Oxford, Oxford, UK
5Department of Orthopaedics, Blackpool Victoria Hospital, Blackpool, UK
6School of Medicine, University of Central Lancashire, Preston, UK
7School of Health & Life Sciences, Teesside University, Middlesbrough, UK
8University Hospitals of Leicester NHS Trust, Leicester, UK
9Glasgow Royal Infirmary, Glasgow, UK
10Centre for Health Economics, University of York, York, UK
11Postgraduate Medical Institute, Edge Hill University, Ormskirk, UK
12Physiotherapy Research Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
*Corresponding author amar.rangan@york.ac.uk
Background: Frozen shoulder causes pain and stiffness. It affects around 10% of people in their fifties
and is slightly more common in women. Costly and invasive surgical interventions are used, without
high-quality evidence that these are effective.
Objectives: To compare the clinical effectiveness and cost-effectiveness of three treatments in
secondary care for adults with frozen shoulder; to qualitatively explore the acceptability of these
treatments to patients and health-care professionals; and to update a systematic review to explore
the trial findings in the context of existing evidence for the three treatments.
Design: This was a pragmatic, parallel-group, multicentre, open-label, three-arm, randomised superiority
trial with unequal allocation (2 : 2 : 1). An economic evaluation and a nested qualitative study were also
carried out.
Setting: The orthopaedic departments of 35 hospitals across the UK were recruited from April 2015,
with final follow-up in December 2018.
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Participants: Participants were adults (aged ≥ 18 years) with unilateral frozen shoulder, characterised
by restriction of passive external rotation in the affected shoulder to < 50% of the opposite shoulder,
and with plain radiographs excluding other pathology.
Interventions: The inventions were early structured physiotherapy with a steroid injection, manipulation
under anaesthesia with a steroid injection and arthroscopic capsular release followed by manipulation.
Both of the surgical interventions were followed with post-procedural physiotherapy.
Main outcome measures: The primary outcome and end point was the Oxford Shoulder Score at
12 months post randomisation. A difference of 5 points between early structured physiotherapy and
manipulation under anaesthesia or arthroscopic capsular release or of 4 points between manipulation
under anaesthesia and arthroscopic capsular release was judged clinically important.
Results: The mean age of the 503 participants was 54 years; 319 were female (63%) and 150 had
diabetes (30%). The primary analyses comprised 473 participants (94%). At the primary end point of
12 months, participants randomised to arthroscopic capsular release had, on average, a statistically
significantly higher (better) Oxford Shoulder Score than those randomised to manipulation under
anaesthesia (2.01 points, 95% confidence interval 0.10 to 3.91 points; p = 0.04) or early structured
physiotherapy (3.06 points, 95% confidence interval 0.71 to 5.41 points; p = 0.01). Manipulation
under anaesthesia did not result in statistically significantly better Oxford Shoulder Score than
early structured physiotherapy (1.05 points, 95% confidence interval –1.28 to 3.39 points; p = 0.38).
No differences were deemed of clinical importance. Serious adverse events were rare but occurred
in participants randomised to surgery (arthroscopic capsular release, n = 8; manipulation under
anaesthesia, n = 2). There was, however, one serious adverse event in a participant who received
non-trial physiotherapy. The base-case economic analysis showed that manipulation under anaesthesia
was more expensive than early structured physiotherapy, with slightly better utilities. The incremental
cost-effectiveness ratio for manipulation under anaesthesia was £6984 per additional quality-adjusted
life-year, and this intervention was probably 86% cost-effective at the threshold of £20,000 per quality-
adjusted life-year. Arthroscopic capsular release was more costly than early structured physiotherapy
and manipulation under anaesthesia, with no statistically significant benefit in utilities. Participants
in the qualitative study wanted early medical help and a quicker pathway to resolve their shoulder
problem. Nine studies were identified from the updated systematic review, including UK FROST, of
which only two could be pooled, and found that arthroscopic capsular release was more effective than
physiotherapy in the long-term shoulder functioning of patients, but not to the clinically important
magnitude used in UK FROST.
Limitations: Implementing physiotherapy to the trial standard in clinical practice might prove challenging
but could avoid theatre use and post-procedural physiotherapy. There are potential confounding effects
of waiting times in the trial.
Conclusions: None of the three interventions was clearly superior. Early structured physiotherapy with
a steroid injection is an accessible and low-cost option. Manipulation under anaesthesia is the most
cost-effective option. Arthroscopic capsular release carries higher risks and higher costs.
Future work: Evaluation in a randomised controlled trial is recommended to address the increasing
popularity of hydrodilatation despite the paucity of high-quality evidence.
Trial registration: Current Controlled Trials ISRCTN48804508.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 71. See the NIHR Journals Library website for further project information.
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Plain English summary
Frozen shoulder occurs when the soft tissue envelope around the shoulder joint becomes inflamed,scarred and contracted, making movement painful and stiff. It affects around 1 in 10 people and is
more common in women. Most patients are treated in the community. Those who do not improve are
offered treatments in hospital. This includes costly and invasive surgical options. It is unclear which
treatment provides the best patient outcomes and is cost-effective.
UK FROST (UK FROzen Shoulder Trial) comprised 503 patients (from 35 UK hospitals) who randomly
received one of three commonly offered treatments for frozen shoulder:
1. early physiotherapy to restore movement, including a steroid injection for pain relief
2. manipulation under anaesthesia, to stretch and tear the tight capsule to restore movement, and a
steroid injection followed by physiotherapy
3. arthroscopic capsular release, which uses keyhole surgery, including manipulation, to restore
movement, followed by physiotherapy with pain medication.
No important differences were found between the three treatments in shoulder function or pain at
12 months. Fewer patients who received arthroscopic capsular release required further treatment,
and patients who received arthroscopic capsular release had slightly better shoulder function and
pain outcomes than those who received the manipulation procedure or early physiotherapy. This
improvement, however, was unlikely to be of clinical benefit to patients. Arthroscopic capsular release
had slightly higher risks and substantially higher costs. Six serious complications were reported in
patients who received arthroscopic capsular release (mostly owing to co-existing health problems)
and two were reported in patients who received manipulation under anaesthesia. Physiotherapy
was the least expensive treatment, but patients who received manipulation under anaesthesia had
slightly better general health than those who received physiotherapy. Early physiotherapy with steroid
injection could be accessed quicker than the surgical alternatives. Manipulation under anaesthesia cost
more than physiotherapy but provided the best value for money. Patients in the study wanted early
access to medical help to improve their shoulder problems.
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Scientific summary
Background
Frozen shoulder occurs when the capsule, or soft tissue envelope, around the ball-and-socket shoulder
joint becomes inflamed, scarred and contracted. This makes the shoulder very painful and stiff. Less
invasive treatments, such as pain medication, are provided in primary care in the UK. When stiffness
becomes more established, treatments include physiotherapy with a steroid injection, manipulation
under anaesthesia, and arthroscopic capsular release. With the intention of facilitating quicker recovery,
more invasive and costly surgical interventions (manipulation under anaesthesia and arthroscopic capsular
release) are being used despite a lack of good evidence that these are effective.
Objectives
The objectives of UK FROST (UK FROzen Shoulder Trial) were to evaluate the clinical effectiveness and
cost-effectiveness of early structured physiotherapy compared with manipulation under anaesthesia
compared with arthroscopic capsular release for patients referred to secondary care for the treatment
of primary frozen shoulder; to carry out a qualitative study to explore the acceptability of the different
interventions to trial participants and health-care professionals; and to undertake a systematic review
update to explore the trial findings in the context of existing evidence.
Methods
Randomised controlled trial
Design
This was a pragmatic, parallel-group, multicentre, open-label, three-arm, randomised superiority trial.
The randomisation sequence was based on a computer-generated randomisation algorithm provided by
a remote randomisation service. Individual patients were allocated to manipulation under anaesthesia,
arthroscopic capsular release or early structured physiotherapy in the ratio of 2 : 2 : 1, stratified by the
presence of diabetes, using random blocks sizes of 10 and 15.
Eligibility criteria
Adults aged ≥ 18 years presenting with a clinical diagnosis of frozen shoulder, characterised by
restriction of passive external rotation in the affected shoulder to < 50% that of the contralateral
shoulder, and radiographs to exclude other pathologies were eligible for inclusion. Exclusion criteria
were a bilateral concurrent frozen shoulder; frozen shoulder secondary to trauma that required hospital
care; frozen shoulder secondary to other causes; contraindication to any of the trial treatments; not
resident in a catchment area of a trial site; or lack of mental capacity to understand the trial.
Setting
The orthopaedic departments of 35 NHS hospitals in the UK across a range of urban and rural areas
(April 2015–December 2018).
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Interventions
Early structured physiotherapy
Early structured physiotherapy consisted of up to 12 weekly sessions comprising essential ‘focused
physiotherapy’ and optional supplementary physiotherapy. Focused physiotherapy comprised an
information leaflet providing education and advice on pain management and function; an intra-articular
steroid injection; and hands-on mobilisation techniques, increasingly stretching into the stiff zone of
the shoulder as the condition improved. Participants received supervised exercises and instructions on
a graduated home exercise programme.
Manipulation under anaesthesia
Manipulation under anaesthesia involved the affected shoulder being manipulated to stretch and
tear the tight capsule and to improve the range of movement. An intra-articular corticosteroid
injection to the glenohumeral joint was used while the patient was under anaesthesia, unless this
was contraindicated. Post-procedural physiotherapy was provided.
Arthroscopic capsular release
Arthroscopic release of the contracted rotator interval and anterior capsule was performed, followed
by manipulation under anaesthesia to complete the release of the inferior capsule. Steroid injections
were permitted at the surgeon’s discretion. Post-procedural physiotherapy was provided.
Outcome measures
The primary outcome was the Oxford Shoulder Score at 12 months post randomisation. The Oxford
Shoulder Score is a 12-item patient-reported outcome measure with a score range from 0 (worst)
to 48 (best). This was also completed at 3 and 6 months post randomisation. Secondary outcomes,
gathered at 3, 6 and 12 months, were the QuickDASH (Quick Disabilities of the Arm, Shoulder and
Hand); a Numeric Rating Scale for shoulder pain during the past 24 hours; extent of recovery using
a visual analogue scale (0–100); and the EuroQol-5 Dimensions, five-level version. Expected and
unexpected complications and adverse events were also recorded.
Sample size
The minimum clinically important difference on the Oxford Shoulder Score was defined as a 5-point
difference (standard effect size 0.42) between surgery and no surgery and a 4-point (standard effect
size 0.33) difference between manipulation under anaesthesia and arthroscopic capsular release.
A total sample size of 500 patients was required to observe these effect sizes, with 90% power and
5% two-sided significance, adjusting for a moderate estimate (r = 0.4) of the correlation between
Oxford Shoulder Score over 12 months and allowing for 20% attrition.
Analyses
Analyses were conducted for arthroscopic capsular release compared with early structured physiotherapy,
manipulation under anaesthesia compared with early structured physiotherapy and arthroscopic capsular
release compared with manipulation under anaesthesia using Stata® version 15 (StataCorp LP, College
Station, TX, USA) and two-sided statistical significance at the 0.05 level. The intention-to-treat primary
analysis was based on a linear mixed model incorporating the Oxford Shoulder Score at all available time
points and using an unstructured covariance pattern to model the relationship of repeated measurements
by the same individual. The model was adjusted for Oxford Shoulder Score at baseline and included as
further fixed effects treatment arm, time, arm-by-time interaction, age, sex and diabetes, with recruitment
site as a random effect. The model provided estimates for each of the three treatment comparisons at
individual time points, including the primary end point of 12 months, as well as an overall treatment effect
over 12 months. The estimates are reported as mean differences between treatment arms with 95%
confidence intervals and associated p-values. Continuous secondary outcomes were analysed using the
same method as the primary outcome and adjusting for the same covariates.
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Prespecified sensitivity analyses explored the effect of non-compliance with early structured physiotherapy
using complier average causal effect analysis; the effect of waiting times for interventions using additional
data collected just before and 6 months following treatment; the impact of missing data; and the effect
of questionnaire return outside the intended follow-up time. The Data Monitoring and Ethics Committee
advised that employment status be included as a model covariate in a sensitivity analysis. Prespecified
subgroup analyses explored possible treatment effect interactions with diabetes, previous receipt of
physiotherapy and patient baseline treatment preference. The Trial Steering Committee advised on
including a subgroup analysis for duration of symptoms at the time patient eligibility was confirmed.
Economic evaluation
Costs and health benefits were compared for the three treatment arms over the 12 months and
hence discounting was not required. All costs were expressed in Great British pounds at a 2017–18
price base. Health outcomes were assessed in terms of quality-adjusted life-years, based on patients’
health-related quality-of-life outcomes obtained from trial participants using the EuroQol-5 Dimensions,
five-level version, at baseline and at 3, 6 and 12 months. Differences in mean costs and mean quality-
adjusted life-years at 12 months were used to derive the incremental cost-effectiveness ratio for surgery
and non-surgical treatment. The base-case analysis was conducted on an intention-to-treat basis, with
multiple imputation for missing data, and using a UK NHS and Personal Social Services perspective.
A secondary analysis took a broader perspective that included private care and productivity costs
(i.e. days lost from work).
Qualitative study
This study explored the trial participants’ experience and acceptability of the treatments and taking
part in the trial, and surgeons’ and physiotherapists’ experience of the treatments they delivered in
the trial. Face-to-face or telephone interviews were undertaken. Interviews were undertaken by
a physiotherapy researcher trained in qualitative research methods who was not involved in the
trial. Interviews were semistructured and used open questions, and they were audio-recorded and
transcribed. The interviews were analysed using constant comparative methods. Transcripts were
coded and categorised into themes using NVivo 11 qualitative data software (QSR International,
Warrington, UK) and reviewed by a second researcher. Data from trial participants were mapped
against the World Health Organization’s International Classification of Functioning, Disability and
Health framework.
Systematic review update
MEDLINE/PreMEDLINE, CENTRAL (Cochrane Central Register of Controlled Trials), EMBASE,
PEDro, Science Citation Index, ClinicalTrials.gov and World Health Organization International Clinical
Trials Registry were searched from January 2010 to December 2018, and studies reported prior to
2010 were obtained from our previous Health Technology Assessment review [Maund E, Craig D,
Suekarran S, Neilson A, Wright K, Brealey S, et al. Management of frozen shoulder: a systematic review
and cost-effectiveness analysis. Health Technology Assessment 2012;16(11)]. Randomised controlled
trials evaluating manipulation under anaesthesia, arthroscopic capsular release, hydrodilatation or
physiotherapy plus a steroid injection for treatment of primary frozen shoulder were compared with
each other, no treatment or supportive care were eligible. The primary outcome was patient-reported
function and disability at 12 months. Study selection was undertaken independently by two researchers.
For continuous outcomes, the post-intervention mean (standard deviation, and number of participants)
for each arm was extracted, where available. The standardised mean difference was calculated to allow
comparison between studies. Data extraction and assessment using the Cochrane Risk of Bias tool was
undertaken by one researcher and checked by a second. Narrative and tabular summaries of key study
characteristics, results and quality assessment are provided. A pairwise meta-analysis using a random-
effects model was undertaken for a single comparison only because of limited data and methodological
and statistical heterogeneity.
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Results
Randomised controlled trial
Of 914 patients screened, 503 were randomised to one of manipulation under anaesthesia (n = 201),
arthroscopic capsular release (n = 203) and early structured physiotherapy (n = 99). Follow-up rates
were between 85% and 89%, and no evidence was seen of differential dropout across the treatment
arms. The primary analysis comprised all participants with Oxford Shoulder Score outcome data at
one or more follow-ups (94%). Average shoulder function improved in all treatment arms, with many
participants (24%) regaining function to the top Oxford Shoulder Score at 12 months.
At the primary end point at 12 months, participants randomised to arthroscopic capsular release had,
on average, a statistically significantly higher (better) Oxford Shoulder Score than those randomised to
manipulation under anaesthesia (2.01 points, 95% confidence interval 0.10 to 3.91 points) or to early
structured physiotherapy (3.06 points, 95% confidence interval 0.71 to 5.41 points). There was no
statistically significant difference between manipulation under anaesthesia and early structured
physiotherapy (1.05 points, 95% confidence interval –1.28 to 3.39 points).
At the short-term follow-up at 3 months, arthroscopic capsular release had lower (worse) Oxford
Shoulder Score than the other two interventions (vs. manipulation under anaesthesia –3.36 points,
95% confidence interval –5.27 to –1.45 points; vs. early structured physiotherapy –4.72 points,
95% confidence interval –7.06 to –2.39 points). There was no evidence of statistically significant
differences in average Oxford Shoulder Score over the 12 months’ follow-up (manipulation under
anaesthesia vs. early structured physiotherapy 0.61 points, 95% confidence interval –1.31 to 2.53
points; arthroscopic capsular release vs. early structured physiotherapy –0.23 points, 95% confidence
interval –2.15 to 1.70 points; arthroscopic capsular release vs. manipulation under anaesthesia
–0.84 points, 95% confidence interval –2.41 to 0.72 points).
Mean differences were short of the minimal clinically important effect size of 4 (arthroscopic capsular
release vs. manipulation under anaesthesia) to 5 (arthroscopic capsular release or manipulation under
anaesthesia vs. early structured physiotherapy) Oxford Shoulder Score points. However, differences of
that magnitude were included in the 95% confidence intervals for the benefit of manipulation under
anaesthesia and early structured physiotherapy over arthroscopic capsular release at 3 months, and for
the benefit of arthroscopic capsular release over early structured physiotherapy at 12 months. Sensitivity
analyses did not substantially alter the results. There were no significant subgroup interactions.
Around 20% of all trial participants did not complete their treatment. The complexity of the multiple
alternative pathways for each participant limited the analyses of the effect of compliance. At 12 months,
the outcomes for early structured physiotherapy compliers remained lower (worse) than for those who
complied in both surgery arms combined (–1.84 Oxford Shoulder Score points, 95% confidence interval
–4.41 to 0.74 points; p = 0.157).
Among the secondary outcomes, QuickDASH and shoulder pain results followed a similar pattern to
the Oxford Shoulder Score, in that, compared with those allocated to manipulation under anaesthesia or
early structured physiotherapy, statistically significant poorer outcomes were observed for arthroscopic
capsular release participants at 3 months but better outcomes were observed at 12 months. There were
no statistically significant differences between the treatment arms in response to the global question on
the extent of recovery.
In total, there were only 10 serious adverse events, reported for nine participants. All serious
adverse events occurred in the surgical arms (arthroscopic capsular release, n = 8; manipulation under
anaesthesia, n = 2), although one participant in the arthroscopic capsular release arm had a serious
adverse event resulting from non-trial physiotherapy. The events mainly related to serious medical
complications such as chest infection or stroke. Thirty-three non-serious adverse events were reported
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for 31 participants, and these were mainly expected and often were related to persistent or worsening
shoulder pain. There was no evidence of a statistical difference in the proportions of non-serious
adverse events (p = 0.186).
Economic evaluation
The base-case economic analysis showed that, at 12 months, manipulation under anaesthesia was,
on average, £276 more costly per participant (95% confidence interval £65.67 to £487.35) than
early structured physiotherapy. Manipulation under anaesthesia was slightly more beneficial in
terms of utilities (mean 0.0396 more quality-adjusted life-years per participant than early structured
physiotherapy, 95% confidence interval –0.0008 to 0.0800 more quality-adjusted life-years). The
resulting incremental cost-effectiveness ratio for manipulation under anaesthesia was £6984 per
additional quality-adjusted life-year. Arthroscopic capsular release was substantially more costly than
early structured physiotherapy [on average costing £1733.78 more per participant (95% confidence
interval £1529.48 to £1938.06 more per participant)] for a slight benefit in utilities [mean 0.0103
more quality-adjusted life-years per participant than early structured physiotherapy (95% confidence
interval –0.0304 to 0.0510 more quality-adjusted life-years)]; the incremental cost-effectiveness
ratio was > £100,000 per additional quality-adjusted life-year. Arthroscopic capsular release was
more expensive than manipulation under anaesthesia and resulted in slightly fewer quality-adjusted
life-years. Manipulation under anaesthesia was the intervention most likely to be cost-effective at
a threshold of £20,000 per quality-adjusted life-year (manipulation under anaesthesia, 86%; early
structured physiotherapy, 14%; arthroscopic capsular release, 0%).
Qualitative study
Forty-four interviews (most of which were conducted over the telephone) were undertaken with trial
participants, who were evenly distributed across the three interventions, and with eight surgeons
and physiotherapists. Trial participants described how frozen shoulder had a major impact on all
aspects of their life. They were keen to get their shoulder problems resolved, which motivated them
to participate in the trial. They thought that seeking early medical help and having a quicker NHS
care pathway were important. In general, trial participants were satisfied with the trial interventions
and found them acceptable. They reported improvements in pain, shoulder movements and function.
Participants who received arthroscopic capsular release described recovering quicker than they had
expected. Surgeons and physiotherapists followed a stage-based treatment approach in their routine
practice. Both groups felt that people with diabetes tend to have poorer outcomes. They suggested
that hydrodilatation could have been a treatment arm of the trial. Both groups stated that some
people who previously had received ineffective physiotherapy had not wanted to take part in the trial.
Systematic review
Nine studies were identified, including UK FROST, which provided by far the largest and most robust
evidence. The number of participants in the other studies ranged from 26 to 136, and the studies were
mostly single centre. All studies were rated as being at high risk of bias for blinding of participants
and clinicians, and outcome assessment. Considerable heterogeneity of the interventions and generally
limited evidence for many of the comparisons meant that only two studies could be pooled as part of
a meta-analysis (UK FROST and one other trial) comparing long-term shoulder functioning for patients
receiving either arthroscopic capsular release or physiotherapy. The pooled effect favoured arthroscopic
capsular release; however, the second study provided little additional weighted information.
Conclusions
UK FROST has provided robust clinically relevant evidence that none of the three treatments was
clearly superior in patient-reported shoulder pain and functioning at 12 months. Our specifically
designed early structured physiotherapy pathway can be accessed quickly in the NHS and has lower
costs. However, the likelihood of further treatment being required is higher with early structured
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physiotherapy than with the surgical interventions. Manipulation under anaesthesia is the most
cost-effective option, with an incremental cost-effectiveness ratio of £6984 per additional quality-
adjusted life-year. Patients who receive arthroscopic capsular release are least likely to need further
treatment, but arthroscopic capsular release is associated with relatively higher risks and costs.
To address the increasing popularity of hydrodilatation, and the paucity of rigorous evidence of
hydrodilatation’s effectiveness, a high-quality randomised controlled trial is recommended to compare
hydrodilatation with early structured physiotherapy with steroid injection with manipulation under
anaesthesia with steroid injection.
Trial registration
This trial is registered as ISRCTN48804508.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 71.
See the NIHR Journals Library website for further project information.
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Chapter 1 Introduction
Frozen shoulder
Frozen shoulder (also known as adhesive capsulitis) occurs when the capsule, or soft tissue envelope,
around the ball-and-socket shoulder joint becomes inflamed and then scarred and contracted. This
makes the shoulder very painful, tight and stiff. It starts with pain, which increases in intensity as
stiffness develops.1 The exact cause of this condition is unknown. Reported associations include
diabetes mellitus, cardiovascular disease, trauma, stroke, neurosurgery and thyroid disease.1 In the
absence of a known association, the condition is labelled by clinicians as ‘idiopathic’ or ‘primary’
frozen shoulder. The pathology of the capsule involves chronic inflammation, and proliferative fibrosis
has been reported.2 Myofibroblasts contribute to matrix deposition and fibrosis, with the underlying
pathology considered similar to Dupuytren’s contracture.2,3 The macroscopic appearance of these
changes can be seen in the shoulder during arthroscopic visualisation of the rotator interval capsule.
People with this condition may struggle with basic daily activities, suffer serious anxiety and have sleep
disturbance due to shoulder pain. There is a tendency for spontaneous resolution, but recovery may be
slow or incomplete. Even after an average of ≥ 4 years from onset, around 40% of patients can have
mild to severe symptoms.4 Figure 1 illustrates the pathology of frozen shoulder.
Three clinical phases have historically been recognised for this condition,5 where the duration of each
phase is indicative but varies considerably between patients:
(a) painful phase, which may last 3–9 months
(b) adhesive phase, with stiffness lasting for 4–6 months
(c) phase of resolution or ‘thawing’, lasting for 5–24 months.
These phases have considerable overlap, and therefore the current favoured terminology is ‘pain
predominant’ and ‘stiffness predominant’ phases.6
FIGURE 1 Diagram showing site of pathology of frozen shoulder. This figure has been re-used from www.local-physio.co.uk/
articles/shoulder-pain/frozen-shoulder/ with permission from the copyright holders.
DOI: 10.3310/hta24710 Health Technology Assessment 2020 Vol. 24 No. 71
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Brealey et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
1
The cumulative incidence of frozen shoulder is estimated at 2.4 per 1000 population per year, based
on a Dutch general practice sample.7 Frozen shoulder most commonly affects individuals in their sixth
decade of life, and a large primary care-based study in the UK found that frozen shoulder affects 8.2%
of men and 10.1% of women of working age.8 By contrast, an incidence of 1% was reported by a UK
shoulder surgeon in his specialist hospital practice.9 This discrepancy in estimated incidence can be
explained by the use of different populations as the denominators in the different studies.6 Although
not clearly established, when associated with diabetes mellitus, frozen shoulder is considered to be
more resistant to treatment.10
Diagnosis of frozen shoulder
A diagnosis of frozen shoulder is based on clinical criteria that include history of insidious onset
deep-seated pain in the shoulder and upper arm with increasing stiffness, as well as clinical findings
of limited active and passive external rotation in the absence of crepitus.11 Radiographs are reported
as not routinely required,6 but are usually performed in secondary care to exclude pathology like
glenohumeral arthritis or posterior glenohumeral dislocation that could manifest with similar clinical
signs. There is no reference standard for comparison, which explains the lack of diagnostic test
accuracy data.11 The key examination findings were originally described by Codman as restriction of
elevation and external rotation.12 As visual estimation of external rotation has fair to good reliability,13
restrictions (typically with pain) in both passive and active external rotation have been used as diagnostic
criteria in clinical studies.11,14–17 It can be difficult, however, to correctly diagnose the problem, as
highlighted in a qualitative study of patients’ perceptions and priorities when living with primary frozen
shoulder.18 This accords with other studies, which have found that general practitioners (GPs) in the UK
and the USA lack confidence in making shoulder diagnoses.19,20
Treatments for frozen shoulder
The aims of treating a patient with frozen shoulder are to provide advice, education and reassurance;
achieve pain relief; improve shoulder mobility; reduce the duration of symptoms; and facilitate return
to normal activities.21 Generally, less invasive treatments are provided in a primary care setting in the
UK to those in the earlier phases of the disease, particularly for controlling pain. These may include
oral analgesia, physiotherapy, acupuncture, and glucocorticoid (steroid) injection.21 The treatments
utilised in secondary care, when stiffness has become more established, were confirmed in a UK survey
of health professionals conducted in 2009 as physiotherapy, manipulation under anaesthesia (MUA)
and arthroscopic capsular release (ACR).22
Physiotherapy treatment includes combinations of advice, exercises, therapist-applied mobilisation
techniques, and thermo- and electrotherapies. The modalities of treatment recommended for use are
described in the UK national physiotherapy guidelines for frozen shoulder,6 which are based on a
systematic review. These are provided either in isolation or as a supplement to other interventions,
such as intra-articular corticosteroid injection or surgical interventions (MUA or ACR). Intra-articular
corticosteroid injection helps reduce inflammation of the joint capsule and reduce pain, which may
facilitate the performance of exercises and hence enhance the effects of physiotherapy. Intra-articular
corticosteroid injection has been shown to provide short-term benefits, with better improvements in
pain, function and range of movement (up to 6–7 weeks for all three improvements) than placebo13
and probably than isolated manual therapy and exercise.6
Manipulation under anaesthesia is a procedure the surgeon undertakes when the patient is under
general anaesthesia. The affected shoulder joint is manipulated in a controlled fashion to stretch and
tear the tight shoulder capsule. The joint is often injected with corticosteroid as part of this procedure.
MUA is thought to facilitate recovery by releasing the tightness in the capsule, with the injection
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helping control capsular inflammation and pain. This is followed by physiotherapy for mobilisation of
the arm and shoulder to restore mobility and function.
Arthroscopic capsular release is a ‘keyhole’ surgical procedure performed under general anaesthesia.
The keyholes are used to view the joint and divide (release) the contracted capsule using typically
arthroscopic radiofrequency ablation. This is thought to allow more accurate and controlled release of
the tight capsule. The procedure is completed by performing MUA to complete and confirm full release
of the contracted capsule. ACR is also followed by physiotherapy of the arm and shoulder to restore
mobility and function.
Rationale for the UK FROzen Shoulder Trial
It is unknown whether a combination of physiotherapy and steroid injection or either of the surgical
interventions (MUA or ACR) followed by physiotherapy is more effective.13 Similarly, there is
uncertainty about the benefits of MUA compared with other treatment options,23,24 and only limited
evidence on ACR is available from randomised controlled trials (RCTs).13,25
Systematic reviews have identified large gaps in the evidence base and uncertainty about the
effectiveness of treatments for frozen shoulder and, therefore, a need for high-quality primary
research.26 In a systematic review13 commissioned by the National Institute for Health Research Health
Technology Assessment (HTA) programme, 28 RCTs, one quasi-experimental study and two case series
were included. The review found insufficient studies with a similar intervention and comparator to
quantify effectiveness. Most studies were rated as having a high risk of bias, did not report adequate
methods of randomisation, allocation concealment and outcome assessment, and seemed to be
inadequately powered. Few studies reported collecting data on harms.
In view of the paucity of high-quality evidence to guide current practice, considerable uncertainties
remain about the management of frozen shoulder. With the intention of facilitating quicker
recovery, more invasive surgical interventions (MUA and ACR) are being used in spite of the lack
of good evidence.13 There is a clear need for a well-designed, high-quality RCT to determine the
clinical effectiveness and cost-effectiveness of commonly used interventions for the treatment of
frozen shoulder.
The findings of a national survey22 of health-care professionals in the UK, conducted in 2009, were
used to determine the most commonly used interventions that need to be tested in a RCT in a
secondary care setting. Physiotherapy, MUA and ACR were those that health-care professionals
recommended be compared in a RCT. Only 6% of respondents at the time suggested using
hydrodilatation as a comparator in a trial, which did not make this a feasible intervention to test in
a RCT. This survey informed our decision to compare early structured physiotherapy (ESP) combined
with intra-articular steroid injection with the two most frequently used, invasive and costly surgical
interventions, namely MUA and ACR.22 It is important to emphasise that, although physiotherapy
is a common treatment in NHS practice, the ESP intervention was a specifically designed and
standardised physiotherapy pathway to test the optimal delivery of physiotherapy in the NHS.
As evidence about patients’ experiences of frozen shoulder is also limited,18 participants were
interviewed about their experience and the acceptability of treatment, as were health professionals
(physiotherapists and surgeons).
Aim and objectives
The strategic aim of UK FROST (UK FROzen Shoulder Trial), underpinned by the key treatment
uncertainties, was to provide evidence of the clinical effectiveness and cost-effectiveness of three
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common interventions currently provided in the UK NHS for the treatment of frozen shoulder in a
hospital setting. The following objectives were defined to achieve this overarching aim:
1. The primary objective was to determine the effectiveness of ESP compared with MUA compared
with ACR for patients referred to secondary care for the treatment of frozen shoulder. This was
achieved using a parallel-group RCT, with the Oxford Shoulder Score (OSS) (a patient-reported
outcome measure) as the primary outcome at 3, 6 and 12 months. The primary time point was
12 months after randomisation.
2. To compare the cost-effectiveness of the three interventions, to identify the most efficient provision
of future care, and to describe the resource impact that the various interventions for frozen
shoulder would have on the NHS.
3. To qualitatively explore the acceptability of different interventions for frozen shoulder to patients
and health-care professionals and to provide important patient-centred insight to further guide
clinical decision-making.
4. To update the HTA programme-funded systematic review examining the management of frozen
shoulder by assessing current RCT evidence for the effectiveness of interventions used in secondary
care. This would allow the trial findings to be considered in the context of the existing evidence for
the interventions under evaluation.
5. To widely disseminate the findings of this study to all stakeholders through networks of health-care
professionals, patients, health service managers and commissioning groups. This would be in addition
to publishing the results of the study in key journals and publishing the National Institute for Health
Research HTA report.
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Chapter 2 Trial design and methods
This chapter describes the trial design and methods used to address the objectives about the clinicaleffectiveness of the health-care interventions being compared. The methods of the health economic
evaluation and the nested qualitative study are described in the corresponding chapters. The trial
protocol has been published.27
Trial design
This was a pragmatic, multicentre, stratified (diabetes present or not) superiority trial comparing three
parallel groups (MUA vs. ACR vs. ESP, with unequal allocation of 2 : 2 : 1) in adult patients referred to
secondary care in England, Wales and Scotland for the treatment of primary frozen shoulder, and for
whom surgery was being considered.
Participants
Patients with primary frozen shoulder were identified through clinical examination and plain
radiographs.28 To minimise diagnostic uncertainty, clinical examination included the key diagnostic
assessment of restriction of passive external rotation in the affected shoulder,29 for which there is
evidence of good inter-rater agreement on whether or not restriction is present30 and a high threshold
(50% restriction of movement) for inclusion. Plain radiographs (anteroposterior and axillary projections)
were obtained routinely for all patients to see whether or not these were normal and could allow the
exclusion of glenohumeral arthritis and other pathology that could lead to similar clinical presentation
(e.g. locked posterior dislocation).
Inclusion criteria
Patients, including those with diabetes, were eligible if:
l they were aged ≥ 18 years
l they presented with a clinical diagnosis of frozen shoulder characterised by restriction of passive
external rotation in the affected shoulder to < 50% of that of the contralateral shoulder
l they had radiographs that excluded other pathologies.
Exclusion criteria
Patients were excluded if:
l they had a bilateral concurrent frozen shoulder
l their frozen shoulder was secondary to trauma that necessitated hospital care (e.g. fracture,
dislocation, rotator cuff tear)
l their frozen shoulder was secondary to other causes (e.g. recent breast surgery, radiotherapy)
l any of the trial treatments (e.g. unfit for anaesthesia or corticosteroid injection) were contraindicated
l they were not resident in a catchment area of a trial site
l they lacked the mental capacity to understand the trial.
Setting
The trial recruited from the orthopaedic departments of 35 NHS hospitals in the UK across a range
of urban and rural areas. This comprised 28 hospitals in England, six in Scotland and one in Wales.
Two additional hospitals in England screened for patients but did not recruit into the trial.
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Recruitment started in April 2015 and the final follow-up was in December 2018. All 37 participating
hospitals are listed in Appendix 1.
Interventions
The components and standardisation of the surgical trial interventions were informed by a survey
of 53 surgeons, who were the principal investigators of two multicentre shoulder surgical RCTs.31,32
The standalone physiotherapy and post-procedural physiotherapy programmes were developed using
evidence from a systematic review,13 UK guidelines,6 previous surveys of UK physiotherapists33,34 and
consensus of expert shoulder physiotherapists in secondary care derived from a Delphi survey specific
to UK FROST.18 Ethics approval for the last of these was obtained from the School of Health and Social
Care Research Governance and Ethics Committee of Teesside University on 23 May 2014 (Research
Ethics Committee reference 069/14). The physiotherapy programmes developed are available online.35
It is important to emphasise that, although physiotherapy is a common treatment in NHS practice, the
ESP intervention was a specifically designed, standardised, new physiotherapy pathway to test the
optimal delivery of physiotherapy in the NHS based on the best available evidence and expert consensus.
Participants assigned to either of the two surgical procedures were placed on the surgical waiting list
and underwent routine preoperative screening. In keeping with NHS waiting time targets, both surgical
procedures were expected to be performed within 18 weeks of randomisation. Participants would
undergo these procedures under general anaesthetic and were expected to be admitted as day cases.
Physiotherapy was delivered by qualified physiotherapists (i.e. not students or assistants), and
participating surgeons were familiar with the surgical procedure(s). There was no minimum number of
surgical procedures that the surgeon had to have performed, and no grades of surgeon were excluded.
Which surgeon operated on participants and whether or not the individual surgeon needed to be
supervised by a consultant was at the discretion of the participating site, and followed normal care
pathways and practices. The experience of physiotherapists and surgeons delivering the trial treatments
was quantified and recorded in terms of their salary bands and the number of frozen shoulder patients
they treated in a typical month.
Manipulation under anaesthesia with an intra-articular steroid
The affected shoulder was manipulated to stretch and tear the tight capsule and to improve range of
movement. Intra-articular injection of corticosteroid to the glenohumeral joint was to be administered
while the participant was under the same anaesthetic, unless the injection was contraindicated at the
time of surgery. Postoperative analgesia, including nerve blocks, was provided as per usual care in
the treating hospital. The details of MUA were collected prospectively using the MUA surgery form
(see Report Supplementary Material 1). In the unlikely event that the MUA was judged to be incomplete,
it was recommended that the surgeon should not cross over intraoperatively to capsular release.
The need for this was to be reviewed at another clinic appointment to allow the outcome of the MUA
to be assessed and the need for any further intervention to be decided. Details of any further
intervention were collected prospectively.
Arthroscopic capsular release with manipulation under anaesthesia
Arthroscopic release of the contracted rotator interval and anterior capsule was performed, followed
by MUA to complete the release of the inferior capsule. Additional procedures such as posterior
capsular release or subacromial decompression were permitted at the operating surgeon’s discretion.
Steroid injections, which slightly increase the risk of infection and morbidity, were permitted at the
surgeon’s discretion.36 Postoperative analgesia, including nerve blocks, was provided as per usual care
in the treating hospital. The details of ACR were collected prospectively using the ACR surgery form
(see Report Supplementary Material 2).
TRIAL DESIGN AND METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
Nested shoulder capsular tissue and blood samples study
At six selected hospitals, 16 participants allocated to ACR who had not had a steroid injection within
6 weeks from the day of surgery were included in an exploratory nested capsular tissue and blood study.
This was undertaken between January 2017 and December 2017 and had the following objectives:
1. to determine molecular and cellular abnormalities in tissue obtained during surgery from patients
with frozen shoulder
2. to determine serum protein and cytokine signatures in patients with frozen shoulder
3. to correlate any tissue and serum abnormalities detected with clinical presentation and response
to treatment.
When the date of surgery was known, the research nurse posted a letter about the nested study,
a patient information leaflet and a consent form. Written informed consent was obtained at the
participant’s pre-surgery assessment. A tissue sample of capsule from the rotator interval, which is
routinely incised or removed as part of ACR, and a venous blood sample were obtained for analysis.
All samples were fresh frozen, stored on dry ice and transported securely by courier to the Oxford
Musculoskeletal Biobank at the University of Oxford, and housed at the Botnar Research Centre for
formal analysis. The biopsy material was small (2 mm by 2 mm) and obtained with the use of arthroscopic
graspers, and biopsy was not expected to have any significant effect on patient outcomes. The results of
this study have been published.37
Early structured physiotherapy
Participants received up to 12 sessions of structured physiotherapy, comprising essential ‘focused
physiotherapy’ and optional supplementary physiotherapy, over a period of up to 12 weeks. The focused
physiotherapy package included an information leaflet (see Report Supplementary Material 3) providing
education and advice on pain management and function; an intra-articular steroid injection; and hands-on
mobilisation techniques, increasingly stretching into the stiff part of the range of movement as the
condition improved.38,39 Participants received supervised exercises and were provided with instructions
for a graduated home exercise programme (see Report Supplementary Material 4), progressing from
gentle pendular exercises to firm stretching exercises according to stage, as is accepted good practice.
All participants randomised to ESP underwent all elements of the focused physiotherapy package unless
there was a specific clinical reason for them not to do so (e.g. a steroid injection might be withheld from
a participant with currently uncontrolled diabetes, or from a participant with a stiff but painless and
non-irritable shoulder).
Supplementary physiotherapy comprised those interventions that were non-essential but permissible
additions, allowing physiotherapists some flexibility. These interventions, which may have been omitted
from the national guidelines because they were outside their scope (e.g. acupuncture) and/or because
there was a lack of evidence of their effectiveness in the primary academic literature (e.g. hydrotherapy,
soft-tissue release techniques), were explored using a Delphi process.
Participants who did not improve with ESP were referred for further treatment in consultation with the
treating clinician following a 12-week assessment. When further treatment after ESP involved surgical
intervention, participants were placed on the normal surgical waiting list. Any further treatment provided
was recorded. Participants allocated to ESP were offered reimbursement of their travel expenses. The
ESP given during each session (e.g. injection, advice and education, gentle active exercise) was recorded
in the structured physiotherapy log book (see Report Supplementary Material 5).
Post-procedural physiotherapy
Following MUA or ACR, participants underwent up to 12 weeks of physiotherapy, normally commencing
within 24 hours of the procedure. The aim was to reduce pain and aid with regaining/maintaining the
mobility achieved by the operation. The post-procedural physiotherapy (PPP) differed from ESP to suit
its very different context.
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As the research literature was uninformative, two essential ‘focused physiotherapy’ interventions were
prespecified, based on established good practice. These were:
1. an information leaflet giving education and advice on pain management and function
2. instructions for a graduated home exercise programme.
All participants randomised to MUA or ACR were to undergo all elements of this focused physiotherapy
package unless there was a specific clinical reason for them not to do so. The Delphi survey, which was
interpreted as had been done for ESP, provided optional, supplementary interventions. A steroid injection
was to be avoided where possible during PPP. The PPP log book (see Report Supplementary Material 6)
was used to record the PPP given during each session.
Steroid injections
Steroid injections were administered with or without imaging guidance, depending on the usual practice
of the hospital site. Current evidence does not support the superiority of either approach.40
Modifications to interventions
There were no explicit criteria for modifying, discontinuing or crossing over from the assigned trial
treatment. The clinician and participant discussed whether or not to continue with the assigned treatment
for reasons such as the patient having poorly controlled diabetes or no longer requiring the treatment.
Adherence to interventions
Adherence to the trial treatments was explained in the trial site manual and during site initiation
visits. A requirement of the internal pilot was to check the feasibility of delivering the ESP programme.
This was expanded to include the surgical interventions and PPP. Every month, a designated trial
co-ordinator extracted data from the hospital case report forms (CRFs) and updated a spreadsheet
to record information about aspects of the treatments. The spreadsheet was reviewed for treatment
adherence by the chief investigator, a consultant orthopaedic surgeon and the lead physiotherapist,
who decided whether or not any action was required at a site. This was further monitored by the Trial
Management Group (TMG), the independent Trial Steering Committee (TSC) and the Data Monitoring
and Ethics Committee (DMEC).
Concomitant care
Analgesia for pain relief, general advice on care of the arm (e.g. axillary hygiene) and general advice
to prevent further stiffness in the limb were all permitted at part of the management of a participant
awaiting surgery. Specific home exercise programmes, such as that provided with the structured
physiotherapy intervention, were not permitted. Steroid injections were avoided, as these were
considered active interventions.
Outcomes
Primary outcome
The primary outcome was the OSS, a patient-reported measure of functional limitation following shoulder
surgery. The development and validation of this measure included patients with frozen shoulder,41 and it has
been used in the follow-up of these patients.4 The OSS is a 12-item measure with five response categories
and a range of scores from 0 (worst) to 48 (best).42 It has been validated against the professionally endorsed
Constant score43 and the SF-36 (Short Form questionnaire-36 items),44 and its responsiveness over a
6-month period following surgical intervention has been established.45
Participants completed the OSS at baseline prior to randomisation. The questionnaire was then posted
to the participants 3, 6 and 12 months after randomisation. The primary end point was 12 months
after randomisation, allowing the interventions and co-treatment interventions to be delivered and
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the majority of complications to be treated. The OSS was also completed at the hospital at the start of
treatment. This was either the day of the operation or, for participants allocated to ESP, the day when
the steroid injection was given or at the first visit to physiotherapy, whichever was first. The OSS was
then posted to participants for them to complete 6 months from when treatment started.
Secondary outcomes
Secondary outcomes were collected at baseline and at 3, 6 and 12 months from randomisation, unless
otherwise stated.
Quick Disabilities of the Arm, Shoulder and Hand
The DASH (Disabilities of the Arm, Shoulder and Hand) is a well-validated and reliable measure of
symptoms and functional limitation in the upper extremity.46 To minimise responder burden, the
validated 11-item short version, the QuickDASH (Quick Disabilities of the Arm, Shoulder and Hand),
was used.47 This is scored from 0 to 100, and an 8-unit improvement in scores has been defined as the
minimum clinically important difference for patients with shoulder problems.48 Its validity with and
responsiveness to frozen shoulder has been established.49
EuroQol-5 Dimension, five-level version
The EuroQol-5 Dimensions (EQ-5D) is a validated, generic and health economic, self-completed, patient-
reported outcome measure covering five health domains with three response options.50,51 The EuroQol-5
Dimensions, five-level version (EQ-5D-5L), consists of the same five domains as the original EuroQol-5
Dimensions, three-level version (EQ-5D-3L), but with five levels rather than three to help overcome
problems with ceiling effects and to improve sensitivity.52,53 The EQ-5D-3L has been validated for use
with a range of shoulder conditions.54,55 The EQ-5D-5L provides a simple descriptive profile of health
status that can be used to estimate quality-adjusted-life-year (QALY) scores in economic evaluations.
Pain
Shoulder pain ‘during the past 24 hours’ was measured using the Numerical Rating Scale for pain,56
a single 11-point numerical scale on which 0 represents ‘no pain’ and 10 represents ‘worst possible
pain’. This measure is considered the most valid for use in this population.57
Extent of recovery
A simple subjective global question asked to what extent the participant’s frozen shoulder symptoms
in the past 24 hours had affected their assessment of needing treatment. This informed the extent to
which symptoms resolved over time. Responses were measured using a visual analogue scale with
anchors from 0 to 100 (e.g. 0, no need to ask for treatment; 100, definitely ask for treatment).
Complications
At 12 months, sites recorded all expected and unexpected complications on the 52-week complication
forms (see Report Supplementary Material 7). Infection was defined as for the ‘surgical site infection’
audit.58 Delayed wound healing was defined as any wound that had not healed by 2 weeks post
surgery. Complex regional pain syndrome was defined as pain, swelling and stiffness of the affected
shoulder, and arm and/or hand restrictions limiting the full tuck of the fingers. In addition, nerve, blood
vessel, tendon or bone injury and complications related to steroid injection, including steroid flare and
septic arthritis, were recorded.
Adverse events
A non-serious adverse event (AE) was defined as any untoward medical occurrence in a trial participant
related to the affected shoulder up to 12 months from randomisation. A serious adverse event (SAE)
was defined as any untoward medical occurrence that resulted in death, threat to life, hospitalisation or
prolongation of existing hospitalisation, persistent or significant disability or incapacity, a congenital
abnormality or birth defect, or any other medical condition that may require medical or surgical
intervention to prevent any of these from occurring.
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Sample size
The primary trial outcome was the OSS, and this was assessed for three treatment comparisons:
ESP with MUA, ESP with ACR, and MUA with ACR.
Data suggest that a 5-point improvement can be found on the OSS (standard effect size of 0.42) between
surgically and non-surgically treated patients,59 with a stable standard deviation (SD) of 12 points across
different populations. This larger effect size was required to justify the higher costs and potential risks
associated with surgery when comparing ESP with MUA, and ESP with ACR.42 A smaller difference of
4 points on the OSS (standard effect size of 0.33) was expected to distinguish between MUA and ACR.
To observe the above effect sizes with 90% power and 5% two-sided significance, adjusting for a
moderate estimate (r = 0.4) of the correlation between OSS over 12 months and allowing for 20%
attrition, a total sample size of 500 patients was required (MUA, n = 200; ACR, n = 200; ESP, n = 100).
The sample size calculation was not adjusted for multiple comparisons owing to the a priori specified
sequence of treatment comparisons and the analysis of the primary outcome in a single analysis model.60
There were no planned interim analyses for the trial or stopping guidelines. An internal pilot from
which data contributed to the final analyses was performed to confirm the feasibility of the trial,
and this is explained in the following section.
Internal pilot study
There were two phases of the internal pilot study.
Phase 1 (months 4–9)
It was important to critically test our assumptions after 6 months of recruitment by reviewing the
number of sites set up and the number of eligible patients identified, approached and consented.
This was to help inform the number of participating sites required to achieve the recruitment target.
Secondary reasons for undertaking this phase of the pilot were to review (1) whether or not the
participating sites were being provided with enough training and documentation; (2) the number of
reasons why patients were not eligible for the trial; (3) the length of time it took to consent a patient
and the reasons why patients did not take part; (4) whether or not all clinicians at a site were actively
taking part in the trial, and, if not, why not; and (5) patient adherence to treatment allocation.
The independent oversight committees assessed the success of phase 1 based on the following objectives:
l to have a minimum of four sites recruiting during the 6 months that had recruited 24 patients
(i.e. evidence that sites could recruit the expected one participant per month)
l to ensure that adequate progress was made with setting up other sites to recruit in order to have
12 sites set up (i.e. 50% of sites).
Phase 2 (months 10–27)
This phase of the internal pilot continued for a further 18 months and was reviewed at 6-monthly
intervals with the independent oversight committees. Patients were likely to have already suffered
from frozen shoulder for several months and received physiotherapy in primary care before their
referral to hospital. There was concern that this could have an impact on patient consent and adherence
to the ESP intervention, which were threats to both the feasibility and the validity of the trial. Evidence
from simulation work was that, with 80% power, a true treatment effect size of 0.2 or 0.4 and 30%
non-compliance, the power is reduced to 54%.61 In UK FROST, with a sample size that had 90% power
and effect sizes of around 0.3–0.4, 20–30% non-compliance in the ESP arm was expected to reduce the
power to between 60% and 70%. Therefore, if at the 24-month review, when 50% of the patients were
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expected to have been recruited, the non-compliance in the ESP arm was between 20% and 30%, the
oversight committees would advise on whether to continue with a three-arm trial or with the surgical
comparisons only. The following were also monitored:
l reasons for patient non-consent to participate in the trial, their treatment preferences and a
member of the trial team to informally discuss this with willing patients
l whether or not all 25 sites were set up and had recruited 250 patients (50% of our target)
l waiting times at sites from randomisation to intervention, with consideration of the need to replace
sites that were not meeting the waiting time targets agreed in the protocol (i.e. the surgical
procedure being performed within 18 weeks of randomisation).
Recruitment
Initial estimates for recruitment were based on Hospital Episode Statistics for NHS hospitals in England
in 2009/10 and 2010/11. These excluded post-trauma or secondary referrals from other specialties,
giving a stable rate of 210 per million patients treated for frozen shoulder. Assuming that 50% of frozen
shoulder patients presenting in secondary care met the inclusion criteria and 40% of these consented,
this left around 40 patients per million to be recruited into the trial. It was estimated that, to recruit
500 trial participants from trusts each serving catchment areas of around half a million people,
25 hospitals would be required to recruit for a minimum of 1 year. This assumed that there would be no
delays in set-up or problems at any subsequent time point, that all surgeons at the sites would be willing
to participate and that all potential participants would be screened for eligibility. Following the pilot
phase, the number of sites required was increased to ensure that recruitment was achieved to target.
Patients who had been referred for a frozen shoulder to an outpatient hospital clinic were identified by
the research nurse or assessing clinician. In the clinic, a designated individual within the shoulder team
(e.g. surgeon or physiotherapist) completed the study eligibility form (see Report Supplementary Material 8)
to confirm whether or not the patient was eligible and, when applicable, approached the patient about the
study. The research nurse then provided the patient with an information sheet (see Report Supplementary
Material 9) and answered any questions. The patient was able to consent at that time or they could take
up to 1 week to decide.When a patient consented (see Report Supplementary Material 10), he or she was
asked to complete the baseline form (see Report Supplementary Material 11). The research nurse completed
the consent status form (see Report Supplementary Material 12) to confirm the patient’s status.
When a patient did not consent, the research nurse recorded the reason and the treatment plan in
another section of the consent status form. The patient was also offered an optional patient preference
form (see Report Supplementary Material 13) to complete if they wanted to provide more information
about why they chose not to take part.
Training in recruitment was provided to hospital staff as part of the site initiation visit, and a trial site
manual was prepared that included guidance on consenting patients into the trial and how to answer
questions that might arise during consent-taking. In addition, a poster was provided to publicise the
trial to hospital staff and patients. During the trial, training and reminders were implemented using
regular e-mail bulletins and face-to-face meetings with principal investigators and research nurses,
with trial co-ordinators providing support and guidance to staff as required.
Randomisation
The randomisation sequence was based on a computer-generated randomisation algorithm provided
by a remote randomisation service (telephone or online access) at York Trials Unit, University
of York. The unit of randomisation was the individual patient, allocated to the trial interventions MUA,
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ACR and ESP in the ratio of 2 : 2 : 1, stratified by the presence of diabetes,62 using random blocks
sizes of 10 and 15. The research nurse used the remote randomisation service to register eligible and
consenting patients before computer generation of the allocation. This ensured treatment concealment
and immediate unbiased allocation.
The research nurse then informed the treating clinician and the patient of the treatment allocation.
Blinding
Given the nature of the trial treatments, comparing surgical and non-surgical treatment options, the
blinding of participants and clinicians to treatment allocation was not possible or desirable in this
pragmatic trial. Therefore, patients and clinicians were informed of the treatment allocation after
randomisation. The statistician was blind to treatment allocation until after data were hard locked
and no further changes could be made.
Statistical methods
Analyses were conducted for the three treatment comparisons of interest, ACR with ESP, MUA with
ESP, and ACR with MUA, according to the principle of intention to treat (ITT). All analyses were
conducted in Stata® version 15 (StataCorp LP, College Station, TX, USA) using two-sided statistical
significance at the 0.05 level. The statistical analyses plan was completed prior to completion of data
collection on 12 February 2019.
Trial progression
The characteristics (age, sex, diabetes, symptom duration, laterality and patient preferences) of ineligible
and non-consenting patients were compared with the randomised patient population. Reasons for
exclusion and non-consent were tabulated, including free-text entries summarised by the trial team.
The agreed treatment for excluded patients was tabulated. The flow of participants from eligibility
and randomisation to follow-up and analysis of the trial was presented in a Consolidated Standards of
Reporting Trials (CONSORT) flow diagram.
Baseline characteristics
All participant baseline characteristics were summarised descriptively by trial arm both for participants
‘as randomised’ and for those ‘as analysed’. The ‘as analysed’ population comprised all participants
included in the primary analysis (i.e. patients who had complete data for the baseline covariates and
outcome data for at least one post-randomisation time point). No formal statistical comparisons were
undertaken between arms. Continuous measures were summarised using numbers, mean, SD, median,
minimum and maximum, and categorical data were reported as counts and percentages.
Intervention delivery/fidelity
Details of the interventions as delivered were presented, including time to treatment, receipt of steroid
injections, and optimal or suboptimal release achieved during surgery, as well as number and content of
physiotherapy sessions. Fidelity was reported descriptively by trial arm, with baseline characteristics
tabulated for each arm. Reasons for not receiving randomised treatment, alternative treatments and any
further recorded treatments were tabulated by trial arm. Caseload by site and surgeon/physiotherapist
were reported descriptively. The grades/bands and experience of treating surgeons and physiotherapists
were presented.
Missing data
Item-level missing data for individual outcomes (OSS and QuickDASH) were managed according to the
instrument scoring guidance, and patterns of missing items were reported by trial arm. As the follow-up
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dates for the 6-month CRF and 6-month post-treatment CRF were in proximity for some participants,
OSS data from these CRFs were used as a substitute if data were available for one and missing for the
other, and if the two CRFs had been sent to the participant within 4 weeks (28 days). Missing baseline
covariates for the primary analysis were imputed for the purpose of the analysis if participants provided
follow-up data for at least one time point. Two participants with follow-up data had missing OSS baseline
scores. Using the QuickDASH as a proxy, their scores were imputed as the median OSS of any participants
with the same QuickDASH value.
Primary outcome (Oxford Shoulder Score) analysis
The OSS was summarised descriptively at each collected time point by trial arm, and mean scores and
confidence intervals (CIs) were illustrated graphically.
The primary analysis was conducted on an ITT basis, including patients in the treament arm to which
they were randomised. The primary analysis compared the OSS between treatment arms at 12 months.
The primary outcome, OSS, was analysed using a covariance pattern linear mixed model, including
assessments at all available time points with reference to the date of randomisation (3, 6 and 12 months,
thereby increasing power) and treating patients as a random effect. The model was adjusted for OSS at
baseline and included as further fixed effects: treatment arm, time, arm-by-time interaction, age, sex and
diabetes. Differences in local practice and expertise were accounted for by including recruitment site
as a random effect in the model. Given the low individual practitioner caseload (designated surgeon or
physiotherapist in the shoulder team) expected in this multicentre trial, surgeons or physiotherapists
were not specifically adjusted for.
For the modelling of repeated measurements, the best-fitting (based on Akaike information criterion
and Bayesian information criterion), simple (not significantly different from an unstructured pattern)
covariance pattern was selected. For all three treatment comparisons, the model provided estimates
at individual time points (the estimate at the 12-month time point served as the primary end point
for each of the three treatment comparisons), as well as an overall treatment effect over 12 months.
These are reported as mean differences between treatment arms, with 95% CIs and associated p-values.
Data were assumed missing at random (MAR). Model assumptions were checked, and, if they were in
doubt, the data were transformed prior to analysis or alternative non-parametric analysis methods
were explored.
Secondary analyses
Analysis adjusted for treatment compliance
To take account of an expected degree of participant non-compliance with the allocated treatment,
a secondary complier-average causal effect (CACE) analysis was carried out. This retains the initial
randomised assignments but overcomes the problems of a per-protocol analysis. Given the three active
treatments under investigation with different adherence criteria and the multiple alternative treatment
pathways for each participant, not all comparisons were suitable for CACE analysis. Therefore, only
compliance with ESP (minimum of eight ESP sessions or participant/physiotherapist satisfied with
progress) was assessed using instrumental variable regression, predicting OSS at the primary end point
at 12 months. The analysis adjusted for covariates of the primary analysis model. Assuming that the
same proportion of participants in the comparator arm would have adhered to the intervention if they
had been offered it (which should be achieved by way of randomisation), the group differences from this
model provided an estimate of the treatment effect among participants who adhered to the treatment.
Analysis adjusted for waiting times
A separate secondary ITT random intercept linear mixed-model analysis including pre-treatment OSS
and OSS 6 months from the start of treatment in addition to the 3- and 6-month post-randomisation
data was conducted, including the same covariates as the primary analysis. Time was included as a
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continuous variable in order to explicitly model participant trajectories over time using all available
data and thereby explore the influence of variable waiting times on the results of the study. Treatment
effect estimates and p-values were derived at 3, 6 and 12 months post randomisation.
Missing data
The extent and pattern of missing outcomes over time were explored by trial arm. Logistic regression
models were used to identify predictors of non-response and included all baseline data and primary
outcome assessments before any missing values as potential predictors. Any variables found to be
predictive of non-response were included in a repeat of the model specified for the primary analysis.
Analysis by multiple imputation was considered if missing data exceeded the planned level of attrition
(i.e. at least 20% of missing total OSS scores at 12 months).
Analysis using data close to intended follow-up points
If > 5% of all questionnaires were returned outside their intended time of follow-up [general follow-up:
on or after 6 weeks, i.e. after the telephone reminder; pre-treatment form (see Report Supplementary
Material 14); day of operation or the earlier of first day of physiotherapy or steroid injection], then
the primary analysis and analysis adjusted for waiting times were repeated with data from such
questionnaires excluded.
Analysis adjusting for baseline imbalances
The UK FROST DMEC observed an imbalance of employment status between randomised treatment
arms during the monitoring of the trial. On its recommendation, a binary variable of working status
(working vs. not working) was included as a covariate in the same model as the primary analysis if it
was found to be associated with the OSS outcome.
Subgroup analyses
To explore differences in treatment response for different participant populations, three planned
exploratory subgroup analyses were conducted: one exploring the influence of whether or not the
participant was diabetic (yes/no), one exploring whether or not the participant had been in previous
receipt of physiotherapy (yes/no) and one exploring patient treatment preferences as expressed at
baseline (allocated to preferred treatment/not allocated to preferred treatment/had no preference).
In addition, the TSC proposed a further subgroup analysis based on the duration of frozen shoulder
symptoms at baseline (using the median of less than/more than 9 months as the cut-off point). For
each analysis, a treatment-arm-by-subgroup interaction term was included in the primary analysis
model, and the p-value of the interaction term was reported along with descriptives of the primary
outcome for each subgroup–treatment arm pairing.
Analysis of secondary outcomes
QuickDASH, pain, extent of recovery
Continuous secondary outcomes were reported descriptively (unadjusted mean, SD, median, minimum
and maximum). ITT linear mixed models were conducted for each outcome, adjusting for the same
covariates as the primary analysis.
Pain or stiffness
As part of physiotherapy, the participant’s predominant problem, pain or stiffness, was recorded at
each session. Equal pain and stiffness was classified, managed and recorded as pain. The proportion of
each category at the first and last recorded physiotherapy session for each participant was presented
by treatment arm.
Complications/adverse events
Based on the overlap between recorded complications and AE data, these data sets were reviewed, and a
single list of serious and non-serious AEs was compiled to avoid duplication in reporting. These events
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were then summarised by type for each treatment arm. A logistic regression model was used to determine
treatment arm differences in having experienced at least one AE if the number of participants with one or
more events exceeded 10 in each arm. The same covariates as those used in the primary analysis were
adjusted for.
Other analyses
Treatment preferences
Patient and clinician treatment preferences were explored for non-consenting patients where this
information was provided.
Baseline patient preferences and expectations of randomised patients were explored descriptively by
trial arm as well as for patients who had and patients who had not received prior physiotherapy and
for patients who did and patients who did not receive their allocated intervention. Any change in
preferences was explored by tabulating participants’ preferences at the 12-month follow-up against
their baseline preferences and against their allocated treatment.
Oxford Shoulder Score change scores
Patients’ comparative shoulder assessment at 12 months (e.g. slightly better or much better) was
matched with their change in OSS between baseline and 12 months in order to explore the magnitude
of meaningful differences in the outcome in the study population.
Oxford Shoulder Score subdomains
Exploratory and confirmatory factor analysis of OSS from a population of patients with rotator cuff
tears in the UKUFF trial63 identified reliable OSS subdomains of pain (items 1, 8, 11 and 12) and function
(items 2, 3, 4, 5, 6, 7, 9 and 10). To further explore the nature of shoulder outcomes, descriptive statistics
and associated graphs were presented for OSS subdomains of pain and function by treatment arm at
each time point.
Outcomes for participants receiving no treatment
The OSS and QuickDASH scores were summarised descriptively at baseline and at all follow-up points
for participants who did and participants who did not receive any treatment as indicated on their change
in status form (see Report Supplementary Material 15). Where available, the average time to the decision
of no treatment was reported for this group.
Update of systematic review
To place the trial findings in the context of current evidence, the HTA systematic review about the
management of frozen shoulder was updated.13 MEDLINE/PreMEDLINE, CENTRAL, EMBASE, PEDro,
Science Citation Index, Clinicaltrials.gov and WHO International Clinical Trials Registry were searched
from January 2010 to December 2018 and studies reported prior to 2010 obtained from our previous
HTA review. The updated review focused only on evidence from RCTs and the interventions and
outcomes collected in UK FROST. Hydrodilatation, however, was also included, as its popularity has
increased since a survey was undertaken to inform the design of UK FROST.22 Moreover, during
the qualitative interviews with health-care professionals in the nested study, some surgeons and
physiotherapists commented that hydrodilatation could have been a treatment option in the trial.
The review protocol has been registered (PROSPERO CRD42019122999).
Data management
A central database at York Trials Unit was used to manage data collection, including the sending
and return of participant questionnaires (see Report Supplementary Material 16) and hospital CRFs.
This included automated e-mail reminders to participating sites to help ensure the timely return of
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hospital CRFs. Participant questionnaires and hospital CRFs were designed using TeleForm software
(version 10; Cardiff Software, Cambridge, UK) and marked up with variable names and appropriate
scoring. To maximise data quality, when hospital CRFs were returned to York Trials Unit the key
variables required for the statistical analysis and checking adherence in the delivery of the treatments
were reviewed for completion and accuracy by a research data administrator, who resolved any queries
with the research nurse at the site. The hospital site was reimbursed for the completion of all CRFs
up to a maximum value of £124.00. This was agreed by the trust and trial sponsor using a clinical
trial agreement during the site set-up. No checks of the quality of data in the postal questionnaires
were made on return of the questionnaires to York Trials Unit, although a trial co-ordinator checked
whether the participant had given extreme responses to the last EQ-5D-5L question and/or given a
free-text response that indicated they could be at harm. When either of these occurred, the principal
investigator, research nurse and chief investigator were notified by e-mail. After this initial check,
all postal questionnaires and hospital CRFs passed through a process of scanning in the TeleForm
software, second checking and validating against predetermined rules.
Active and systematic follow-up of all randomised participants by post included pre-notification
reminders, 2- and 4-week letter reminders and the option to complete an abridged questionnaire
(a minimum of the OSS and EQ-5D) over the telephone after 6 weeks. At 12 months, the primary end
point, an unconditional incentive of £5 was included. If the patient agreed at the time of consent, text
messages were sent on the day the participant was sent the postal questionnaire64 and newsletters
were circulated to trial participants.65 Trial participants could withdraw entirely from the study at
any time for any reason, but any data collected up to that point were included in the analysis. The
participant could agree to being withdrawn from only postal questionnaire collection or from only
hospital CRF collection.
Essential trial documentation were kept with the trial master file and investigator site files, allowing
the conduct of the trial and quality of the data produced to be evaluated. The documentation will be
retained for a minimum of 5 years after the conclusion of the trial. The postal questionnaires and
hospital CRFs will be stored for a minimum of 5 years after the conclusion of the trial as paper
records, and for a minimum of 20 years in electronic format.
Adverse event management
All AEs and SAEs were recorded by the site principal investigator or delegated clinician and returned
to the trial office on a CRF (see Report Supplementary Materials 17 and 18). In accordance with good
clinical practice, SAEs were reported within 24 hours and AEs were reported within 5 days of the
investigator becoming aware.
Once this information was received, the chief investigator determined causality and expectedness.
The Research Ethics Committee was notified of SAEs that were unexpected and related to the trial
within 15 days for a non-life-threatening event and within 7 days for a life-threatening event. For
non-serious AEs, the central office was notified within 5 days of the event being known. All AEs and
SAEs were reported to the DMEC, TSC and TMG. Expected AEs for this shoulder condition included
infection; bleeding; delayed wound healing; conversion of a planned day-case procedure to an overnight
stay for control of pain; post-procedural worsening of shoulder pain; injury to adjacent structures such
as nerve, tendon, bone or joint; recurrent stiffness requiring further treatment; transient hyperglycaemia,
steroid flare or joint sepsis following corticosteroid injection; and injuries related to the heating or cooling
of tissues. The chief investigator reviewed follow-up reports 1 month later (see Report Supplementary
Material 19) to ensure that adequate action had been taken and progress had been made.
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Ethics approval and monitoring
Ethics committee approval and any changes to the project protocol
National Research Ethics Service Committee North East – Newcastle and North Tyneside 2 approved
the study on 18 November 2014 (Research Ethics Committee reference 14/NE/1176). Health Research
Authority approval for the study with an existing UK-wide review was granted on 15 June 2016.
A summary of the changes made to the protocol since the original Research Ethics Committee
approval is in Appendix 2.
Trial Management Group
The day-to-day management of the trial was overseen by the TMG, which met quarterly. A
representative of the sponsor attended when available. These meetings monitored progress with
recruitment (e.g. enrolment, consent, eligibility), allocation to study groups, adherence of the trial
interventions to the protocol, retention of trial participants, monitoring of AEs/SAEs and reasons
for participant withdrawal. The review of progress was undertaken at a participating site level and,
as necessary, feedback was given to the principal investigator and research nurses at each site.
Trial Steering Committee
A TSC was appointed by the funding body to provide overall supervision of the trial and to advise on
its continuation. The membership of the TSC is listed in the Acknowledgements.
Data Monitoring and Ethics Committee
The DMEC was appointed by the funding body and had access to the unblinded comparative data
as provided by a statistician at York Trials Unit who was independent of the trial team. The DMEC
monitored the data and made any recommendations about (dis)continuation of the trial to the
independent TSC. The membership of the DMEC is listed in the Acknowledgements.
Patient and public involvement
Two patients who had previously received treatment for frozen shoulder at the lead site (James Cook
University Hospital) and the independent patient representative member of the TSC were invited to
comment on the patient information leaflet, the patient-facing data collection forms and the consent
process for trial participation. The need to develop a leaflet to provide general information about
frozen shoulder was identified following a qualitative study of patients with frozen shoulder using
semistructured interviews.18 The two patient representatives were invited to attend the TMG during
the early stages of the study and it was later agreed to seek their opinion outside the meetings when
necessary. Recruitment was steady and the target was met on time. The retention of participants
also went well and the target was exceeded. Therefore, there was little further contact with the
two patient representatives during the trial, although they did advise on the newsletters to be
sent to trial participants.
Following the initial analyses of the study results, we sought the advice of the two patient
representatives and a wider group of seven patients with frozen shoulder at the lead site. Study
results, associated risks for individual trial treatments and their health economic impact were
discussed. Members shared their thoughts on their preferred choice of treatment based on the study
results and agreed to support the trial team with dissemination to various platforms. This included
contributing to the Plain English summary of this report, journal publications and web-based outputs,
such as updating the entry about management of frozen shoulder on Wikipedia and helping to develop
content for other appropriate web pages. These patients will also meet with local (shoulder research
users group) and national shoulder patient groups (British Elbow and Soulder Society patient liaison
group) to ensure that the current evidence base for treatment options is available and disseminated
appropriately to patients and the wider public.
DOI: 10.3310/hta24710 Health Technology Assessment 2020 Vol. 24 No. 71
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Brealey et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
17

Chapter 3 Trial results
This chapter begins with a summary of the findings of the internal pilot study and the nested shouldercapsular tissue and blood samples study. It then summarises recruitment, the flow of participants
through the trial, the characteristics of participants at baseline and the results of analyses of the primary
and secondary outcomes, as well as the integration of the findings into the existing literature.
Summary findings of the internal pilot
The objective of phase 1 of the internal pilot (months 4–9) was to have a minimum of four sites
recruiting during the 6 months that had recruited 24 patients (i.e. evidence that they could recruit the
expected one participant per month). To ensure that adequate progress had been made with setting up
sites to recruit, 12 sites were to be set up (i.e. 50% of the total sites). At the end of month 9, we had
recruited 20 patients (i.e. 83% of the target). This was in spite of not starting recruitment until month 7
and having only three of the four pilot sites set up. There were, however, two sites at which we were
waiting on approval, and 16 out of 26 sites with which we had held a preliminary meeting.
We also reviewed other aspects of the study. In summary, of the 34 patients who had a clinically
confirmed frozen shoulder, four met the exclusion criteria, 10 did not consent and 20 consented.
Early data showed that treatment preference was the reason for all non-consent, rather than patients
being too busy or not wanting to be involved in research. The time taken to consent ranged from
15 minutes to 1 hour. Participating sites had confirmed that they had received sufficient training
and supporting documentation. Except at one of the four pilot sites, all surgeons were supportive of
the study. At this one site, one surgeon was taking part, another surgeon felt that he did not see a
sufficient number of patients to take part, and a third surgeon lacked equipoise to consent patients.
All three surgeons, however, had agreed to deliver the surgical interventions to which patients were
allocated. No patient non-compliance with treatment had yet been reported.
Although we had not met our patient recruitment or site set-up targets, both oversight committees
were satisfied with the overall progress made during phase 1.
The primary objective of phase 2 was to review the feasibility of the ESP intervention and whether
non-compliance in the ESP arm did not exceed 20–30%. At the end of this phase (month 27), of the
65 trial participants who had been allocated to ESP, 37 had ended their treatment and could be assessed
for non-compliance. The remaining 28 participants either had started their treatment or were waiting to
start treatment. Of the 37 participants who had ended their treatment, 29 (78%) met our criteria for
completing the intervention as had been agreed with the trial team and independent committees: the
participant had attended eight sessions or more (n = 19); or had attended fewer than eight sessions
but both the participant and the physiotherapist were satisfied with their progress (n = 9); or had
attended fewer than eight sessions and declined to attend more because they were satisfied with their
progress, their ability to manage independently, or both (n = 1). Therefore, non-compliance with the ESP
intervention applied to 22% of participants, which was within the threshold of 20–30%. The oversight
committees agreed that this was an acceptable degree of non-compliance and that the trial should
continue with all three treatment arms.
Another aspect of trial feasibility that was reviewed at month 27 was non-consent into the trial.
This was because there was concern that patients would often have already received physiotherapy
in primary care and that this could affect their decision to take part in the trial, given that the ESP
intervention was one of the treatment options. It was found that 55% (n = 72) of the 131 reasons
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for patients not taking part was because they either ‘want surgery’ or ‘do not want physiotherapy’.
This compared with 18% (n = 24) of patients who ‘want physiotherapy’ or ‘do not want surgery’.
Other reasons for non-consent were infrequent. The main treatment that non-consenting patients
went on to have was keyhole surgery (45%, n = 67). Of patients randomised into the trial, the majority
had no treatment preference (53%, n = 159), over one-third preferred surgery (39%, n = 116) and the
rest preferred physiotherapy (8%, n = 25). Despite the preferences for surgery, this did not have an
impact on the feasibility of the trial, with 36 sites set up, compared with the target of 25 sites, and
325 participants recruited against the target of 250 participants. We also reviewed the timing of the
delivery of interventions, which confirmed that only one site had regularly failed to deliver surgery on
time because of local pressures. The local trial team and principal investigator were very engaged and
responsive to the trial team’s concerns and prioritised the trial participants for the surgical procedures.
In short, UK FROST was being delivered on time and to target, with an acceptable degree of non-
compliance with the ESP intervention. The oversight committees were satisfied with the progress of all
aspects of the trial and for it to continue as planned.
Summary findings of the shoulder capsule tissue and blood samples study
The primary aim of this nested study was to determine the key molecular processes and changes seen in
the shoulder capsular tissue of patients with frozen shoulder in order to better understand these processes;
and to determine the relationship between tissue changes, serum biomarkers and clinical symptoms and
signs at presentation. This was done by determining the molecular and cellular abnormalities in shoulder
capsular tissue obtained during surgery, by determining serum protein and cytokine signatures, and by
correlating any tissue and serum abnormalities detected with the clinical presentation.
Following research ethics approval from the Oxford Musculoskeletal Biobank (09/H0606/11)
and National Research Ethics Service Committee Newcastle and North Tyneside (14/NE/1176),
appropriate informed consent was sought from UK FROST participants randomised to receive the
ACR intervention. For a small sample of 16 patients who consented to the study, the shoulder capsular
tissue and a venous blood sample were collected. The findings from the analysis of the capsular tissue
samples were then compared with data available in the Oxford Tissue Biobank of findings from both
healthy and diseased rotator cuff tendon tissues.
Inflammation signatures differed between tissue from frozen shoulder and that from tendon tears.
Compared with tendon tear tissue, frozen shoulder capsular tissue showed reduced expression of
nuclear factor-κB response genes, including TNFA, IL6 and IL8, and increased expression of IL10,
CD14, CD163 and C1QA messenger RNA. The fibroblast activation markers podoplanin (PDPN),
CD106 (VCAM1) and CD248 and the fibroblast activation protein were highly expressed in adhesive
capsulitis and torn tendons, compared with healthy tendons. However, fibroblast activation marker
CD90 was significantly reduced in adhesive capsulitis compared with healthy and diseased tendon
tissue. Proresolving receptors mediating resolution of inflammation, including ALX/FPR2, CMKLR1
and GPR32, were highly expressed in frozen shoulder capsular tissue.37
This study in patients of a similar age has provided some insight into why inflammation ultimately
resolves in frozen shoulder but persists in tendon tears. This study suggests that the phenotypes of
fibroblast subsets populating diseased shoulder tissues differ between conditions with self-limiting and
and those with persistent inflammation. CD90 therefore represents an important pathogenic marker
and possible molecular checkpoint regulating persistent stroma-mediated inflammation in common soft
tissue diseases of the shoulder. Proresolving proteins were highly expressed in frozen shoulder tissue
compared with established shoulder tendon tears. These findings have provided a novel insight into the
disease mechanism of frozen shoulder, which points towards a resolving inflammatory environment.
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Further studies to better understand the biological mechanisms governing successful resolution of
inflammation should inform new therapeutic strategies to accelerate disease resolution in frozen shoulder.
Recruitment into UK FROST
A total of 37 sites screened patients for the UK FROST trial, of which 35 randomised at least one
patient. Appendix 3 presents the number of patients screened and randomised at each site, as well as
the number of participants who withdrew before the end of the study.
Flow of participants
The flow of participants from screening to randomisation, treatment, follow-up and analysis is illustrated
in the CONSORT flow diagram (Figure 2). Of 914 screened patients, 503 were randomised into the
UK FROST trial. The reasons for exclusion were not meeting eligibility criteria (n = 95), non-consent
(n = 295) and other reasons (n = 21). The most frequent reason for exclusion was having frozen shoulder
symptoms secondary to trauma that required hospital care. Most patients who provided information
about why they were not willing to join the trial said that this was because they had already had
physiotherapy and wanted to have surgery (Table 1).
Treatment allocations were 2 : 2 : 1 to MUA with steroid injection (n = 201), ACR with MUA (n = 203),
and ESP with steroid injection (n = 99). Follow-up rates at 3, 6 and 12 months post randomisation were
between 85% and 89%, above the target of 80% assumed in the sample size and with no evidence of
differential dropout in any of the treatment arms. The primary analysis at 12-month follow-up included
all participants with OSS outcome data at one or more follow-ups, and therefore 94% of participants
could be included in the analysis.
Baseline characteristics
Eligible patients who did and eligible patients who did not consent to participate in the trial were
comparable in their baseline characteristics (Table 2). The demographic and clinical characteristics of
participants at baseline are presented in Table 3, comparing the profile of the total patients randomised
(n = 503) with that of participants included in the primary analysis (n = 473). No systematic differences
between the two populations were evident. The characteristics of patients in the three randomised
arms were broadly similar, with the exception of a greater number of participants in the MUA arm
being currently in paid work and some group imbalance in having had a similar shoulder problem on
the opposite side to the reference shoulder.
Intervention delivery
The criteria for having completed each of the three trial interventions were agreed and documented in
the statistical analysis plan. For MUA and ACR, this was the completed surgical procedure, regardless
of the completion of any PPP. In the ESP arm, completion of the intervention was defined as receipt of
a minimum of eight physiotherapy sessions, unless the patient was discharged as satisfied with their
progress earlier.
Table 4 shows that 82% of patients completed MUA, 80% of patients completed ACR and 81% of
patients completed ESP. Overall, 16 participants (3%) crossed over to a different trial treatment, and
17 (3%) received an alternative non-trial treatment. Participants who did not start or complete any
trial or non-trial treatment were classed as ‘no treatment recorded’ (n = 64, 13%).
DOI: 10.3310/hta24710 Health Technology Assessment 2020 Vol. 24 No. 71
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Brealey et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
21
Randomised to MUA
(n = 201)
33 sites
(median of 4 patients per site, IQR 3–9 patients)
Randomised to ACR with MUA
(n = 203)
33 sites
(median of 5 patients per site, IQR 2–8 patients)
Assessed for eligibility
(n = 914)Enrolment
Excluded
(n = 411)
Randomised
(n = 503)
Randomised to ESP
(n = 99)
30 sites
(median of 2 patients per site, IQR 2–4 patients)
• Surgeons (median of 2 patients
    per surgeon, IQR 1–3), n = 64
• Physiotherapists (median of 1 patient
    per physiotherapist, IQR 1–2 patients;
    median of 8 physiotherapy sessions
    per patient, IQR 5–11 sessions), n = 175
• Surgeons (median of 2 patients
    per surgeon, IQR 1–3 patients), n = 58
• Physiotherapists (median of 1 patient
    per physiotherapist, IQR 1–2 patients; 
    median of 7 physiotherapy sessions
    per patient, IQR 4–11 sessions), n = 148
• Physiotherapists (median of 1 patient
    per physiotherapist, IQR 1–2  patients;
    median of 9 physiotherapy sessions
    per patient, IQR 6–12 sessions), n = 78
Follow-up at 3 months
• Completed, n = 178
• Withdrawn, n = 3
• Non-return, n = 19
• Returned but missing OSS, n = 1
Follow-up at 6 months
• Completed, n = 177
• Withdrawn, n = 7
• Non-return, n = 14
• Returned but missing OSS, n = 3
Follow-up at 12 months
• Completed, n = 183
• Withdrawn, n = 7
• Non-return, n = 11
• Returned but missing OSS, n = 0
Follow-up at 3 months
• Completed, n = 90
• Withdrawn, n = 1
• Non-return, n = 8
• Returned but missing OSS, n = 0
Follow-up at 6 months
• Completed, n = 83
• Withdrawn, n = 2
• Non-return, n = 14
• Returned but missing OSS, n = 0
Follow-up at 12 months
• Completed, n = 88
• Withdrawn, n = 2
• Non-return, n = 8
• Returned but missing OSS, n = 1
Follow-up at 3 months
• Completed, n = 179
• Withdrawn, n = 4
• Non-return, n = 20
• Returned but missing OSS, n = 0
Follow-up at 6 months
• Completed, n = 170
• Withdrawn, n = 6
• Non-return, n = 23
• Returned but missing OSS, n = 4
Follow-up at 12 months
• Completed, n = 175
• Withdrawn, n = 10
• Non-return, n = 15
• Returned but missing OSS, n = 3
Analysed
(n = 189)
Excluded from analysis
(n = 12)
Reason: no OSS data at any follow-up
Analysed
(n = 191)
Excluded from analysis
(n = 12)
Reason: no OSS data at any follow-up
Analysed
(n = 93)
Excluded from analysis
(n = 6)
Reason: no OSS data at any follow-up
Allocation
Treatment
Follow-up
Analysis
Did not meet eligibility criteria, n = 95
• Bilateral concurrent frozen shoulder, n = 20
• Secondary to trauma or other causes, n = 23
• Trial treatments contraindicated, n = 16
• Unfit for general anaesthesia, n = 16
• Not resident in catchment area of a
    participant trial site, n = 20
• Lacked mental capacity to comply with
    treatment or data collection, n = 5
Other reason for exclusion, n = 21
Declined to participate, n = 295
Received allocated treatment
(n = 164)
Received allocated treatment
(n = 162)
Received allocated treatment
(n = 80)
Reasons:
• Symptoms improved, n = 9
• Not fit for surgery, n = 5
• Started alternative treatment, n = 4
• Change of diagnosis, n = 2
• Did not want any trial treatment, n = 1
• Reason unknown, n = 16
Crossovers:
• ESP, n = 4
Alternative treatment recorded:
• Other physiotherapy, n = 5
• ACR without MUA, n = 1
• Subacromial decompression, n = 1
• Steroid injection, n = 1
Did not receive allocated treatment
(n = 37)
Reasons:
• Symptoms improved, n = 7
• Not fit for surgery, n = 5
• Another problem intervened, n = 4
• Change of diagnosis, n = 2
• Administrative error, n = 2
• Did not want any trial treatment, n = 1
• Unable to follow protocol, n = 1
• Reason unknown, n = 19
Crossovers:
• MUA, n = 3
• ESP, n = 2
Alternative treatment recorded:
• Other physiotherapy, n = 4
• Steroid injection, n = 2
• ACR without MUA, n = 1
Did not receive allocated treatment
(n = 41)
Did not receive allocated treatment
(n = 19)
Reasons:
Did not start ESP:
• Patient wanted surgery, n = 1
• Reason unknown, n = 6
Did not complete ESP:
• Not satisfied with progress, n = 7
• Another problem intervened, n = 1
• Stopped attending, no reason, n = 4
Crossovers:
• ACR with MUA, n = 7
Alternative treatment recorded:
• Hydrodilatation and other
    physiotherapy, n = 1
• Steroid injection, n = 1
FIGURE 2 The CONSORT flow diagram. IQR, interquartile range.
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TABLE 1 Reasons for exclusion
Reason
Number
excluded
Per cent of total
excluded (N= 411)
Trial exclusion criteria (n = 116; more than one reason possible)
Bilateral concurrent frozen shoulder 20 4.9
Frozen shoulder secondary to trauma (i.e. trauma to the shoulder that required
hospital care, e.g. fracture, dislocation, rotator cuff tear)
23 5.6
Frozen shoulder secondary to other causes (e.g. recent breast surgery
or radiotherapy)
16 3.9
Any of the trial treatments are contraindicated (e.g. patient is unfit for
anaesthesia or corticosteroid)
16 3.9
Not resident in a catchment area of a participating site 20 4.9
Lacks mental capacity and unable to understand the trial or instructions
for treatment
5 1.2
Other reason 21 5.1
Patient non-consent (n = 295; grouped free-text information from screening form)
Wanted surgery 79 19.2
Did not want surgery 40 9.7
Wanted physiotherapy 22 5.4
Did not want physiotherapy 48 11.7
Wanted steroid injection 2 0.5
Wanted clinician to decide 3 0.7
Wanted no further treatment 2 0.5
Could not travel to trial site 1 0.2
Was too busy to take part 7 1.7
Too many questionnaires 1 0.2
Did not want to take part 29 7.1
Unclear/no reason given 61 14.8
Patient non-consent (n = 295; selection of possible reasons from list of preference form if agreed to complete,
more than one reason possible)
I wanted the treating clinician to make a decision for me 13 3.2
I have already had physiotherapy 84 20.4
I do not want physiotherapy 38 9.2
I do not want surgery 36 8.8
I do want physiotherapy 28 6.8
I do want surgery 75 18.2
I am too busy to take part in research 10 2.4
I do not want to be involved in research 6 1.5
I thought there were too many questionnaires to complete 1 0.2
I just did not want to take part 10 2.4
Other 29 7.1
Did not agree to complete preference form 109 26.5
DOI: 10.3310/hta24710 Health Technology Assessment 2020 Vol. 24 No. 71
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Brealey et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
23
TABLE 2 Baseline characteristics of different populations
Characteristic Eligible but non-consenting (N= 295) Eligible and randomised (N= 503)
Sex, n (%)
Female 200 (68) 319 (63)
Age (years)
n 293 503
Mean (SD) 53.7 (8.0) 54.3 (7.7)
Median (minimum, maximum) 53 (32, 82) 54 (30, 77)
Diabetic, n (%)
No 219 (74) 353 (70)
Type 1 23 (8) 29 (6)
Type 2 51 (17) 121 (24)
Missing 2 (1) 0 (0)
Affected shoulder, n (%)
Left 181 (61) 304 (60)
Right 110 (37) 196 (39)
Missing 4 (1) 3 (1)
Duration of symptoms (months)
n 288 495
Mean (SD) 10.5 (7.0) 10.9 (9.2)
Median (IQR) 9 (6–12) 8 (6–12)
Minimum, maximum 1, 48 0, 96
Duration of symptoms (grouped), n (%)
< 9 months 135 (46) 249 (50)
≥ 9 months 153 (52) 246 (49)
Missing 7 (2) 8 (2)
IQR, interquartile range.
TABLE 3 Baseline characteristics of randomised participants
Characteristic
As randomised (N= 503) As analysed (N= 473)
MUA ACR ESP MUA ACR ESP
Sex, n (%)
Female 129 (64) 126 (62) 64 (65) 121 (64) 117 (61) 62 (67)
Age (years)
n 201 203 99 189 191 93
Mean (SD) 54.5 (7.7) 53.9 (7.7) 54.5 (7.8) 54.4 (7.3) 54.4 (7.6) 54.8 (7.8)
Median (minimum, maximum) 54 (30, 75) 54 (33, 76) 53 (39, 77) 54 (30, 75) 55 (33, 76) 53 (39, 77)
Diabetic, n (%)
No 141 (70) 143 (70) 69 (70) 131 (69) 135 (71) 66 (71)
Type 1 12 (6) 12 (6) 5 (5) 12 (6) 11 (6) 5 (5)
Type 2 48 (24) 48 (24) 25 (25) 46 (24) 45 (24) 22 (24)
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TABLE 3 Baseline characteristics of randomised participants (continued )
Characteristic
As randomised (N= 503) As analysed (N= 473)
MUA ACR ESP MUA ACR ESP
Affected shoulder, n (%)
Left 127 (63) 121 (60) 56 (57) 119 (63) 114 (60) 54 (58)
Right 73 (36) 80 (39) 43 (43) 69 (37) 75 (39) 39 (42)
Missing 1 (1) 2 (1) 0 (0) 1 (1) 2 (1) 0 (0)
Duration of symptoms (months)
n 196 201 98 185 190 92
Mean (SD) 10.5 (8.6) 11.3 (10.0) 10.8 (8.8) 10.7 (8.7) 11.3 (10.1) 11.0 (9.0)
Median (IQR) 8 (6–12) 9 (6–12) 8 (6–12) 8 (6–12) 9 (6–12) 8 (6–12)
Minimum, maximum 2, 60 0, 96 2, 72 2, 60 2, 96 2, 72
Duration of symptoms (grouped), n (%)
< 9 months 103 (51) 95 (47) 51 (52) 96 (51) 90 (47) 48 (52)
≥ 9 months 93 (46) 106 (52) 47 (47) 89 (47) 100 (52) 44 (47)
Missing 5 (2) 2 (1) 1 (1) 4 (2) 1 (1) 1 (1)
Radiographs, n (%)
Anteroposterior view 200 (100) 201 (99) 99 (100) 188 (99) 190 (99) 93 (100)
Axillary view 174 (87) 179 (88) 86 (87) 163 (86) 169 (88) 80 (86)
Modified axillary 29 (14) 24 (12) 14 (14) 27 (14) 24 (13) 14 (15)
Ethnicity summary, n (%)
White British 187 (93) 185 (91) 84 (85) 176 (93% 175 (92) 80 (86)
Other 13 (6) 17 (8) 15 (15) 12 (6) 15 (8) 13 (14)
Missing 1 (0.5) 1 (0.5) 0 (0) 1 (0.5) 1 (0.5) 0 (0)
Education, n (%)
Left school before 16 years old 33 (16) 28 (14) 15 (15) 31 (16) 26 (14) 14 (15)
Left school at 16 years old 75 (37) 74 (37) 37 (37) 70 (37) 71 (37) 34 (37)
Left education at 18 years old 27 (13) 28 (14) 14 (14) 25 (13) 26 (14) 12 (13)
Degree-level education 28 (14) 36 (18) 18 (18) 27 (14) 33 (18) 18 (19)
Other vocational/work-related
qualifications
23 (11) 19 (9) 6 (6) 22 (12) 18 (9) 6 (6)
Other 11 (5) 16 (8) 9 (9) 11 (6) 15 (8) 9 (10)
Missing 4 (2) 2 (1) 0 (0) 3 (2) 2 (1) 0 (0)
Employment status summary, n (%)
In paid work 129 (64) 118 (58) 53 (54) 124 (66) 111 (58) 50 (54)
Not in paid work 69 (34) 82 (40) 46 (46) 62 (33) 78 (41) 43 (46)
Missing 3 (1) 3 (1) 0 (0) 3 (2) 2 (1) 0 (0)
continued
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TABLE 3 Baseline characteristics of randomised participants (continued )
Characteristic
As randomised (N= 503) As analysed (N= 473)
MUA ACR ESP MUA ACR ESP
Type of employment, n (%)
Unskilled manual 17 (8) 15 (7) 8 (8) 16 (8) 13 (7) 7 (8)
Skilled manual 21 (10) 18 (9) 18 (18) 19 (10) 16 (8) 17 (18)
Unskilled non-manual 19 (9) 17 (8) 4 (4) 19 (10) 17 (9) 4 (4)
Skilled non-manual 41 (20) 37 (18) 13 (13) 40 (21) 37 (19) 12 (13)
Professional 13 (6) 19 (9) 10 (10) 13 (7) 18 (9) 10 (11)
Other 20 (10) 17 (8) 10 (10) 18 (10) 15 (8) 10 (11)
Currently taking steroids for affected shoulder, n (%)
Yes 2 (1) 7 (3) 0 (0) 2 (1) 7 (4) 0 (0)
No 196 (98) 195 (96) 99 (100) 184 (97) 183 (96) 93 (100)
Missing 3 (1) 1 (< 0.5) 0 (0) 3 (2) 1 (1) 0 (0)
Had steroid injection for affected shoulder, n (%)
Yes 97 (48) 117 (58) 55 (56) 93 (49) 112 (59) 53 (57)
No 102 (51) 86 (42) 44 (44) 94 (50) 79 (41) 40 (43)
Missing 2 (1) 0 (0) 0 (0) 2 (1) 0 (0) 0 (0)
If yes
Number of injections, median
(IQR)
1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2)
Weeks since last injection,
median (IQR)
12 (8–24) 12 (6–20) 10 (6–20) 12 (8–24) 12 (6–20) 10 (6–20)
Delivered by GP, n (%) 59 (29) 74 (36) 36 (36) 56 (30) 72 (38) 35 (38)
Delivered by physiotherapist,
n (%)
26 (13) 27 (13) 11 (11) 26 (14) 25 (13) 11 (12)
Other delivery, n (%) 5 (2) 6 (3) 4 (4) 4 (2) 5 (3) 4 (4)
Previous physiotherapy for affected shoulder, n (%)
Yes 125 (62) 124 (61) 59 (60) 117 (62) 117 (61) 58 (62)
No 76 (38) 77 (38) 39 (39) 72 (38) 73 (38) 35 (38)
Missing 0 (0) 2 (1) 1 (1) 0 (0) 1 (1) 0 (0)
If yes
General practice 31 (15) 25 (12) 13 (13) 28 (15) 23 (12) 13 (14)
Hospital 60 (30) 58 (29) 30 (30) 56 (30) 54 (28) 29 (31)
Home 6 (3) 5 (2) 2 (2) 6 (3) 5 (3) 2 (2)
Other 22 (11) 35 (17) 15 (15) 21 (11) 33 (17) 14 (15)
Number of physiotherapy
sessions, median (IQR)
5 (3–8) 5 (3–6) 4 (2–6) 5 (3–8) 5 (3–6) 4 (2.5–6)
Number of weeks had
physiotherapy, median (IQR)
6 (4–12) 6 (4–12) 7.5 (5–10) 6 (4–12) 6 (4–12) 7.5 (5–10)
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TABLE 3 Baseline characteristics of randomised participants (continued )
Characteristic
As randomised (N= 503) As analysed (N= 473)
MUA ACR ESP MUA ACR ESP
Dominant arm affected, n (%)
Yes 81 (40) 82 (40) 39 (39) 77 (41) 76 (40) 36 (39)
No 115 (57) 120 (59) 59 (60) 107 (57) 114 (60) 56 (60)
Ambidextrous 0 (0) 1 (< 0.5) 0 (0) 0 (0) 1 (1) 0 (0)
Missing 5 (2) 0 (0) 1 (1) 5 (3) 0 (0) 1 (1)
Number of weeks had shoulder
problem, median (IQR)
32 (24–52) 35 (24–52) 32 (24–48) 34 (24–52) 35.5 (24–52) 32 (24–48)
Similar shoulder problem on the same side, n (%)
Yes 19 (9) 26 (13) 12 (12) 17 (9) 24 (13) 12 (13)
No 178 (8) 177 (87) 87 (88) 168 (89) 167 (87) 81 (87)
Missing 4 (2) 0 (0) 0 (0) 4 (2) 0 (0) 0 (0)
Similar shoulder problem on the opposite side, n (%)
Yes 62 (31) 53 (26) 13 (13) 59 (31) 51 (27) 12 (13)
No 132 (66) 146 (72) 85 (86) 124 (66) 136 (71) 80 (86)
Missing 7 (3) 4 (2) 1 (1) 6 (3) 4 (2) 1 (1)
OSS (0–48)
n 200 202 99 188 190 93
Mean (SD) 20.5 (8.9) 19.1 (7.7) 20.3 (8.0) 20.6 (8.9) 19.2 (7.5) 20.3 (8.1)
Median 20 19 20 20 19 20
Minimum, maximum 2, 48 1, 37 2, 42 2, 48 1, 37 2, 42
QuickDASH (0–100)
n 192 197 96 181 187 90
Mean (SD) 57.0 (21.0) 61.7 (18.5) 59.4 (19.7) 56.8 (21.1) 61.3 (18.5) 59.1 (20.0)
Median 59 64 60 59 64 59.5
Minimum, maximum 0, 100 14, 100 14, 98 0, 100 14, 100 14, 98
Numeric Rating Scale for Pain (0–10)
n 199 201 99 187 190 93
Mean (SD) 6.8 (2.2) 7.0 (1.9) 6.9 (2.4) 6.7 (2.3) 7.0 (1.9) 6.8 (2.4)
Median 7 7 7 7 7 7
Minimum, maximum 0, 10 0, 10 0, 10 0, 10 0, 10 0, 10
Symptom severity (0–100)
n 198 201 99 186 189 93
Mean (SD) 83.8 (21.8) 86.2 (20.1) 89.2 (15.4) 83.9 (22.1) 86.0 (20.4) 89.0 (15.5)
Median 90 95 100 90 95 100
Minimum, maximum 0, 100 0, 100 50, 100 0, 100 0, 100 50, 100
IQR, interquartile range.
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The profile of surgeons and physiotherapists treating patients who completed their randomised intervention
is presented in Appendix 4. Based on the available data, operating surgeons were predominantly consultants
who had experience of routinely performing the trial operations up to once per month. Physiotherapists
delivering ESP or PPP were most frequently band 6, treating between two and three frozen shoulders
per month.
Waiting times to the start of each randomised intervention varied considerably. Table 5 shows that
ESP patients received their first physiotherapy session or steroid injection within a median of 14 days,
whereas patients waited a median of 56.5 days for MUA and a median of 71.5 days for ACR. Seventy
patients in the ESP arm received a steroid injection on average within 12.8 days of randomisation.
Nearly half (46%, n = 32) of these injections were administered on the day of randomisation.
Following completion of their randomised treatment, a number of patients received further treatment, as
detailed in Table 6. Most commonly, this was ACR for patients randomised to MUA and further physiotherapy
for patients randomised to ESP. Patients in the ACR arm received fewest further treatments.
As part of the surgical treatments, optimal release was reported as achieved in 92% of MUA procedures
and in 98% of ACR procedures (Table 7). Steroid injection was delivered for all completed MUAs and
28% of ACRs. Steroid injection was also given to 80% of patients randomised to ESP (Table 8).
The number of delivered physiotherapy sessions is presented in Table 9. Participants who completed
the ESP intervention attended a median of 9 sessions, whereas PPP following surgical procedures
attended slightly fewer sessions (median of 7 for MUA and 8 for ACR). Individual therapeutic elements
delivered as part of ESP and PPP sessions are summarised in Appendix 5.
TABLE 4 Completed treatment
Treatment received
Randomised treatment, n (%)
MUA (N= 201) ACR (N= 203) ESP (N= 99)
Trial treatment
MUAa 164 (82) 3 (1) –
ACRb – 162 (80) 7 (7)
ESPc 4 (2) 2 (1) 80 (81)
Alternative treatmentd
Other physiotherapy 5 (2) 4 (2) –
ACR without MUA 1 (0.5) 1 (0.5) –
Steroid injection 1 (0.5) 2 (1) 1 (1)
Subacromial decompression 1 (0.5) – –
Hydrodilatation and other physiotherapy – – 1 (1)
No treatment recordede 25 (12) 29 (14) 10 (10)
a Patient had trial MUA (regardless of release status, receipt of steroid injection or PPP).
b Patient had trial ACR and MUA (regardless of release status or receipt of PPP).
c Patient completed eight or more ESP sessions, or fewer if patient and/or physiotherapist were satisfied with
progress (regardless of receipt of steroid injection).
d Patient did not receive any trial treatment as defined under a, b and c, but alternative treatment was recorded.
e No trial or alternative treatment as defined under a, b, c and d was recorded for patient.
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TABLE 5 Time to start/end of treatment
Day started
Treatment arm
MUA ACR ESP
Days from the date of randomisation to . . . . . . the day of operation . . . the day of operation
. . . the first day of
physiotherapy/injection
n 164 162 80
Mean (SD) 63 (39.3) 82 (52.2) 20 (21.2)
Median 56.5 71.5 14
Minimum, maximum 4, 244 1, 249 0, 140
Days from the date of randomisation to . . . . . . the first day of PPP . . . the first day of PPP
n 158 156 –
Mean (SD) 64 (39.6) 83 (52.0) –
Median 57.5 71.5 –
Minimum, maximum 4, 245 1, 249 –
Days from the date of surgery to . . . . . . the first day of PPP . . . the first day of PPP
n 158 156 –
Mean (SD) 3 (7.0) 3 (8.6) –
Median 1 1 –
Minimum, maximum –6, 40 –40, 76 –
Days from the first day of physiotherapy to . . . . . . the last day of PPP . . . the last day of PPP . . . the last day of ESP
n 158 156 80
Mean (SD) 86 (53.1) 91 (46.0) 100 (46.5)
Median 78 85.5 92
Minimum, maximum 1, 243 1, 285 15, 246
TABLE 6 Further treatment (any treatment following completion of trial treatment)
Further treatment
Subgroup: randomised and completed treatment
MUA ACR ESP
Further surgical treatment
ACR 4 0 3
ACR without MUA 3 0 0
ACR plus injection to opposite shoulder 0 0 1
Arthroscopic arthrolysis and decompression 0 0 1
MUA 1 1 3
Further non-surgical treatment
Steroid injection 3 3 3
Glenohumeral joint injection 2 0 0
Ultrasound guided injection 0 1 1
Other/further physiotherapy 2 3 6
Rheumatology clinic 0 0 1
Total number of further treatments 15 8 19
Total number (%) of patients having one or more further treatments 14 (7) 8 (4) 15 (15)
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TABLE 7 Fidelity (surgery and injection)
Fidelity
MUA ACR ESP
n
% of patients
randomised to
MUA (N= 201)
% of patients
randomised to
and completed
MUA (N= 164) n
% of patients
randomised
to ACR
(N= 203)
% of patients
to and
completed
ACR (N= 162)
% of patients
randomised
to ESP
(N= 99)
% of patients
randomised
to and
completed
ESP (N= 80)
Surgery
delivered
164 82 100 162 80 100 – –
Optimal
release
achieved
151 75 92 158 78 98 – –
Steroid
injection
received
164 82 100 45 22 28 80 86
TABLE 8 Fidelity (physiotherapy)
Number of
physiotherapy
sessions
MUA ACR ESP
Randomised to
and completed Randomised
Randomised to
and completed Randomised
Randomised to
and completed Randomised
n 164 201 162 203 80 99
Mean (SD) 7.7 (4.39) 6.3 (4.93) 8.1 (4.00) 6.5 (4.78) 8.7 (3.26) 7.6 (3.95)
Median 7 6 8 6 9 8
Minimum,
maximum
0, 18 0, 18 0, 18 0, 18 2, 15 0, 15
TABLE 9 Unadjusted OSS by treatment arm: follow-up since randomisation
Time point
Treatment arm
TotalMUA ACR ESP
Baseline
N 200 202 99 501
Mean (SD) 20.5 (8.88) 19.1 (7.72) 20.3 (7.97) 19.9 (8.26)
Median 20 19 20 20
Minimum, maximum 2, 48 1, 37 2, 42 1, 48
n (%) maximum score (48) 1 (1) 0 (0) 0 (0) 1 (< 0.5)
3 months
N 178 179 90 447
Mean (SD) 31.7 (10.41) 27.4 (11.12) 32.7 (10.95) 30.2 (11.03)
Median 34 28 35 32
Minimum, maximum 5, 48 2, 48 4, 48 2, 48
n (%) maximum score (48) 2 (1) 1 (1) 2 (2) 5 (1)
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Primary outcome
Descriptives
The OSS was the trial primary outcome and was collected using questionnaires at baseline and at 3,
6 and 12 months post randomisation. When OSS data from either the 6-month post-randomisation or
the 6-month post-treatment questionnaire were available, and the two questionnaires had been sent
to patients within 28 days, the available responses were used to complete any missing OSS outcomes.
A summary of descriptive statistics of OSS scores is presented in Table 9 and Figure 3 (see Appendix 6
for the scores split by pain and function subdomains). By 12-month follow-up, many participants (24%)
had regained function up to the top OSS score of 48, and a ceiling effect of OSS scores for all three
arms could be observed. This restricted variability of scores at the top end meant that the ability of
the trial to detect clinically meaningful differences at the primary end point was reduced.
TABLE 9 Unadjusted OSS by treatment arm: follow-up since randomisation (continued )
Time point
Treatment arm
TotalMUA ACR ESP
6 months
N 177 170 83 430
Mean (SD) 38.6 (9.70) 36.5 (9.96) 36.5 (11.08) 37.3 (10.11)
Median 41 39 40 40
Minimum, maximum 3, 48 7, 48 6, 48 3, 48
n (%) maximum score (48) 23 (13) 11 (6) 10 (12) 44 (10)
12 months
N 183 175 88 446
Mean (SD) 39.4 (9.87) 40.7 (9.99) 38.9 (10.49) 39.8 (10.05)
Median 43 45 42.5 43
Minimum, maximum 4, 48 2, 48 4, 48 2, 48
n (%) maximum score (48) 44 (24) 45 (26) 17 (19) 106 (24)
0
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12
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24
30
36
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48
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Time point
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MUA
ACR
FIGURE 3 Unadjusted mean OSS and 95% CIs by treatment arm.
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Primary analysis
The ITT primary analysis was based on a linear mixed model incorporating all time points and using
an unstructured covariance pattern to model the relationship of repeated measurements by the same
individual. The model adjusted for age, sex, diabetes and OSS at baseline and incorporated a random
effect for site. The results in Table 10 present adjusted estimates of group means and mean differences
for each treatment comparison. At the primary end point at 12 months, participants randomised
to ACR were shown to have, on average, statistically significantly higher (better) OSS scores than
participants randomised to MUA (2.01 points, 95% CI 0.10 to 3.91 points) and ESP (3.06 points, 95% CI
0.71 to 5.41 points). Although statistically significant, mean estimates were short of the sought minimal
clinically important effect size of 4–5 OSS points (the trial was powered for differences of 4 points for
comparing MUA with ACR and of 5 points for comparisons with ESP).
For the short-term follow-up at 3 months post randomisation, ACR was shown to result in lower
(worse) outcomes than the other two interventions. Mean differences for all treatment comparisons
are in Appendix 7. There was no evidence of statistically significant differences in average OSS scores
over the 12 months’ follow-up. Differences of clinically important magnitude, as defined above, were
included in the 95% CIs for the benefit of MUA and ESP compared with ACR at 3 months, and ACR
compared with ESP at 12 months. Clinically meaningful group differences may therefore exist for
these comparisons in the population.
TABLE 10 Estimated mean OSS differences by treatment arm (estimates from primary analysis modela)
Time point
Treatment arm
Difference, mean (95% CI) p-valueMean (95% CI) Mean (95% CI)
MUA ESP
3 months 30.2 (28.8 to 31.6) 31.6 (29.7 to 33.5) –1.36 (–3.70 to 0.98) 0.25
6 months 37.1 (35.7 to 38.4) 34.9 (33.0 to 36.8) 2.15 (–0.12 to 4.42) 0.06
12 monthsb 38.3 (36.9 to 39.7) 37.2 (35.3 to 39.2) 1.05 (–1.28 to 3.39) 0.38
Average 35.2 (34.0 to 36.4) 34.6 (33.0 to 36.2) 0.61 (–1.31 to 2.53) 0.53
ACR ESP
3 months 26.9 (25.5 to 28.3) 31.6 (29.7 to 33.5) –4.72 (–7.06 to –2.39) < 0.01
6 months 35.9 (34.6 to 37.3) 34.9 (33.0 to 36.8) 0.98 (–1.31 to 3.26) 0.40
12 monthsb 40.3 (38.9 to 41.7) 37.2 (35.3 to 39.2) 3.06 (0.71 to 5.41) 0.01
Average 34.4 (33.2 to 35.5) 34.6 (33.0 to 36.2) –0.23 (–2.15 to 1.70) 0.82
ACR MUA
3 months 26.9 (25.5 to 28.3) 30.2 (28.8 to 31.6) –3.36 (–5.27 to –1.45) < 0.01
6 months 35.9 (34.6 to 37.3) 37.1 (35.7 to 38.4) –1.17 (–3.02 to 0.67) 0.21
12 monthsb 40.3 (38.9 to 41.7) 38.3 (36.9 to 39.7) 2.01 (0.10 to 3.91) 0.04
Average 34.4 (33.2 to 35.5) 35.2 (34.0 to 36.4) –0.84 (–2.41 to 0.72) 0.29
a Linear mixed covariance pattern model adjusted for age, sex, diabetes, OSS at baseline (fixed effects) and site
(random effect).
b Primary end point for each treatment comparison.
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Secondary analyses
Analysis incorporating different waiting times
In addition to questionnaires completed at post-randomisation follow-ups, participants were asked
to complete the OSS just before and 6 months following receipt of treatment in order to account
for the differential waiting times for each trial treatment. Descriptive results for these outcomes at
these two points are given in Table 11 and are presented together with OSS scores at baseline and at
12 months’ post-randomisation follow-up in Figure 4. The OSS scores appeared to stay stable between
baseline and the start of any of the treatments, which was later for the surgical arms (95% CI of mean
difference ESP vs. MUA –2.0 to 2.7, ESP vs. ACR –1.5 to 3.2, MUA vs. ACR –1.4 to 2.5). Six months
following treatment, scores had improved to a greater extent in the surgical arms than in the ESP arm
(95% CI of mean difference ESP vs. MUA –5.5 to –2.2, ESP vs. ACR –6.1 to –0.6, MUA vs. ACR –2.6 to 1.6)
and were similar to final follow-up scores by 8 months.
TABLE 11 Unadjusted OSS by treatment arm: pre treatment and 6 months post treatment
Time point
Treatment arm
TotalMUA ACR ESP
Pre treatment
n 159 157 77 393
Mean (SD) 21.5 (8.79) 21.0 (8.92) 21.8 (8.02) 21.4 (8.68)
Median 21 21 22 21
Minimum, maximum 3, 46 1, 42 6, 42 1, 46
Post treatment (6 months)
n 157 152 81 390
Mean (SD) 39.0 (9.03) 39.4 (9.68) 36.1 (10.67) 38.5 (9.70)
Median 42 43 39 42
Minimum, maximum 6, 48 2, 48 6, 48 2, 48
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FIGURE 4 Unadjusted mean OSS and 95% CIs by treatment arm (using scores at baseline, follow-up before treatment
and 6 months after treatment; and at 3, 6 and 12 months post randomisation).
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A linear mixed random intercept model incorporated time as a continuous variable, included data from
all available time points for each patient (up to five measurements) and adjusted for the same covariates
as the primary analysis model. OSS estimates at 3, 6 and 12 months post-randomisation follow-up were
derived from the model and are presented in Table 12. Compared with the primary analysis model,
group differences tended to be of smaller magnitude, with the exception of the difference between
ACR and ESP at 12 months (3.26 points in favour of ACR, 95% CI 1.18 to 5.35 points). The 95% CI
interval still included the minimal clinically important difference for this comparison of 5 OSS points.
Analysis incorporating treatment compliance
Baseline characteristics for participants who did and participants who did not complete their randomised
treatment according to the trial definitions are presented in Table 13. The profile of non-completers in
each treatment arm tended to be different.
Owing to the three active treatments under investigation and multiple alternative treatment pathways
for each patient, the scope for conducting CACE analysis was limited, as assumptions of the analysis
did not hold. Only one treatment comparison was conducted at the primary end point at 12 months,
that of compliance with ESP as defined in the fidelity section of this report (Table 8).
Instrumental variable regression was implemented predicting OSS at the primary end point at 12 months
in order to quantify the effect of compliance with ESP. From the model, outcomes for ESP compliers
remained lower than for patients in the other treatment arms (–1.84 OSS points, 95% CI –4.41 to 0.74
OSS points; p = 0.157); however, the difference was not statistically significant. Based on Appendix 8,
patients tended to have better outcomes if they completed their randomised treatment.
TABLE 12 Estimated mean OSS differences by treatment arm (estimates from model incorporating follow-ups before and
after treatment in addition to post-randomisation outcomesa)
Time point
Treatment arm
Difference, mean (95% CI) p-valueMean (95% CI) Mean (95% CI)
MUA ESP
3 months 28.2 (27.1 to 29.3) 29.4 (27.8 to 30.9) –1.18 (–3.10 to 0.73) 0.23
6 months 32.5 (31.5 to 33.5) 32.7 (31.2 to 34.1) –0.15 (–1.90 to 1.60) 0.87
12 months 41.1 (40.0 to 42.3) 39.2 (37.5 to 40.9) 1.92 (–0.16 to 4.00) 0.07
ACR ESP
3 months 26.0 (24.9 to 27.2) 29.4 (27.8 to 30.9) –3.33 (–5.25 to –1.40) < 0.01
6 months 31.5 (30.5 to 32.5) 32.7 (31.2 to 34.1) –1.13 (–2.88 to 0.62) 0.21
12 months 42.5 (41.3 to 43.7) 39.2 (37.5 to 40.9) 3.26 (1.18 to 5.35) < 0.01
ACR MUA
3 months 26.0 (24.9 to 27.2) 28.2 (27.1 to 29.3) –2.14 (–3.71 to –0.57) 0.01
6 months 31.5 (30.5 to 32.5) 32.5 (31.5 to 33.5) –0.98 (–2.40 to 0.44) 0.18
12 months 42.5 (41.3 to 43.7) 41.1 (40.0 to 42.3) 1.35 (–0.33 to 3.02) 0.12
a Linear mixed random intercept model adjusted for age, sex, diabetes, OSS at baseline (fixed effects) and site
(random effect).
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
Missing data
Possible predictors of missing OSS data at 3-, 6- or 12-month follow-up are presented in Table 14.
Only age (younger participants being more likely to have missing data) and OSS outcomes prior to the
time of missing data (participants with poorer outcomes being more likely to have missing data) were
significant predictors of missingness. As these are already covariates in the primary analysis model,
no model adjustments were undertaken.
TABLE 13 Comparison of baseline characteristics by treatment compliance
Characteristic
MUA ACR ESP
Completed
treatment
(N= 164)
Did not
complete
treatment
(N= 37)
Completed
treatment
(N= 162)
Did not
complete
treatment
(N= 41)
Completed
treatment
(N= 80)
Did not
complete
treatment
(N= 19)
Sex, n (%)
Male 54 (33) 18 (49) 63 (39) 14 (34) 29 (36) 6 (32)
Female 110 (67) 19 (51) 99 (61) 27 (66) 51 (64) 13 (68)
Age (years)
n 164 37 162 41 80 19
Mean (SD) 54.0 (7.4) 56.8 (8.8) 54.3 (7.5) 52.3 (8.3) 55.6 (7.7) 49.8 (6.3)
Median (minimum, maximum) 54 (30, 57) 56 (36, 73) 54 (33, 76) 52 (34, 71) 55 (39, 77) 50 (39, 69)
Diabetic, n (%)
No 115 (70) 26 (70) 118 (73) 25 (61) 55 (69) 14 (74)
Type 1 12 (7) – 8 (5) 4 (10) 4 (5) 1 (5)
Type 2 37 (23) 11 (30) 36 (22) 12 (29) 21 (26) 4 (21)
Employment status summary, n (%)
In paid work 113 (69) 16 (43) 95 (59) 23 (56) 44 (55) 9 (47)
Not in paid work 48 (29) 21 (57) 65 (40) 17 (41) 36 (45) 10 (53)
Missing 3 (2) – 2 (1) 1 (2) – –
Duration of symptoms (months)
n 160 36 161 40 79 19
Mean (SD) 10.6 (8.5) 10.3 (8.9) 11.5 (10.5) 10.56 (7.5) 10.3 (6.1) 13.0 (15.8)
Median (minimum, maximum) 8 (2, 60) 7.5 (2, 48) 9 (2, 96) 9 (0, 36) 9 (3, 36) 8 (2, 72)
Previous physiotherapy for affected shoulder, n (%)
Yes 100 (61) 25 (68) 99 (61) 25 (61) 49 (6) 10 (53)
No 64 (39) 12 (32) 63 (39) 14 (34) 31 (39) 8 (42)
Missing – – – 2 (5) – 1 (5)
OSS, points (0–48)
n 163 37 161 41 80 19
Mean (SD) 20.4 (8.9) 20.8 (8.9) 19.0 (7.6) 19.9 (8.4) 20.7 (7.8) 18.3 (8.4)
Median (minimum, maximum) 20 (2, 48) 20 (3, 36) 19 (1, 37) 19 (4, 35) 20 (2, 42) 18 (4, 34)
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Based on the low drop-out rate at the primary end point at 12 months (11%), and the fact that nearly
all patients could be included in the primary analysis (94%), further adjustments for missing data,
such as multiple imputation, were not implemented.
Other secondary analyses
Further secondary analyses excluded responses received beyond 6 weeks of each intended follow-up
and adjusted for the observed baseline imbalance in employment status (see Appendix 9). The results
were similar to those observed in the primary analysis.
TABLE 14 Comparison of patient characteristics by missingness of OSS over time
Not missing Missing p-value
3-month follow-up N = 447 N = 56
Age (years), mean (SD) 54.6 (7.6) 51.5 (8.4) 0.01a
Male, n (%) 161 (36%) 23 (41%) 0.46
Diabetic, n (%) 128 (29%) 22 (39%) 0.10
In employment, n (%) 270 (60%) 30 (54%) 0.45
Duration of symptoms (months), mean (SD) 11.1 (9.4) 9.6 (7.1) 0.26
Previous physiotherapy, n (%) 281 (63%) 27 (48%) 0.07
Baseline OSS (points), mean (SD) 20.1 (8.2) 18.5 (8.6) 0.19
6-month follow-up N = 430 N = 73
Age (years), mean (SD) 54.7 (7.6) 51.6 (8.1) < 0.01a
Male, n (%) 155 (36%) 29 (40%) 0.55
Diabetic, n (%) 122 (28%) 28 (38%) 0.09
In employment, n (%) 257 (60%) 43 (59%) 0.90
Duration of symptoms (months), mean (SD) 11.0 (9.1) 10.2 (9.9) 0.50
Previous physiotherapy, n (%) 266 (62%) 42 (58%) 0.65
Baseline OSS (points), mean (SD) 20.2 (8.2) 18.2 (8.4) 0.06
3-month OSS (points), mean (SD) 30.4 (10.9) 26.2 (11.9) 0.05a
12-month follow-up N = 446 N = 57
Age (years), mean (SD) 54.5 (7.5) 52.1 (9.0) 0.03a
Male, n (%) 164 (37%) 20 (35%) 0.80
Diabetic, n (%) 136 (30%) 14 (25%) 0.36
In employment, n (%) 266 (60%) 34 (60%) 0.82
Duration of symptoms (months), mean (SD) 11.0 (9.4) 10.4 (7.8) 0.68
Previous physiotherapy, n (%) 278 (62%) 30 (53%) 0.26
Baseline OSS (points), mean (SD) 20.1 (8.2) 18.3 (8.7) 0.11
3-month OSS (points), mean (SD) 30.4 (10.8) 25.9 (13.4) 0.05
6-month OSS (points), mean (SD) 37.4 (10.1) 36.5 (10.7) 0.72
a Statistically significant at the 5% level.
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Subgroup analyses
The possibility of differential treatment effects were explored for subgroups based on diabetes status,
receipt of previous physiotherapy and baseline treatment preference, and, in addition, length of frozen
shoulder symptoms at baseline following advice from the trial oversight committee. Interaction terms
between treatment allocation and subgroups were added to the primary analysis model and p-values
for interactions for each treatment comparison were derived (Table 15). None of the interaction terms
was statistically significant, although the study was not powered to detect such interactions and the
number of participants in some of the subgroups in each treatment arm was very small.
Possible trends are illustrated in Figures 5–8 and descriptive tables are in Appendix 10. Diabetic patients
tended to have poorer outcomes than non-diabetic patients at all time points, and especially at the
3-month follow-up for patients in the ACR arm. Patients who had previous physiotherapy tended to
have worse outcomes if they were randomised to ESP, especially at the 3- and 6-month follow-ups,
whereas patients who had indicated a prior preference for physiotherapy tended to have better outcomes
if they were randomised to ESP and worse outcomes if they were randomised to either surgical treatment.
Participants who reported frozen shoulder symptoms for ≥ 9 months before entering the trial tended to
have worse outcomes at 3 months if they were randomised to ACR and better outcomes at 3 months if
they were randomised to ESP.
TABLE 15 Subgroup analyses summary
Subgroup
Treatment arm (n)
Treatment
comparison Contrast 95% CI
p-value of
allocation
interaction
with subgroupMUA ACR ESP
Diabetes
Diabetic (n = 150) 60 60 30 MUA vs. ESP –0.34 –4.58 to 3.90 0.88
ACR vs. ESP 0.09 –4.16 to 4.34 0.97
Not diabetic (n = 353) 141 143 69 ACR vs. MUA 0.43 –2.98 to 3.85 0.80
Previous physiotherapy
Had previous physiotherapy
(n = 308)
125 124 59 MUA vs. ESP –2.08 –6.04 to 1.89 0.30
ACR vs. ESP –0.87 –4.86 to 3.12 0.67
Did not have previous
physiotherapy (n = 192)
76 77 39 ACR vs. MUA 1.21 –2.02 to 4.44 0.46
Patient treatment preference
Allocated to preferred treatment
(n = 131)
56 64 11 MUA vs. ESP 2.10a –4.32 to 8.52 0.81
1.28b –4.66 to 7.22
Allocated to non-preferred
treatment (n = 105)
40 27 38 ACR vs. ESP 3.11a –3.50 to 9.73 0.65
2.18b –3.73 to 8.09
Had no treatment preference
(n = 263)
103 111 49 ACR vs. MUA 1.01a –3.84 to 5.87 0.87
0.90b –2.70 to 4.50
Duration of symptoms at baseline
< 9 months (n = 249) 103 95 51 MUA vs. ESP –2.41 –6.29 to 1.46 0.22
ACR vs. ESP –2.00 –5.85 to 1.85 0.31
≥ 9 months (n = 246) 93 106 47 ACR vs. MUA 0.41 –2.73 to 3.56 0.80
a Allocated to non-preferred vs. allocated to preferred treatment.
b No treatment preference vs. allocated to preferred treatment.
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FIGURE 5 Unadjusted mean OSS function items and 95% CIs by treatment arm and diabetes: (a) diabetic; and
(b) not diabetic.
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FIGURE 6 Unadjusted mean OSS function items and 95% CIs by treatment arm and previous physiotherapy: (a) had
previous physiotherapy; and (b) did not have previous physiotherapy.
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FIGURE 7 Unadjusted mean OSS function items and 95% CIs by treatment arm and baseline preference: (a) preference
for physiotherapy; (b) preference for surgery; and (c) no preference. (continued )
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FIGURE 7 Unadjusted mean OSS function items and 95% CIs by treatment arm and baseline preference: (a) preference
for physiotherapy; (b) preference for surgery; and (c) no preference.
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FIGURE 8 Unadjusted mean OSS function items and 95% CIs by treatment arm and length of time with symptoms:
(a) symptoms for < 9 months; and (b) symptoms for ≥ 9 months. (continued )
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Secondary outcomes
Among the secondary outcomes, QuickDASH and shoulder pain followed a similar pattern to the OSS,
in that ACR patients were observed to have significantly poorer outcomes at 3 months (note that
many patients had only recently had or were still waiting for their surgery at this point) but better
outcomes at 12 months post randomisation than those allocated to MUA or ESP (Tables 16 and 17).
Unadjusted means are presented and illustrated in the tables and figures below (see Appendix 11 and
Figures 9 and 10).
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FIGURE 8 Unadjusted mean OSS function items and 95% CIs by treatment arm and length of time with symptoms:
(a) symptoms for < 9 months; and (b) symptoms for ≥ 9 months.
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FIGURE 9 Unadjusted mean QuickDASH scores and 95% CIs by treatment arm.
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Shoulder pain
TABLE 16 Estimated mean QuickDASH differences by treatment arma
Time point Mean (95% CI) Mean (95% CI) Mean difference (95% CI) p-value
MUA ESP
3 months 38.8 (35.7 to 42.0) 37.1 (32.7 to 41.4) 1.77 (–3.41 to 6.96) 0.50
6 months 25.7 (22.6 to 28.7) 29.2 (24.9 to 33.5) –3.55 (–8.68 to 1.58) 0.18
12 months 22.9 (19.8 to 26.0) 23.4 (19.0 to 27.8) –0.50 (–5.70 to 4.70) 0.85
ACR ESP
3 months 44.4 (41.3 to 47.5) 37.1 (32.7 to 41.4) 7.33 (2.16 to 12.49) < 0.01
6 months 27.4 (24.4 to 30.4) 29.2 (24.9 to 33.5) –1.82 (–6.94 to 3.31) 0.49
12 months 18.2 (15.1 to 21.3) 23.4 (19.0 to 27.8) –5.20 (–10.42 to 0.02) 0.05
ACR MUA
3 months 44.4 (41.3 to 47.5) 38.8 (35.7 to 42.0) 5.55 (1.32 to 9.78) 0.01
6 months 27.4 (24.4 to 30.4) 25.7 (22.6 to 28.7) 1.73 (–2.39 to 5.86) 0.41
12 months 18.2 (15.1 to 21.3) 22.9 (19.8 to 26.0) –4.71 (–8.91 to –0.50) 0.03
a Linear mixed covariance pattern model adjusted for age, sex, diabetes, QuickDASH at baseline (fixed effects) and
site (random effect).
0
1
3
2
4
5
7
6
8
9
10
N
u
m
er
ic
 R
at
in
g 
Sc
al
e 
fo
r 
P
ai
n
Baseline 3 months 6 months
Time point
12 months
Treatment arm
ESP
MUA
ACR
FIGURE 10 Unadjusted mean shoulder Numeric Rating Scale for Pain and 95% CIs by treatment arm.
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Extent of recovery
There was no evidence of statistically significant differences between treatment arms in the reduction
in frozen shoulder symptoms as measured by the extent of recovery (‘To what extent would your
frozen shoulder symptoms in the past 24 hours prompt you to ask for further treatment?’; response
on visual analogue scale of 0–100). Descriptives are presented in Appendix 11 (see Table 53) and
illustrated in Figure 11, and the results of the analysis are in Table 18.
TABLE 17 Estimated shoulder Numeric Rating Scale for Pain differences by treatment arma
Time point Mean (95% CI) Mean (95% CI) Mean difference (95% CI) p-value
MUA ESP
3 months 4.1 (3.8 to 4.5) 3.7 (3.2 to 4.2) 0.43 (–0.17 to 1.03) 0.16
6 months 2.8 (2.4 to 3.1) 3.0 (2.5 to 3.5) –0.19 (–0.78 to 0.40) 0.53
12 months 2.4 (2.1 to 2.8) 2.5 (2.0 to 3.0) –0.08 (–0.66 to 0.50) 0.78
ACR ESP
3 months 4.7 (4.3 to 5.1) 3.7 (3.2 to 4.2) 1.02 (0.42 to 1.61) < 0.01
6 months 2.8 (2.5 to 3.2) 3.0 (2.5 to 3.5) –0.14 (–0.74 to 0.45) 0.63
12 months 1.7 (1.4 to 2.0) 2.5 (2.0 to 3.0) –0.81 (–1.39 to –0.23) < 0.01
ACR MUA
3 months 4.7 (4.3 to 5.1) 4.1 (3.8 to 4.5) 0.59 (0.10 to 1.07) 0.02
6 months 2.8 (2.5 to 3.2) 2.8 (2.4 to 3.1) 0.05 (–0.43 to 0.52) 0.85
12 months 1.7 (1.4 to 2.0) 2.4 (2.1 to 2.8) –0.73 (–1.20 to –0.25) < 0.01
a Linear mixed covariance pattern model adjusted for age, sex, diabetes, Numeric Rating Scale for Pain at baseline
(fixed effects) and site (random effect).
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FIGURE 11 Unadjusted mean extent of recovery visual analogue scale and 95% CIs by treatment arm. Scale is 0–100,
where 100 is equivalent to maximum belief that symptoms require further treatment.
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Stiffness
Although stiffness was not collected as a separate outcome, it was of interest whether the trial
interventions differentially addressed pain or stiffness associated with frozen shoulder. The proportion
of predominant pain or stiffness reported by patients at the first and last physiotherapy session of
their treatment is presented in Appendix 11 (see Table 54). Patients in the ESP arm had relatively
lower levels of predominant pain by the end of physiotherapy, whereas patients in the ACR arm
had relatively lower levels of predominant stiffness than those in the other arms.
Complications/adverse events
Any reported complications were reconciled with recorded AEs by two senior surgeons (independently
initially and by consensus following any disagreement) to arrive at a single record of untoward
occurrences. Some variables recorded as standard through the AE reporting process (e.g. expectedness
and event severity following clinical review) were not available or relevant for any events identified
from the complications form or change in status form alone. This is why some of the information
appears as missing in the events listed in Table 19. Only possible relatedness to the trial treatments
was recorded retrospectively, where this information was missing.
In total, there were only 10 SAEs, reported for nine patients (summarised in Appendix 12; an itemised
list is in Table 19). All SAEs occurred for patients randomised to the surgical arms (ACR, n = 8; MUA,
n = 2). However, one SAE in the ACR arm was experienced by a participant who had non-trial-specific
physiotherapy. The events mainly related to serious medical complications such as chest infection
or stroke, some of which may be related to having received surgery in general, rather than being
specifically related to the trial surgical procedures. Numbers were insufficient to allow formal analysis.
Thirty-three non-serious AEs were reported for 31 patients, with comparable rates in the three arms
(7% of MUA patients, 6% of ACR patients and 5% of ESP patients). These events were mainly expected
and often related to persistent or worsening shoulder pain (summarised in Appendix 12; an itemised
list is in Table 20). Sufficient numbers of patients experienced one or more AE to allow for a valid
statistical comparison between the two surgical arms, which confirmed no evidence of statistical
differences in the proportion of non-serious AEs (p = 0.186).
TABLE 18 Estimated mean extent of recoverya visual analogue scale differences by treatment armb
Time point Mean (95% CI) Mean (95% CI) Mean difference (95% CI) p-value
MUA ESP
3 months 51.4 (45.8 to 56.9) 53.9 (46.3 to 61.5) –2.55 (–11.68 to 6.58) 0.58
6 months 31.9 (26.5 to 37.2) 38.6 (30.9 to 46.3) –6.71 (–15.83 to 2.42) 0.15
12 months 27.3 (22.4 to 32.3) 26.9 (20.0 to 33.8) 0.46 (–7.79 to 8.70) 0.91
ACR ESP
3 months 54.0 (48.5 to 59.5) 53.9 (46.3 to 61.5) 0.11 (–9.02 to 9.23) 0.98
6 months 34.7 (29.3 to 40.0) 38.6 (30.9 to 46.3) –3.93 (–13.06 to 5.21) 0.40
12 months 21.2 (16.3 to 26.2) 26.9 (20.0 to 33.8) –5.65 (–13.91 to 2.61) 0.18
ACR MUA
3 months 54.0 (48.5 to 59.5) 51.4 (45.8 to 56.9) 2.66 (–4.84 to 10.15) 0.49
6 months 34.7 (29.3 to 40.0) 31.9 (26.5 to 37.2) 2.78 (–4.50 to 10.06) 0.45
12 months 21.2 (16.3 to 26.2) 27.3 (22.4 to 32.3) –6.11 (–12.86 to 0.64) 0.08
a Scale is 0–100, where 100 is equivalent to the maximum belief that symptoms require further treatment.
b Linear mixed covariance pattern model adjusted for age, sex, diabetes, symptom severity at baseline (fixed effects)
and site (random effect).
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TABLE 19 Serious adverse events (itemised)
Source
Treatment
Description Type Relatedness
Potentially
long-lasting
consequencesAllocated Received
SAE CRF MUA None Attended A&E for numbness of
right arm and heaviness with
kaleidoscope vision and headache
Medically
important
Not related No
SAE CRF ACR ACR Elevated blood sugar levels Prolonged
hospitalisation
Probably
related
No
SAE CRF ACR ACR Decreased oxygen saturation Prolonged
hospitalisation
Not related No
SAE CRF ACR ACR Hypoglycaemic seizure while under
anaesthetic
Prolonged
hospitalisation
Unlikely to
be related
No
SAE CRF ACR ACR Patient noticed facial drooping/
weakness after surgery
Medically
important
Definitely
related
No
Review MUA MUA Septic joint arthritis –a Definitely
related
Yes
Review ACR ACR Stroke –a Not related Yes
Review ACR MUA Likely anterior dislocation –a Definitely
related
Yes
Review ACR Other Deep-vein thrombosis –a Not related Yes
Review ACR ACR Chest infection –a Unlikely to
be related
No
A&E, accident and emergency.
a Event was identified following review rather than from the AE CRF; not all information is available.
TABLE 20 Non-serious AEs (itemised)
Source
Treatment
Description Related Expectedness SeverityAllocated Received
AE CRF ESP ESP Persistent pain Not related Expected Unknown
AE CRF ESP ESP Long head of the biceps tendon
pain and rupture
Not related Unexpected Mild
AE CRF ESP ACR Post-procedural worsening of
shoulder pain
Possibly related Expected Mild
AE CRF ESP ACR Recurrent stiffness requiring
further treatment
Not related Expected Moderate
AE CRF MUA MUA Transient hyperglycaemia, steroid
flare or joint sepsis following
corticosteroid injection
Possibly related Expected Mild
AE CRF MUA MUA Additional diagnosis requiring
further treatment
Not related Expected Severe
AE CRF MUA MUA Post-procedural worsening of
shoulder pain
Possibly related Expected Mild
AE CRF MUA MUA Transient hyperglycaemia, steroid
flare or joint sepsis following
corticosteroid injection
Probably related Expected Unknown
AE CRF MUA MUA Ipsilateral face swelling, face
flushed and neck and face hot
Possibly related Unexpected Moderate
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TABLE 20 Non-serious AEs (itemised) (continued )
Source
Treatment
Description Related Expectedness SeverityAllocated Received
AE CRF MUA MUA Neuropathic symptoms Not related Unexpected Moderate
AE CRF MUA MUA Post-procedural worsening of
shoulder pain
Unlikely to be
related
Expected Moderate
AE CRF MUA MUA Injury to adjacent structures such
as nerve, tendon, bone or joint
Possibly related Expected Severe
AE CRF MUA MUA Post-procedural worsening of
shoulder pain
Not related Expected Moderate
AE CRF MUA MUA Persistent pain requiring
further treatment
Unlikely to be
related
Expected Moderate
AE CRF MUA MUA Persistent stiffness and pain
requiring treatment
Not related Unexpected Unknown
AE CRF MUA ESP Transient hyperglycaemia, steroid
flare or joint sepsis following
corticosteroid injection
Definitely related Expected Mild
AE CRF ACR ACR Infection Possibly related Expected Mild
AE CRF ACR ACR Persistent pain Possibly related Expected Mild
AE CRF ACR ACR Post-procedural worsening of
shoulder pain
Definitely related Expected Mild
AE CRF ACR ACR Persistent pain requiring
further treatment
Possibly related Expected Moderate
AE CRF ACR ACR Neuropathic symptoms Unlikely to be
related
Expected Mild
AE CRF ACR ACR Adverse reaction to concurrent
medication
Possibly related Unexpected Severe
AE CRF ACR ACR Allergic reaction to dressing Definitely related Unexpected Mild
AE CRF ACR ACR Post-procedural worsening of
shoulder pain
Possibly related Expected Mild
AE CRF ACR MUA Injury to adjacent structures such
as nerve, tendon, bone or joint
Definitely related Expected Severe
AE CRF ACR Other Neuropathic symptoms Unlikely to be
related
Unexpected Moderate
Review ESP ESP Supraspinatus tendinopathy –a –a –a
Review MUA MUA Episode of inflammation –a –a –a
Review MUA MUA Pins and needles in hand –a –a –a
Review MUA MUA Chest infection –a –a –a
Review ACR ACR Post-procedural worsening of
shoulder pain
–a –a –a
Review ACR ACR Patient being investigated for
neck problems
–a –a –a
Review ACR Other Surgical site infection –a –a –a
a Event was identified following review rather than from the AE CRF; not all information is available.
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Other analyses
Treatment preferences
Summaries of treatment preference data are presented in Appendix 13. Non-consenting patients tended
to have a preference for ACR, which they expected to be more effective. Although randomised patients
also expected ACR to be the most effective treatment, they were more likely than non-consenting
patients to be undecided about the effectiveness of any of the treatments. At the end of 12 months’
follow-up, many patients had changed their preference to the treatment they had received. ACR
remained the most popular, especially among participants who had received this as their preferred
treatment at baseline.
Oxford Shoulder Score change scores
Details of participants’ comparative assessment of their symptoms at baseline and 12 months with
reference to their change OSS are presented in Appendix 14. Unfortunately, this analysis was not able
to reveal a more nuanced understanding of minimal clinically meaningful differences using the OSS, as
symptoms of the majority of participants improved substantially over the course of the trial, which was
associated with very large increases in OSS scores.
Outcomes for patients receiving no treatment
The OSS and QuickDASH scores for participants who did (n = 441) and participants who did not (n = 62)
receive any treatment for their frozen shoulder are presented in Appendix 15. Patients for whom no
treatment was recorded tended to have progressively lower rates of improvement by 6- and 12-month
follow-up; however, the proportion of participants with available data was also much smaller in this
group (e.g. 66% of valid OSS scores at 12 months vs. 92% of participants who did receive treatment).
Systematic review: integrating the new evidence
A systematic review was undertaken to assess the effectiveness of MUA, ACR, hydrodilatation and
physiotherapy with steroid injection in the management of patients with a primary frozen shoulder
in order to place the findings of UK FROST in the context of existing evidence for these treatments.
Nine relevant studies were identified, including UK FROST, which provided by far the most, and the
most robust, evidence.
Owing to considerable heterogeneity of the interventions and study populations, only two studies
could be pooled as part of a meta-analysis, comparing long-term shoulder functioning for patients
receiving either ACR or physiotherapy in UK FROST and one other trial. The pooled effect favoured
ACR (standard effect size 0.32, 95% CI 0.08 to 0.56), which was largely determined by the UK FROST
results, as the second trial was much smaller (n = 44). The pooled effect was of smaller magnitude than
the clinical threshold of 5 OSS points, equivalent to a standard effect size of approximately 0.42.
Full details are presented in Report Supplementary Material 20.
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Chapter 4 Economic evaluation
Objective
The objective of this economic evaluation is to assist decision-making to identify the most efficient
provision of future care for the management of frozen shoulder in secondary care in the NHS.
Overview
A prospective economic evaluation was conducted alongside the UK FROST trial, the aim being to
estimate the cost-effectiveness of the three most commonly used interventions for the management of
frozen shoulder in secondary care. The three interventions in the study were ESP with an intra-articular
steroid injection compared with MUA with a steroid injection or ACR followed by manipulation. Both
surgical interventions were followed with a programme of PPP.
Costs and health benefits were compared for the three groups over 12 months, and hence discounting
was not required. All costs were expressed in Great British pounds at a 2017–18 price base. Health
benefits were expressed in terms of QALYs based on patients’ health-related quality of life (HRQoL)
assessed using the EQ-5D-5L.50,66 Differences in mean costs and mean QALYs at 1 year were used to
derive an estimate of the cost-effectiveness of surgery and of non-surgical treatment.
The base-case analysis was conducted on an ITT basis as with the statistical analyses in Chapter 3.
The perspective of the UK NHS and Personal Social Services was adopted for the analysis, and hence
costs incurred by families and informal carers were excluded from the base case. A secondary analysis
was undertaken from a broader perspective. The National Institute for Health and Care Excellence
(NICE) guidelines were applied to all methods used in this economic analysis.67
Owing to the impact of missing data, the base-case analysis was conducted as an imputed analysis;68
the choice of method for handling missing data (multiple imputation) was grounded in the assumed
missing data mechanism (MAR), which in turn was supported by the UK FROST data set. The impact
of alternative assumptions about the missing data mechanism was carefully assessed in sensitivity
analyses.
Methods
Data sources
The data required for the analyses were collected from both participants (self-reported using postal
questionnaires) and health-care professionals (via hospital forms) during the 12 months’ follow-up.
Data relating to surgical care were collected using surgical forms that were specifically designed for
the trial. Similarly, physiotherapy logs were completed by physiotherapists providing patient care.
These logs were used to record the essential components of physiotherapy at each session for each
participant, and they were also used to estimate the cost of ESP and the costs of PPP following
MUA or ACR.
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Data on resource use in primary health-care consultations were collected using participant
questionnaires only. All resource use data recorded by participants were split into ‘shoulder related’
and ‘non-shoulder related’ and were collected at 3, 6 and 12 months. The base-case analysis was based
on shoulder-related resource use. Hospital stays and hospital outpatient appointments were recorded
on two sources (patient questionnaires and hospital forms). Our health economic analysis plan indicated
that when data could be sourced from patient questionnaires and hospital forms, hospital forms would
be used as the main source for calculating resource use. Two main hospital data sources were available
for the analysis: (1) complication form and (2) change in status form. On these forms was recorded any
hospitalisation from discharge after initial treatment up to 12 months.
Sensitivity analysis explored the impact of including both shoulder-related and non-shoulder-related
resource use in the results. As stated before, hospital cost data were available from two sources
(self-reported questionnaires and hospital forms). To avoid estimation bias from using multiple
sources for the analysis of the same cost, the sensitivity analysis of non-shoulder-related costs was
restricted to primary care data, as these data were collected using patient questionnaires exclusively.
Broader resource use data (i.e. private care and productivity costs) were collected during the period
between randomisation and 12 months after enrolment into the study, which was also analysed as per
the broader sensitivity analysis.
Data on health benefits, expressed in terms of HRQoL, were elicited from participants using the
EQ-5D-5L at baseline and at 3, 6 and 12 months.
Measurement of resource use and costs
There are two main cost components in the analysis: (1) the cost of both non-surgical (i.e. ESP) and
surgical (i.e. MUA and ACR) interventions; and (2) the costs of health-care usage at both primary and
secondary care level.
Surgery (manipulation under anaesthesia and arthroscopic capsular release)
An accurate record of procedures at hospital level (e.g. centres in the trial) was put in place of
per-patient information on surgical procedures and complications related to surgery. Data extracted
from surgical forms, which include the main items of resource use relating to each operation, were
used to calculate the costs of MUA and ACR. The PPP form was used to cost post-surgical physiotherapy
care for participants receiving MUA or ACR.
Non-surgery (early structured physiotherapy)
The structured physiotherapy form was used for patients receiving ESP. This form was used to record
information on the physiotherapy sessions (i.e. the duration of the session and the staff band of the
physiotherapist delivering the session). Information on physiotherapy visits was also available from
participant questionnaires at 3, 6 and 12 months. As stated in our health economic analysis plan,
PPP and structured physiotherapy forms were used as the primary sources of the base-case analysis.
As part of ESP, patients were offered an intra-articular steroid injection at the earliest opportunity.
To cost injections, we collected information on the type of steroid used (e.g. methylprednisolone
acetate, triamcinolone acetonide, triamcinolone hexacetonide or another steroid), the dose of steroid
used (i.e. 20 mg, 30 mg, 40 mg or another dose), whether local anaesthetic or image guidance was used,
and the job title of the person administering the injection (i.e. specialist registrar, associate specialist,
consultant, band 6 physiotherapist or band 7 physiotherapist).
Health-care consultations and hospital care
Data on health-care consultations and hospital care were used to assess whether or not participants
allocated to MUA and ACR experienced different levels of resource use from those in the ESP group.
The costs of health-care consultations consist of all costs of visits to both primary and secondary
health-care professionals. Participant questionnaires were used to estimate the number of visits to
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primary care facilities (e.g. contacts with a GP and general practice nurse), visits to the physiotherapist
and use of community care (occupational therapist). Data on resource use were collected at 3, 6 and
12 months. As stated before, hospital forms were used to calculate the number of hospital stays
and hospital outpatient appointments because of additional treatments (i.e. treatments the patient
received before or during receipt of the randomised treatment), further treatments (i.e. treatments
the patients received after completing the randomised treatment), other treatments (i.e. any non-trial
treatments the patient received if they did not start or did not complete their randomised treatment)
or medical complications.
Resource use items were summarised by trial allocation group and follow-up period.
Estimation of costs
The cost for each trial participant was calculated by multiplying the health-care resource use by the
associated unit costs.
Costs relating to both surgical interventions were based on time in theatre, staff time, consumables
and length of stay. The staff cost per minute was estimated using PSSRU 2018 (Personal Social Services
Research Unit) data69 for hospital-based health staff. These unit cost estimates were inclusive of staff
salaries, salary on-costs, overheads and capital overheads. To cost length of stay, we used NHS Reference
Costs 2017 to 2018,70 taking the weighted average inpatient bed-day for all major and intermediate
shoulder procedures (footnote to Healthcare Resource Group codes). Drug tariffs per milligram
for medications (i.e. anaesthesia, antibiotics and steroid injections) were obtained from the British
National Formulary.71
Costs relating to the ESP intervention were based on staff time. The cost of a physiotherapist per
hour was estimated using PSSRU 201869 based on data for hospital-based health staff (bands 5–8).
The full course of ESP was up to 12 sessions; exceptionally, the physiotherapist could decide that more
than 12 sessions were needed. The costs relating to the ESP intervention comprised the costs of the
physiotherapy sessions and the cost of the steroid injection, the latter of which was obtained from the
British National Formulary.70
The use of other hospital-based care was valued by applying unit costs extracted from national tariffs.69,71
Similarly, costs of the primary care and community-based services were estimated by applying unit costs
from national tariffs69,71 to resource volumes. Other costs included lost productivity measured as missed
work; the costs of time taken off work were estimated by applying costs from the Office for National
Statistics72 to occupational information derived from self-reported work status information.
Costs were estimated in Great British pounds and based on the financial year 2017–18. Table 21
details the unit costs used in the analysis. The total cost has three main components: (1) the cost of
the initial intervention (i.e. ESP, MUA or ACR); (2) the cost of hospital stays and hospital outpatient
appointments after the initial intervention; and (3) the cost of visits to primary and community health-
care professionals (GP, practice/community nurse, physiotherapist and occupational therapist).
The total costs for the base-case analysis included only shoulder-related resource use, except for
hospital stay, which included both shoulder and general medical complications that could apply to
the affected shoulder-specific and general medical complications. Sensitivity analyses were used to
explore the impact of a broader perspective (i.e. private care costs and productivity costs) on the
cost-effectiveness results.
The mean [standard error (SE)] costs by cost category and the mean (SE) total cost were estimated for
each treatment group, using regression analysis to control for patients’ covariates [i.e. age, sex, treatment
group, baseline OSS and diabetes (yes/no)].
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Health-related quality of life and quality-adjusted life-years
This economic evaluation took the form of a cost–utility analysis, whereby health outcomes were
assessed in terms of QALYs. HRQoL was expressed in terms of utilities, which were obtained from
trial patients using the EQ-5D-5L at baseline and at 3, 6 and 12 months. The EQ-5D-5L has two
principal measurement components. The first is a descriptive system that defines HRQoL in terms
of five dimensions: ‘mobility’, ‘self-care’, ‘usual activities’, ‘pain/discomfort’ and ‘anxiety/depression’.
Responses to each dimension are divided into five ordinal levels, coded (1) no problems, (2) slight
problems, (3) moderate problems, (4) severe problems and (5) extreme problems/unable to perform.
We evaluated the raw EQ-5D-5L scores by domain to examine the movements between levels for
each domain by trial arm. The second component is the visual analogue scale, which is used to record
a patient’s self-rated health on a vertical visual analogue scale, on which the end points are labelled
‘the best health you can imagine’ and ‘the worst health you can imagine’.
According to the responses to the EQ-5D classification system, a health status can be defined and a
single index utility can be assigned. A value set for the EQ-5D-5L is now available that reflects the
preference of members of the public in England for health states that are defined by the EQ-5D-5L
descriptive system.73 However, at the time of this analysis, the most recent guidance issued by NICE
regarding the EQ-5D-5L74 recommended the use of the mapping function (i.e. crosswalk) developed
by van Hout et al.66 to derive utilities. Therefore, this crosswalk was applied to each set of responses
to generate an EQ-5D utility score (preference weight) for each trial participant. The resulting utility
scores range from –0.281 to 1.0, with 0 representing death and 1.0 representing full health; values of
< 0 indicate health states worse than death.
TABLE 21 Resource use and costs related to initial surgery: MUA and ACR
Characteristic of the surgical procedure MUA (N= 168) ACR (N= 170)
25.11 (14.20) 76.64 (24.22)
6.41 (1.42) 6.36 (1.40)
162 (97) 46 (27)
163 (97) 153 (90)
5 (3) 17 (10)
1.2 (0.45) 2.8 (7.31)
160 (80) 159 (78)
6.42 (4.95); 18 6.65 (4.81); 18
Theatre time (minutes), mean (SD)
Number of staff in operation, mean (SD)
Patients had injection during operation, n (%)
Intervention delivered as day case, n (%)
Intervention delivered as inpatient, n (%)
Length of stay (nights), mean (SD)
Patients had PPP in their allocated group
Number of physiotherapy sessions (PPP), mean (SD); maximum 
Patients had injection, n (%) 162 (97) 46 (27)
Costs of the components of the surgical procedure (£), mean (SD)
Staff in theatre 106.45 (79.47) 360.50 (140.21)
Anaesthesia and steroid injection 99.84 (39.34) 219.15 (89.12)
Hospital stay (day case/length of stay) 218.52 (8.03) 1590.81 (398.29)
Total cost of surgical procedure 424.81 (115.55) 2170.46 (431.11)
Cost of surgical procedure – sensitivity analysis 428.57 (242.45) 1308.26 (413.43)
Cost of PPP 213.61 (157.13) 209.44 (152.95)
Total cost of surgical procedure including PPP 638.42 (204.75) 2379.90 (457.88)
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Differences in the baseline utility values between groups may lead to biases in the results even if these
differences are not statistically significant.75 Therefore, utility values were adjusted using a univariate
generalised linear model, including group as a fixed factor and baseline EQ-5D-5L score as a covariate.
Models were estimated separately for each of the time points at which utility data were collected.
We converted the utilities derived from the EQ-5D-5L into QALYs for each patient using the area
under the curve method, following the trapezium rule, which assumes linear interpolation between
follow-up points.76
Incremental mean QALYs between treatments groups were estimated with regression models
according to treatment allocation. Despite the randomisation process, which ensures that baseline
variables are balanced between trial arms, in practice (regardless of sample size) it is normal to find
an imbalance in mean baseline utility. As baseline utility is likely to be correlated with patients’ QALYs
gained over time, there are robust reasons to control for baseline utilities when estimating QALYs.
Therefore, QALYs were analysed both (1) adjusting for baseline EQ-5D-5L and (2) adjusting for
baseline EQ-5D-5L plus the same set of covariates used in the clinical effectiveness analysis, which
included baseline utility, that is age, sex, treatment group, baseline OSS and diabetes (yes or no).
Missing data
Missing data occur frequently in RCTs, irrespective of how well designed the data collection is. This is
a major concern for within-trial cost-effectiveness analyses, as costs and QALYs, the main outcomes in
cost-effectiveness analyses, are cumulative measures collected over trial follow-up. Therefore, missing
data at one follow-up time point (e.g. one dimension response missing on the EQ-5D at one time point)
result in missing aggregate data (e.g. total QALYs over the trial) for that participant. This problem is
common in economic evaluations, as the analysis has to draw on all aspects of the study, including
resource use and health outcomes. Non-response to questionnaires and returned but incomplete
questionnaires reduce, often considerably, the number of data on resource use that are available for
analysis. The problem is amplified when there are frequent assessments, as in UK FROST.
Different methods of handling missing data can yield different results and decisions about the value
for money of the assessed interventions. Complete-case assessment and available case analysis are
proposed as useful preliminary estimations for economic evaluation but should not constitute the
base case for within-trial economic evaluation.77 Therefore, it was decided prior to the analysis that
complete-case assessment would be presented only for comparison purposes. Additionally, the analysis
of the missing pattern of the UK FROST data set would support this decision, as the results suggest
that data are not missing completely at random (the assumption driving the complete-case mechanism).
An alternative method for addressing missing data in cost-effectiveness analyses alongside RCTs is
multiple imputation,77 which has been recommended as the appropriate method to reflect the uncertainty
in the results of economic evaluations attributable to missing data.67 The main assumption that drives the
multiple imputation mechanism is that the data are ‘missing at random’ (MAR). That is, the missing values
in the data set may depend on the value of other observed variables in the data set, but, conditional on
those values, the data are MAR. A major concern is that the chance that data are missing may be linked
directly to the unobserved value itself [missing not at random (MNAR)]; for example, patients with poorer
health may be less likely to complete EQ-5D questionnaires. Therefore, it remains important that the
choice of method be grounded in the assumed missing data mechanism, which, in turn, should be
informed by the available evidence.
Following methodological recommendations for handling missing data in cost-effectiveness analyses
conducted within RCTs,78,79 we conducted descriptive analyses of the missing data to explore whether
or not the MAR assumption is plausible given the actual missing data mechanism of the UK FROST
data set. We assessed the number of missing data by trial arm at each follow-up period, explored
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missing data patterns using graphical tools and investigated the association between missingness and
baseline variables/observed outcomes using logistic regressions.
Based on the results of the descriptive analyses, we could conclude that MAR is a plausible assumption
fitting the UK FROST data set. Therefore, multiple imputation was selected to handle missing data for
the base-case analysis. Multiple imputation using chained equations80 and predicted mean matching
were carried out on the EQ-5D-5L at 3, 6 and 12 months, as well as on the total cost estimates.
Predicted mean matching is a semiparametric imputation approach that ensures that observed data
are used to estimate a predictive model (using the specified covariates) but, instead of replacing
missing values with the model predicted values, the nearest observed value is used to fill the missing
one. This guarantees that the imputed values are sampled from values in the original data set, and,
therefore, no imputed values will lie outside the bounds of the original data distribution. The multiple
imputation model was validated by comparing the distribution of the observed UK FROST data with
the imputed data using graphical plots to visualise whether or not the distribution of imputed data
resembles the distribution of original data. Age, sex, baseline OSS score and diabetes (yes/no) at
baseline were included as explanatory variables in the imputation models. In addition, the baseline
EQ-5D-5L utility score and all predictors of missingness were included as an explanatory variable in
the models. Multiple imputation by chained equations was performed for a total of 60 imputations.
The estimates obtained from each imputed data set are combined to generate mean estimates of
costs and QALYs, variances and CIs using Rubin’s rules.81
Finally, as it is impossible to know whether data are MNAR or MAR from the observed data, we
explored possible departures from the MAR assumption by means of sensitivity analyses, evaluating
the impact of assuming that the data are MNAR rather than MAR. In addition, a mixed model, which
does not require an imputation process, is also presented as per sensitivity analysis.
Cost-effectiveness analyses
The main cost-effectiveness analyses were conducted following multiple imputations of all cost and
outcomes data. The mean difference in costs and QALYs for the base-case analysis was estimated using
regression methods for data on costs and QALYs, adjusting for baseline characteristics.
A bivariate regression model – seemingly unrelated regression (SUR) – of costs and QALYs was used
to calculate incremental estimates, using conventional decision rules and estimating incremental
cost-effectiveness ratios (ICERs) when appropriate.82 SUR allows outcomes to be estimated jointly
and so brings efficiency gains over ordinary least squares.83 In the bivariate model, incremental
costs and QALYs are estimated simultaneously from two separate ordinary least squares regressions,
assuming correlation between the error terms in both regressions.84 The SUR model used the same
set of covariates as the mixed-effect regression model used for the clinical effectiveness analysis
[age, sex, baseline EQ-5D score, baseline OSS score and diabetes (yes/no)].
The cost-effectiveness results were expressed in terms of ICERs. These were estimated as the
difference in mean costs divided by the difference in mean QALYs between the trial comparators.
The ICER is estimated to inform decision-makers about the optimal use of NHS resources. According
to standard cost-effectiveness decision rules, four different eventualities are plausible when comparing
incremental costs and QALYs. If the new intervention provides better outcomes (positive incremental
QALYs) at lower costs (negative incremental costs), it is considered a dominant intervention and, hence,
cost-effective. If the new intervention achieves poorer outcomes (negative incremental QALYs) at higher
costs (positive incremental costs), it is considered a dominated option and, hence, not cost-effective.
Thus, the ICER is considered only if either intervention does not dominate, that is both incremental
costs and incremental QALYs are positive (or negative). In these last two situations, to determine
whether or not the incremental health gain is worth the incremental cost, the ICER needs to be
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compared against a threshold value. For positive incremental costs and QALYs (the most frequent
situation in HTA), an intervention will be considered cost-effective only if the ICER is lower than the
threshold. According to NICE, the willingness-to-pay threshold for an additional QALY ranges from
£20,000 to £30,000.67 This threshold has been used by NICE for more than a decade; however, it has
recently been suggested that the threshold should be decreased to £13,000 per QALY gained.85,86
According to the current established decision rules, if the result of this cost–utility analysis, namely
the estimated cost per QALY, is below the £30,000 threshold, the intervention would be considered
cost-effective in terms of QALYs gained.
To compute the probability that each intervention is cost-effective at a given cost-effective threshold,
the SUR was conducted in a bootstrapping approach on five imputed data sets to generate 10,000
replicates of incremental costs and benefits. These replicates were represented graphically as cost-
effectiveness acceptability curves (CEACs). The probability that each intervention is cost-effective is
reported at the cost-effectiveness threshold of £20,000–30,000 per QALY applied by NICE and at a
threshold of £13,000 per QALY as suggested by recent research.
Sensitivity analyses and uncertainty
The uncertainty around the cost-effectiveness results was explored using sensitivity analyses that
explored the robustness of the results to base-case assumptions. This involved re-estimating the
main cost-effectiveness outcomes under different scenarios for costs and missing data. We conducted
two sensitivity analysis around costs that implied recalculating costs: (1) including non-shoulder costs
(ITT); and (2) adopting a broader perspective that included productivity costs and private care costs.
A further number of sensitivity analyses were conducted to explore the impact of missing data on
cost-effectiveness estimates: (3) restricting the analyses to complete cases following ITT; (4) imputing
QALY data at the aggregated level rather than at the index-score level; (5) using a mixed-model
approach; and (6) under a MNAR scenario.
Results
Study population
The baseline study population for the economic analysis was 503 patients. In total, 99 patients were
allocated to ESP, 201 were allocated to MUA and 203 were allocated to ACR. Nineteen participants
fully withdrew from the trial; for those participants we used multiple imputation techniques to impute
missing economic data. As mentioned in the clinical section, 16 participants crossed over from their
initial randomisation. This involved patients crossing from ESP to ACR (n = 7), from MUA to ESP (n = 4),
from ACR to ESP (n = 2) and from ACR to MUA (n = 3).
Health-care resource use and costs
Costs of delivering surgery (manipulation under anaesthesia and arthroscopic
capsular release)
Detailed resource use and costs of both surgical interventions are given in Table 21. Costs relating to
surgical procedures are based on the time in theatre, the delivery of anaesthesia and injections, and
the length of hospital stay. To estimate the cost of MUA and ACR, this included participants who had
these interventions across any of the treatment groups. MUA surgical information was available for
168 participants: patients allocated to MUA (n = 164), patients who withdrew from treatment but still
consumed surgical resources (n = 2) and patients allocated to ACR who crossed over to MUA and for
whom a surgical form was available (n = 2). ACR surgical information was available for 170 participants:
patients allocated to MUA (n = 162), patients who withdrew from treatment but still consumed surgical
resources (n = 3) and patients allocated to ESP who crossed over to ACR and for whom a surgical form
was available (n = 5).
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The mean cost of MUA was £424.81 (SD £115.55). For 97% of the patients, MUA was delivered as a
day-case procedure; only 3% of the patients required hospitalisation (only 1 night). The average
duration of MUA was 25.11 minutes (SD 14.20 minutes).
The mean cost of ACR was £2170.46 (SD £431.11). For 90% of the patients ACR was delivered as a
day-case procedure; 10% of the patients required hospitalisation of, on average, 2.8 nights (median 1,
minimum 1, maximum 31 nights). The average duration of ACR was 76.61 minutes (SD 24.22 minutes).
The cost of PPP was similar for both groups: £213.61 (£157.13) for MUA and £209.44 (£152.95) for ACR.
Non-surgery (early structured physiotherapy intervention)
The total cost of ESP (Table 22) includes the cost of the injection and physiotherapy that patients
received. The mean cost of ESP was £279.46 (SD £148.56).
The hospital costs related to complications and additional/further/other treatments patients had from
discharge after initial treatment up to 12 months are shown in Table 23.
Descriptive statistics (mean, median and amount missing) of health-care resource use related to
primary and community care, by resource category and by follow-up, are shown in Table 24. The
results presented are based on the available data set. Although resource use was slightly higher for
the ACR group, differences between the groups in resource use in the primary setting appeared small.
In terms of dispersion of the results, the median estimates are smaller than the means for all resource
use, which suggests that the distributions were skewed to the right.
TABLE 22 Costs related to ESP
Cost ESP (n= 92)
Cost of steroid injection, mean (SD) 42.96 (31.82)
Cost of physiotherapy, mean (SD) 217.11 (146.85)
Mean (SD) cost – ESP intervention 260.07 (155.07)
TABLE 23 Cost related to complications and additional treatments by trial arm
Cost
ESP (N= 99) MUA (N= 201) ACR (N= 203)
n (%)
Mean cost (£)
(SD) n (%)
Mean cost (£)
(SD) n (%)
Mean cost (£)
(SD)
Randomised patients: cost
of additional treatments
2 (2.02) 3.39 (23.75) 2 (1) 1.67 (16.71) 5 (2.47) 3.69 (23.43)
Randomised patients: cost
of further treatments
15 (15.1) 89.77 (285.23) 14 (6.96) 53.24 (246.32) 6 (2.95) 6.10 (39.05)
Withdrawals: cost of
alternative treatments
2 (2.02) 8.01 (68.17) 8 (3.98) 5.97 (38.43) 9 (4.43) 7.96 (48.48)
Crossovers: cost of other
treatments after crossover
2 (2.02) 2.52 (17.67) 0 (0) 0 (0) 0 (0) 0 (0)
Cost of complications
(hospital inpatient)
7 (7.07) 9.27 (47.79) 9 (4.47) 42.84 (360.62) 5 (2.46) 34.46 (334.47)
Cost of complications
(hospital outpatient)
11 (11.1) 34.09 (112.69) 16 (7.96) 19.26 (83.92) 11 (5.42) 12.30 (60.90)
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TABLE 24 Average primary care and community care resource use (shoulder related) and days missed off work per treatment group
Resource type
MUA (N= 201) ACR (N= 203) ESP (N= 99)
n Mean (SD) Median Missing, n (%) n Mean (SD) Median Missing, n (%) n Mean (SD) Median Missing, n (%)
GP surgery total 137 1.61 (3.04) 0 64 (31.8) 138 1.73 (3.23) 0 65 (32.0) 62 0.90 (1.89) 0 37 (37.4)
3 months 168 0.82 (1.64) 0 33 (16.42) 171 1.05 (1.97) 0 32 (15.76) 84 0.58 (1.44) 0 15 (15.15)
6 months 162 0.30 (1.25) 0 39 (19.40) 163 0.49 (1.60) 0 40 (19.70) 76 0.35 (0.89) 0 23 (23.23)
12 months 169 0.34 (1.20) 0 64. (31.84) 162 0.24 (0.76) 0 65 (32.02) 80 0.25 (0.88) 0 37 (37.37)
GP telephone total 136 0.54 (2.05) 0 65 (32.3) 134 0.44 (1.1) 0 69 (33.9) 61 0.10 (0.47) 0 38 (38.4)
3 months 168 0.28 (1.24) 0 3 (16.42) 165 0.32 (0.99) 0 28 (18.72) 82 0.06 (0.33) 0 17 (17.17)
6 months 162 0.16 (1.13) 0 39 (19.40) 161 0.09 (0.41) 0 42 (20.69) 74 0.03 (0.16) 0 25 (25.25)
12 months 168 0.05 (0.17) 0 33 (16.42) 162 0.03 (0.22) 0 41 (20.20) 83 0.01 (0.011) 0 16 (16.16)
Physiotherapist 135 0.83 (2.8) 0 66 (32.8) 136 1.25 (3.8) 0 67 (33.0) 64 1.17 (4.0) 0 35 (35.3)
3 months 167 0.66 (2.26) 0 34 (16.92) 167 0.64 (2.95) 0 36 (17.73) 83 0.42 (1.72) 0 16 (16.16)
6 months 161 0.14 (0.79) 0 40 (19.90) 161 0.31 (1.24) 0 42 (20.69) 77 0.49 (2.25) 0 22 (22.22)
12 months 170 0.71 (0.92) 0 31 (15.42) 162 0.31 (1.32) 0 41 (20.20) 83 0.24 (0.22) 0 16 (16.16)
Nurse surgery 132 0.07 (0.3) 0 69 (34.3) 129 0.39 (0.8) 0 74 (36.4) 59 0.05 (0.3) 0 40 (40.4)
3 months 166 0.2 (0.15) 0 35 (17.41) 165 0.34 (1.09) 0 38 (18.72) 79 0.05 (0.32) 0 20 (20.20)
6 months 160 0.01 (0.08) 0 41 (20.40) 156 0.08 (0.30) 0 47 (23.15) 75 0.04 (0.26) 0 24 (24.24)
12 months 165 0.05 (0.29) 0 36 (17.91) 160 0.02 (0.14) 0 43 (21.18) 79 0 (0) 0 20 (20.20)
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TABLE 24 Average primary care and community care resource use (shoulder related) and days missed off work per treatment group (continued )
Resource type
MUA (N= 201) ACR (N= 203) ESP (N= 99)
n Mean (SD) Median Missing, n (%) n Mean (SD) Median Missing, n (%) n Mean (SD) Median Missing, n (%)
Community nurse 135 0 (0) 0 66 (32.8) 136 0.12 (0.9) 0 67 (33.0) 62 0 (0) 0 37 (37.4)
3 months 168 0 (0) 0 33 (16.42) 168 0.07 (0.51) 0 35 (17.24) 83 0 (0) 0 16 (16.16)
6 months 160 0 (0) 0 41 (20.40) 161 0.07 (0.79) 0 42 (20.69) 75 0 (0) 0 24 (24.24)
12 months 170 0.01 (0.15) 0 31 (15.42) 161 0 (0) 0 42 (20.69) 82 0 (0) 0 17 (17.17)
Occupational therapy 137 0.09 (0.7) 0 64 (31.8) 137 0.06 (0.7) 0 66 (32.5) 63 0 (0) 0 36 (36.4)
3 months 168 0.03 (0.46) 0 33 (16.42) 167 0 (0) 0 36 (17.73) 83 0 (0) 0 16 (16.16)
6 months 161 0 (0) 0 40 (19.90) 162 0.01 (0.08) 0 41 (20.20) 76 0 (0) 0 23 (23.23)
12 months 171 0.05 (0.48) 0 32 (15.92) 162 0.05 (0.63) 0 41 (20.20) 82 0 (0) 0 19 (19.19)
Lost days off work 105 17.5 (26.4) 6 96 (47.8) 92 32.8 (44.2) 14 111 (54.) 34 11.5 (27.8) 0 65 (65.6)
3 months 138 12.5 (22.0) 2 63 (31.34) 125 13.3 (23.6) 0 78 (38.42) 61 7.2 (20.6) 0 38 (38.38)
6 months 132 3.5 (10.5) 0 69 (34.32) 125 10.9 (23.2) 0 78 (38.42) 50 5.2 (18.8) 0 49 (49.49)
12 months 138 2.8 (13.3) 0 63 (31.34) 129 3.1 (13.1) 0 74 (36.45) 57 3.9 (13.1) 0 42 (42.42)
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Over the entire follow-up period, a higher proportion of participants in the ACR group incurred a loss of
earnings as a result of their problems with their shoulders than participants in the other two groups. On
average, the number of missed days of work was 11.5 (SD 27.8; median 0; minimum 0, maximum 115)
days in the ESP group, 17.5 (SD 26.4; median 6; minimum 0, maximum 120) days in the MUA group and
32.8 (SD 44.2; median 14; minimum 0, maximum 195) days in the ACR group. The difference between
the groups is large, and this is reflected in the productivity costs shown in Table 26.
Resource use was multiplied by unit costs (Table 25) to estimate the economic costs of each resource
category. Costs for patients with complete data are in Table 26, by trial group and cost category.
Over the entire follow-up period, the mean (SE) total NHS and Personal Social Services costs, inclusive
of the costs of the allocated index intervention, were £599.06 (£359.23) in the ESP arm, £834.20
(£752.66) in the MUA arm and £2271.09 (£902.50) in the ACR arm.
TABLE 25 Unit costs used for the analysis (£, 2017–18 prices)
Item Unit cost (£) Source
Primary and community care
GP visit at GP practicea 37.40 Unit Costs of Health and Social Care 201869
GP visit at homea 93.60 Unit Costs of Health and Social Care 201869
GP by telephonea 15.20 Unit Costs of Health and Social Care 201869
Nurse visit at GP practice 10.85 Unit Costs of Health and Social Care 201869
District/community nurse 38.00 Unit Costs of Health and Social Care 201869
Occupational therapist visit 47.00 Unit Costs of Health and Social Care 201869
Physiotherapist visitb 57.25 NHS Reference Costs 2017 to 201870
Hospital care
Inpatient stay (shoulder)c 258.00–449.00 NHS Reference Costs 2017 to 201870
Inpatient stay (non-shoulder) 384.22 NHS Reference Costs 2017 to 201870
Day-case visit (shoulder)c 420.00–2512.00 NHS Reference Costs 2017 to 201870
Outpatient visit (shoulder) 125.01 NHS Reference Costs 2017 to 201870
Outpatient visit (non-shoulder) 123.93 NHS Reference Costs 2017 to 201870
Hospital physiotherapy visit 54.91 NHS Reference Costs 2017 to 201870
Other health service visit 74.11 NHS Reference Costs 2017 to 201870
Consultant surgical 108.00 Unit Costs of Health and Social Care 201869
Associate specialist 105.00 Unit Costs of Health and Social Care 201869
Specialty registrar 43.00 Unit Costs of Health and Social Care 201869
Foundation doctor FY1 32.00 Unit Costs of Health and Social Care 201869
Foundation doctor FY2 28.00 Unit Costs of Health and Social Care 201869
Physiotherapist band 5 35.00 Unit Costs of Health and Social Care 201869
Physiotherapist band 6 46.00 Unit Costs of Health and Social Care 201869
Physiotherapist band 7 55.00 Unit Costs of Health and Social Care 201869
Physiotherapist band ≥ 8d 72.00 Unit Costs of Health and Social Care 201869
Nurse band 5 37.00 Unit Costs of Health and Social Care 201869
Nurse band 6 45.00 Unit Costs of Health and Social Care 201869
Nurse band 7 54.00 Unit Costs of Health and Social Care 201869
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TABLE 25 Unit costs used for the analysis (£, 2017–18 prices) (continued )
Item Unit cost (£) Source
Medications
Depomedrone 40mg 3.44 BNF71
Depomedrone 80mg 6.88 BNF71
Triamcinolone 40 mg 17.88 BNF71
Triamcinolone 80 mg 35.76 BNF71
Bupivacaine 0.5% (10 ml) 0.915 BNF71
General anaesthesia 30.99 BNF71
Antibiotics 6.11 BNF71
Private care
Private non-NHS physiotherapist 50.00 www.capitalphysio.com
(accessed 1 November 2020)
Private osteopath 42.50 www.nhs.uk/conditions/osteopathy
(accessed 1 November 2020)
Private chiropractitioner 55.00 www.nhs.uk/conditions/chiropractic
(accessed 1 November 2020)
Community care service 49.00 Averaged of three above
Private hospital – night 337.00 NHS Reference Costs 2017 to 201870
BNF, British National Formulary.
a Durations sourced from PSSRU 2015.
b Community health services, physiotherapist, adult, one to one (currency code A08A1).
c Sum of total expenditure on excess bed-days (elective and non-elective) divided by total activity for Healthcare
Resource Group codes relating to shoulder: MUA (HD24E; non-inflammatory, bone or joint disorders, with CC
score 8–11); ACR (HN53A, HN53B, HN53C, HN54A, HN54B, HN54C; major and intermediate procedures for
non-trauma with CC score 4+, 2–3 and 0–1).
d PPP form is featured to record staff at or above band 8. Hence, the unit cost for a physiotherapist at or above band
8 is estimated as the average of 8a (£66) and 8b (£78).
TABLE 26 Costs for patients with complete data by treatment arm and cost category (£, 2017–18 prices)
Costs
Treatment arm, mean (£) (SE)
MUA ACR ESP
MUAa 349.46 (191.91) 5.55 (55.78) 0
ACRa 0 1762.32 (934.61) 113.42 (495.67)
ESPa 6.90 (59.08) 1.25 (13.02) 260.07 (155.07)
Physiotherapy (hospital) 175.88 (163.90) 174.63 (161.73) 6.98 (36.55)
Physiotherapy (community) 43.80 (146.04) 66 (201.67) 61.87 (211.11)
Further treatments 60.27 (248.06) 17.77 (66.72) 103.70 (290.25)
Hospital inpatient 42.84 (360.62) 34.46 (334.46) 9.27 (47.79)
Hospital outpatient 19.26 (83.92) 12.30 (60.90) 34.09 (112.69)
GP at the surgery 60.33 (113.86) 64.77 (120.87) 33.78 (70.61)
GP over the telephone 8.15 (31.22) 6.69 (16.93) 1.49 (7.18)
Nurse at the surgery 0.74 (3.34) 4.20 (9.13) 0.55 (3.14)
Community nurse 0.00 (0.00) 4.75 (33.81) 0.00 (0.00)
Occupational therapist 4.12 (33.95) 3.09 (32.34) 0.00 (0.00)
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The total costs estimates shown here are unadjusted means and relate to complete cases; therefore,
there is limited value in interpreting the differences between treatments. The mean differences for
each surgical treatment compared with ESP, and the corresponding 95% CIs, adjusted for patient
covariates and taking into consideration the correlation between costs and QALYs, are shown in
Cost-effectiveness analysis.
Health-related quality of life and quality-adjusted life-years
A similar decrease in complete EQ-5D-5L questionnaires was seen throughout the trial follow-up
across the three arms. Responses for the complete follow-up (i.e. baseline and 3, 6 and 12 months)
were available for 369 (73%) participants: 156 (78%) in the MUA arm, 149 (73%) in the ACR arm
and 64 (65%) in the ESP arm. The extent of incomplete EQ-5D-5L responses as a result of missing
data strengthened the justification for using the imputed data sets as the base case (see Appendix 16).
The proportions of participants who reported the EQ-5D-5L levels (1–5) by dimension, group and time
point are in Appendix 16. Comparing self-care levels between baseline and 12 months, we found that
more people reported no problems across all the treatments, but the percentage was slightly higher
in the ACR arm. When looking at usual activities, all groups had a similar increase over 12 months in
the number of participants who classed themselves as level 1. A smaller percentage of participants
were level 1 for pain/discomfort after 12 months in the ESP arm than in the MUA and ACR arms.
When looking at anxiety and depression, we found that there was, again, a comparable increase in
the percentage of participants in level 1 between baseline and 12 months across all treatments.
The overall distribution of the EQ-5D-5L scores (utilities) for the different follow-up assessments is
illustrated in Figure 12. Patients allocated to MUA started from a higher utility value than patients
allocated to ACR and ESP.
Table 27 summarises the mean EQ-5D-5L scores reported at each follow-up point for all available
patients. Adjusted analysis shows that patients allocated to ACR and MUA had similar utility values
at 12-month follow-up [ACR (mean 0.739) vs. MUA (mean 0.734)]. Similarly, patients allocated to the
surgical arms had better utility values than those allocated to the ESP arm (mean 0.693). The QALY
estimates at 1-year follow-up (adjusted for baseline utility) show that patients allocated to MUA
accrued more QALYs than those in the other two arms: MUA (0.6765) >ESP (0.6492) >ACR (0.6475).
As for total costs, the HRQoL and QALYs estimates shown in this section are of limited value, as these
estimates correspond exclusively to patients with complete EQ-5D-5L data (i.e. at baseline and at
3, 6 and 12 months). The mean differences in QALYs between the groups and corresponding 95% CIs,
adjusted for all relevant covariates and taking into consideration the correlation between costs and
QALYs, are shown in Cost-effectiveness analysis.
TABLE 26 Costs for patients with complete data by treatment arm and cost category (£, 2017–18 prices) (continued )
Costs
Treatment arm, mean (£) (SE)
MUA ACR ESP
Total costs (NHS)
Shoulder (a) 834.02 (752.66) 2271.09 (902.5) 599.06 (359.23)
aNon-shoulder (b) 182.12 (228.98) 195.76 (304.22) 241.82 (366.23)
Productivity costs (c) 1995.29 (2999.85) 3735.61 (5031.35) 1308.70 (3165.177)
Private care costs (d) 31.23 (117.63) 21.40 (111.22) 40.00 (144.51)
Total broader costs (a+ b+ c+ d) 3200.98 (3824.39) 5377.18 (4240.28) 1475.05 (2367.87)
a The cost of the intervention includes the costs of injections.
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Missing data
The UK FROST study collected data using the EQ-5D-5L at 3, 6 and 12 months. Health-care resource
use was elicited from patients by postal questionnaire at 3, 6 and 12 months, and from health-care
professionals by hospital forms 52 weeks after randomisation. A description of the economic variables
in UK FROST can be found in Appendix 17.
Overall, the proportion of participants with complete economic data remained similar between treatment
arms (see Appendix 17): 46.46% in the ESP arm, 58.21% in the MUA arm and 57.14% in the ACR arm.
In all arms, more individuals are observed in month 12 than in month 6. Therefore, the missing data do
not follow a monotonic pattern; in other words, there are participants with intermittent missing data
(e.g. lost to follow-up at 6 months but remained subsequently). Hence, inverse probability weighting
would be inappropriate under such a pattern. Similarly, complete-case analysis would be, as a minimum,
inefficient because it would discard observed data from individuals with some missing outcomes.
Figures showing the pattern of missing data are in Appendix 17. As discussed above, missing data are
shown to be non-monotonic, as individuals with missing data at one follow-up point may provide
data subsequently.
TABLE 27 Health-related quality of life: EQ-5D-5L summary scores (available cases) at each time point adjusted for
baseline utility
Follow-up point
Treatment arm, mean (SE)
MUA ACR ESP
Baseline 0.456 (0.263) 0.428 (0.234) 0.402 (0.294)
3 months 0.632 (0.017) 0.567 (0.017) 0.606 (0.024)
6 months 0.729 (0.016) 0.677 (0.016) 0.680 (0.024)
12 months 0.734 (0.018) 0.739 (0.184) 0.693 (0.027)
QALYs (adjusted utility) (95% CI) 0.6765 (0.651 to 0.702) 0.6475 (0.621 to 0.674) 0.6492 (0.609 to 0.690)
QALY estimates (complete cases) adjusted for baseline utility.
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FIGURE 12 The EQ-5D-5L scores distribution at the different time points over the 12 months.
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Logistic regressions of indicators of missing cost and QALY data on treatment allocation and a selection
of baseline variables showed that lower EQ-5D-5L scores at baseline are associated with missing cost
and QALY data (see Appendix 17). Baseline age was also found to be a significant predictor of missing
data on HRQoL. This suggests that the data are unlikely to be missing completely at random. The other
baseline covariates (sex and diabetes) were associated with missingness but were not statistically
significant at 5%. However, diabetes was significant predictor of costs and QALYs at 6 months and 1 year,
which would support both covariate-dependent missing completely at random and MAR assumptions.
We also explored whether or not missingness is associated with previously observed outcomes by
regressing indicators of missing costs or QALYs at each year on their previously observed values
(e.g. regressing missing costs and QALYs at 1 year on costs and QALYs in previous months). Most
regressions produced statistically insignificant results (p > 0.05), with two exceptions: missing QALYs
at 1 year were significantly associated with QALYs at 3 months, and missing costs at 1 year were
significantly associated with QALYs at 3 months and QALYs at 6 months. Although these regressions
are likely to be affected by multicollinearity, they provide an indication that data are unlikely to be
covariate-dependent missing completely at random.
Therefore, data were assumed to be MAR, and multiple imputation by chained equations was selected
to handle missing data for this economic analysis. In the analysis, missingness is assumed to depend on
baseline covariates (sex, diabetes, age, EQ-5D-5L at baseline and OSS score at baseline) and observed
costs and QALYs but to be independent of unobservable costs at QALYs at 1 year. As it is impossible
to know whether data are MNAR or MAR from the observed data, a mixed model is presented as per
sensitivity analysis. Complete-case analysis, which is not valid when data are MAR, is presented for
comparison only.
The multiple imputation model was validated by comparing the distribution of the observed UK FROST
data with the imputed data (see Appendix 17).
Cost-effectiveness analysis
Base-case analysis
A bivariate regression, in the form of a seemingly related regression, conducted in the imputed data set
was used to estimate the incremental costs and incremental health outcomes (i.e. QALYs) associated
with the interventions (Table 28). Patients allocated to MUA showed a (non-significant) QALY gain
compared with those allocated to ESP (mean difference 0.0396, 95% CI –0.0008 to 0.0800). Similarly,
patients allocated to ACR showed a (non-significant) QALY gain compared with those allocated to
ESP (mean difference 0.0103, 95% CI –0.0304 to 0.0510). Overall, those allocated to ACR had worse
(non-significant) QALYs than those allocated to MUA at the 12-month follow-up (mean difference
–0.0293, 95% CI –0.0616 to 0.0030).
The results of the fully incremental cost-effectiveness estimates and probability that each intervention
is cost-effective at a threshold of £20,000 per QALY are also shown in Table 28. Compared with
physiotherapy, MUA cost a mean of £276 more per patient (95% CI £65.67 to £487.35) and allowed
patients to experience improved health outcomes at the end of the trial (on average 0.0396 more
QALYs per participant than ESP, 95% CI –0.0008 to 0.0800). The resulting ICER for MUA was £6984
per additional QALY. ACR is significantly more costly than ESP [on average £1733.78 more expensive
per participant (95% CI £1529.48 to £1938.06)], and, despite the QALY gain accrued by ACR participants
(on average 0.0396 more QALYs per participant than ESP, 95% CI –0.0008 to 0.0800), this was not
sufficient to prove that ACR is a cost-effective use of NHS resources when compared with ESP (i.e. ICER
above recommended NICE threshold). Similarly, ACR is dominated by MUA, with higher mean costs and
fewer QALYs.
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The corresponding CEACs showing the probability that each treatment is cost-effective across a range
of thresholds are shown in Figure 13. The probability that MUA surgery is cost-effective is 0.88 at
a threshold of £20,000 per QALY gained. The CEAC indicates that, regardless of the value of the
cost-effectiveness threshold, the probability that ACR is cost-effective does not exceed 0.002.
Sensitivity analyses and uncertainty
A number of scenario analyses were conducted to test the robustness to alternative assumptions,
both related to costs and missing data. As already mentioned, we considered two sensitivity analysis
around costs. Table 29 shows the results of both scenarios that implied recalculating costs: scenario 1
[including non-shoulder costs (ITT)]; and scenario 2 (including productivity costs and private care
costs). The ICER for MUA was £10,485 per QALY gained when including (primary care) non-shoulder
resource use in the analysis, indicating that MUA would continue being a cost-effective use of NHS
resources. By contrast, cost-effectiveness results were sensitive to a wider perspective scenario,
suggesting that the ICER from a wider perspective was higher than the thresholds that NICE normally
considers for reimbursement decisions. ACR continued to be dominated by MUA in both scenarios.
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TABLE 28 Adjusted mean differences in QALYs and costs between interventions (base case)
Treatment arm Adjusted difference in means with SURa (95% CI)
Difference in costs (£)
MUA vs. ESP 276.507 (65.67 to 487.35)
ACR vs. ESP 1733.78 (1529.48 to 1938.06)
ACR vs. MUA 1457.26 (1282.73 to 1631.79)
Difference in QALYs
MUA vs. ESP 0.0396 (–0.0008 to 0.0800)
ACR vs. ESP 0.0103 (–0.0304 to 0.0510)
ACR vs. MUA –0.0293 (–0.0616 to 0.0030)
ICER (£ per QALY) Probability that
intervention is
cost-effective at
£13,000/QALY
Probability that
intervention is
cost-effective at
£20,000/QALY
Probability that
intervention is
cost-effective at
£30,000/QALY
MUA 6984 0.7942 0.8632 0.8978
ACR > 100,000 0.0000 0.0002 0.002
ESP – 0.2058 0.1366 0.1002
SUR, seemingly unrelated regression.
a Compared with ESP, as it is the alternative with lower costs and worse health outcomes.
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TABLE 29 Sensitivity analysis (scenarios 1 and 2): summary for incremental analysis (ITT), cost-effectiveness results and
uncertainty under different cost scenarios
Treatment comparisons
Multiple imputation of
costs (shoulder – NHS
perspective) and QALYs
analysis with SUR:
base-case analysis
Multiple imputation
of costs (shoulder and
non-shoulder – NHS
perspective) and QALYs
analysis with SUR:
scenario 1
Multiple imputation
of costs (broader
perspectivea) and
QALYs analysis with
SUR: scenario 2
MUA vs. ESP
Difference in costs (£)
Mean 276.50 162.76 1031.86
SE 107.4462 112.83 595.33
95% CI 65.67 to 487.35 –58.39 to 383.91 –136.92 to 2200.65
Difference in QALYs
Mean 0.039 0.0375 0.0375
SE 0.0206 0.0207 0.0207
95% CI –0.001 to 0.080 –0.0032 to 0.0782 –0.0032 to 0.0781
ICER 6984 4336 27,522
Probability that MUA is cost-effectiveb 0.88 0.90 0.36
ACR vs. ESP
Difference in costs (£)
Mean 1733.78 1555.48 4109.96
SE 104.147 112.42 647.75
95% CI 1529.48 to 1938.06 1335.14 to 1775.82 2836.20 to 5383.73
Difference in QALYs
Mean 0.0103 0.0080 0.0081
SE 0.0207555 0.0208 0.0208
95% CI –0.0304 to 0.0510 –0.0328 to 0.0488 –0.0327 to 0.0488
ICER 168,613 194,895 507,707
Probability that ACR is cost-effectiveb 0.030 0.008 0.000
ACR vs. MUA
Difference in costs (£)
Mean 1457.26 1392.72 3078.10
SE 88.90998 91.41 548.27
95% CI 1282.73 to 1631.79 1213.56 to 1571.87 1999.07 to 4157.13
Difference in QALYs
Mean –0.0293 –0.0296 –0.0294
SE 0.0164678 0.0165 0.0165
95% CI –0.0616 to 0.0030 –0.0619 to 0.0028 –0.0618 to 0.0030
ICER ACR dominated by MUA ACR dominated by MUA ACR dominated by MUA
Probability that ACR is cost-effectiveb 0.00 0.00 0.00
a The broader perspective includes NHS costs for the shoulder, and non-shoulder, productivity and private costs.
b The probability of being cost-effective is estimated at a threshold of £20,000 per QALY.
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Table 30 shows the results of the sensitivity analyses to test the impact of different methods for
handling missing data in results. Given the results of the base-case analyses, sensitivity analyses
around missing data were restricted to the comparison of MUA with ESP. The mean difference in
costs and QALYs and the ICER changed according to the method. The differences in costs were £339
(95% CI £72 to £606) for complete-case analysis, £193 (95% CI –£14 to £399) for multiple imputation
and £256 (95% CI £2 to £509) for the mixed model. The differences in QALYs adjusted for EQ-5D and
baseline covariates were 0.016 (95% CI –0.034 to 0.066) for complete-case analysis, 0.036 (95% CI
–0.004 to 0.076) for multiple imputation and 0.030 (95% CI –0.014 to 0.073) for the mixed model.
The SEs are larger in the complete-case analysis, which reflects the smaller sample size. The mixed
model has slightly larger SEs than multiple imputation in both the incremental costs and the QALYs,
possibly because of the large number of parameters to estimate compared with the analysis model
post multiple imputation. The average incremental costs in the complete-case analysis are higher
than those estimated with multiple imputation and the mixed model, suggesting that a bias would be
introduced if missing completely at random is assumed. However, both multiple imputation and the
mixed model agree that MUA is the cost-effective alternative.
In this situation, sensitivity analyses to determine which departures from MAR can alter the conclusions
are useful. Hence, the costs and QALYs were imputed under MAR and then shifted under different
scenarios. These scenarios were judged of most interest after discussion with clinical experts. Hence,
we considered a number of scenarios in which the costs of MUA and ESP were increased by 10% and
50% in both arms or by treatment arm; the same approach was followed for QALYs (see Appendix 17).
Increasing costs or decreasing QALYs in both patient groups makes little difference to the results.
The probability changes considerably only when the QALYs of individuals with missing data who were
allocated to MUA are decreased by 50%. Nevertheless, MUA remains the intervention most likely
to be cost-effective even if its imputed QALYs are reduced by 10% or if its cost is increased by 50%.
The results suggest, therefore, that the positive cost-effectiveness profile of MUA is robust to plausible
departures from MAR.
TABLE 30 Sensitivity analyses (scenarios 3, 4 and 5): summary for incremental analysis (ITT), cost-effectiveness results
and uncertainty under different missing data assumptions
MUA vs. ESP
Complete-case
analysis with SUR
Multiple imputation of costs
and utilities followed by SUR
Mixed model with
adjustment for
covariates
Difference in costs (£)
Mean 339.3 192.68 255.7
SE 136.2 107.45 129.5
95% CI 72.2 to 606.3 –13.97 to 399.33 1.73 to 509.50
Difference in QALYs
Mean 0.016 0.0357 0.030
SE 0.026 0.020 0.022
95% CI –0.034 to 0.066 –0.004 to 0.076 –0.014 to 0.073
ICER (£) 21,443 5395.58 8562
Probability that MUA is cost-effective 0.48 0.89 0.76
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Conclusion
This economic analysis has provided robust evidence on whether or not surgical management is cost-
effective for the treatment of frozen shoulder. Over the trial period, the base-case analysis with the
ITT approach showed that MUA was the intervention most likely to be cost-effective. The resulting
ICER for MUA was £6984 per additional QALY when compared with ESP; over common threshold
values of a QALY, the probability that MUA was cost-effective was high (> 85% from an NHS
perspective). The finding indicates that ACR is dominated by MUA (higher mean costs and fewer
QALYs), and ACR showed very low probability of being cost-effective (< 5% from an NHS perspective).
The positive cost-effectiveness profile of MUA is robust to plausible departures from MAR. Similarly,
these results were robust to a number of sensitivity analyses, showing that MUA was the intervention
most likely to be cost-effective at a threshold of £20,000 per QALY, with probabilities ranging across
scenarios from 48% (complete-case analysis) to 99%. The only exemption was when we used the
societal perspective to estimate the costs; ACR appeared to be dominated by MUA across all scenarios.
Discussion
The economic evaluation alongside the UK FROST trial was conducted following NICE methodological
standards. We implemented a comprehensive strategy to handle missing data in accordance with
methodological guidelines, and we used a number of analytical tools to address uncertainty, including
sampling and methodological uncertainty. The results of the analyses suggest that MUA is a cost-
effective option for the treatment of frozen shoulder in terms of QALYs gained calculated using the
EQ-5D-5L. Compared with ESP, MUA cost a mean of £276 more per patient (95% CI £65.67 to
£487.35) and allowed patients to experience improved health outcomes at the end of the trial [on
average 0.0396 more QALYs per participant than ESP (95% CI –0.0008 to 0.0800)]. The ICER for
the ITT approach in the imputed data set was £6984 per additional QALY. The probability that MUA
is cost-effective is > 85%, whereas the probability that ESP is cost-effective does not exceed 20%.
ACR is significantly more costly than ESP [on average £1733.78 more expensive per participant
(95% CI £1529.48 to £1938.06)], and, despite the QALY gain accrued by ACR participants [on average
0.0396 more QALYs per participant than ESP (95% CI –0.0008 to 0.0800)], this was not sufficient
to prove that ACR was a cost-effectiveness use of NHS resources when compared with ESP (i.e. the
ICER was above the recommended NICE threshold). Despite the ACR arm having fewer additional
interventions, ACR was dominated by MUA, with higher mean costs and fewer QALYs. Therefore,
the worse outcomes observed in the ACR arm than in the other two arms, along with ACR’s higher
costs, make this treatment difficult to justify. The results of the base-case analysis remained robust
to several sensitivity analyses that assessed the impact of areas of uncertainty around a number of
study components.
There are two potential limitations to consider when interpreting these results. The first relates to the
issue of missing data. Although the use of hospital forms reduced the number of incomplete data, the
presence of missing data was unavoidable. We followed a comprehensive analysis to explore whether or
not the MAR assumption is plausible given the actual missing data mechanism of the UK FROST data
set. Our analysis showed that MAR is a plausible assumption fitting the UK FROST data set; therefore,
multiple imputation was selected to handle missing data for the base-case analysis. Furthermore,
the results were robust to alternative assumptions about the pattern of missing data, showing
that the positive cost-effectiveness profile of MUA is robust to plausible departures from the MAR
assumption. It is, therefore, highly unlikely that such assumptions regarding missing data will change
the conclusions of our analysis. The second limitation relates to the duration of the study, which at
12 months might still be considered too short in terms of potential functioning. The clinical results
showed that nearly 50% of the patients were only 3 points away from being in perfect health in the
OSS, which, in turn, should influence positively the associated quality of life. Consequently, the clinical
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trends observed during the trial would also suggest that it is unlikely that any important difference in
QALYs would emerge beyond the trial follow-up. It is notable that fewer QALYs were observed in the
ACR group than in the other two treatment arms at 3 months, which is consistent with the results of
the OSS. Conversely, the ACR group had more QALYs and higher OSS scores at 12 months. Moreover,
although MUA had marginally higher estimates of OSS scores than ESP and ACR for the average
treatment effect over 12 months, this also applied to those in the MUA arm accruing more QALYs over
the duration of the study. The extra additional cost for MUA to maximise QALYs would be considered
good value for money to the UK NHS at the NICE threshold of willingness to pay. Regarding costs,
we are confident that important costs, including costs of complications, have been captured during the
trial, especially for MUA, as the most significant risk of this is fracture and it is very unlikely that this
happened beyond follow-up. It should be noted that sensitivity analysis to explore whether the results
were sensitive to under-reporting of complications did not change the positive cost-effectiveness results
in favour of MUA.
Evidence presented in this analysis relates to interventions conducted in the UK. However, given the
pragmatic design of the UK FROST trial, the results are generalisable to other health-care systems
when patients are referred to secondary care with frozen shoulder, where the decision is whether to
offer surgery relatively early or to continue to control symptoms with physiotherapy.
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Chapter 5 Qualitative study
Introduction
Qualitative research is often conducted before, during or after a clinical trial to explore the personal
perspectives of trial participants and/or health professionals on, commonly, the trial feasibility,
participation, the data collection process and the effects of trial interventions.87,88 A comprehensive
understanding of the subjective experiences to complement the quantitative evaluation of clinical
and process outcomes in a trial will better inform patient-centred care and evidence-based practice.88
The use of qualitative research methods in standalone studies or as part of clinical trials is gaining
momentum in research on a wide range of musculoskeletal conditions.89–91 However, there are very few
published qualitative studies of people with frozen shoulder.18,92 Currently, no qualitative exploration
of trial participants’ and health professionals’ experiences is available within frozen shoulder trials.
Therefore, we conducted a qualitative study embedded within UK FROST27 to provide trial participants’
and health professionals’ insights to guide clinical decision-making.
The objectives of the qualitative study were to explore (1) trial participants’ experience and acceptability
of the treatments and taking part in the trial and (2) health professionals’ (surgeons and physiotherapists)
experience of the treatments they delivered in the trial.
Methods
The UK FROST trial participants, surgeons and physiotherapists who had agreed to be contacted
by the study team were invited to participate in the interviews. The trial participants were invited
approximately 12 months after randomisation at the time of the primary end point of the trial.8
This allowed time for post-surgical recovery and for trial participants to reflect on their experience of
the intervention received. Men and women with and without diabetes were included. Surgeons who
delivered both surgical interventions and physiotherapists who delivered physiotherapy in all three
arms of the trial were invited.
The study information sheet and consent forms were sent to the trial participants, surgeons and
physiotherapists by post or e-mail. Non-respondents were sent reminders the second and fourth
weeks after the invitation was sent. Once signed consent for participation and audio-recording
of interviews had been received, a convenient date and time were arranged for a face-to-face or
telephone interview. A physiotherapy researcher (CS) trained in qualitative research methods and not
involved in the delivery of UK FROST treatments conducted the interviews. Interviews with the trial
participants were semistructured, using open questions about their experience of living with frozen
shoulder and the treatments in the trial. An interview schedule (see Report Supplementary Material 21)
was used that was developed following a literature review and discussions with the research team,
people with frozen shoulder, a physiotherapist and a surgeon with expertise in this area. The interview
schedule for surgeons and physiotherapists (see Report Supplementary Material 22) covered the routine
clinical management of frozen shoulder, their experience of treating participants in the trial, their
personal treatment preferences, and the barriers to and enablers of positive treatment outcomes for
frozen shoulder.
We planned to interview to the point of theoretical saturation93 until no further useful categories
emerged. We proposed to interview up to 45 trial participants and 15 health-care professionals.
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The data were analysed in two ways:
1. The interviews were analysed using constant comparative methods.94,95 This involves comparing
similarities and differences and developing themes with a shared essence. The data were coded and
categorised into themes by CS. Another qualitative researcher (FT) reviewed these themes, and the
two researchers discussed and reached an agreement. CS used NVivo 11 qualitative data software
(QSR International, Warrington, UK) to organise the analysis.
2. The World Health Organization’s International Classification of Functioning, Disability and Health
(ICF)96,97 is a biopsychosocial framework used to conceptualise functioning and disability as a
dynamic interaction between the following components: (1) body functions (denoted as ‘b’) and
structures (denoted as ‘s’), (2) activities and participation (denoted as ‘d’), and (3) contextual factors
(environmental factors denoted as ‘e’). Each component is arranged in hierarchal domains and has
up to four levels of categories coded with the alphanumeric system. The first letter of the coding
refers to the component followed by the first-level category (ICF chapter number designated for
each component). For example, in d5, ‘d’ denotes the activities and participation component and
‘5’ denotes the chapter on ‘self-care’. A second-level category, d510, depicts a self-care problem,
‘washing oneself’. Third- and fourth-level ICF categories are also available for some components. For
example, b2801 denotes ‘pain in body part’ and b28013 denotes ‘pain in the back’. A specific set of
ICF categories that relate to common functional problems for different health conditions is available.
We aimed to map the problems reported by the UK FROST trial participants with a reference of second-level
ICF categories (19 in body functions and structures, 34 in activities and participation, and 8 in environmental
factors) identified in a previous study on chronic shoulder conditions, including frozen shoulder.98
Results
Sixty interviews (trial participants, n = 44; surgeons, n = 8; physiotherapists, n = 8) were completed
between August 2016 and January 2018. All interviews with the trial participants were conducted
over the telephone. The majority (75%) of the interviews with surgeons and physiotherapists were
telephone based and a few were face to face (surgeons, n = 2; physiotherapists, n = 2).
Interviews with trial participants
The flow diagram of interviews with the trial participants is presented in Figure 14. The characteristics
of the trial participants are presented in Table 31. This includes participants who were allocated to ESP,
MUA or ACR. All participants who were interviewed received their allocated treatment, except one
participant allocated to MUA and another allocated to ACR, both of whom received ESP.
The five themes of the trial participants’ experiences are described in the following sections. There was
nothing to indicate that the UK FROST themes found for men and women, and those found for people
with and people without diabetes, were different.
Living with frozen shoulder
Trial participants described how frozen shoulder had a major impact on all areas of their life. They
perceived it as a combination of painful, restrictive and disabling. Many were not able to identify what
had caused their shoulder problem. Some reported a previous shoulder injury and others attributed
the problem to tasks such as gardening and lifting heavy weights:
How would I describe it? Well it is one hell of a pain. You are restricted of movement. You cannot move
it like say, very far out from your body. You try and lift something and even when you are grabbing
something, you can feel the pain in your shoulder. Like say if you were trying to lift up a cup of tea,
you could not. I mean it is very awkward.
61 years, female (ESP)
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It was a dramatic impact on my life. I felt I could hardly use my left arm at all, so it was restricting
everything that I did.
53 years, female (ACR)
Trial participants had mixed experiences of the onset of symptoms. Some had a sudden sharp pain or a
constant dull ache that gradually progressed to reduced movements and function. During the course of
frozen shoulder, they experienced pain and movement impairments, sleep disturbances, limitations in
day-to-day activities, and restrictions on participating in leisure, work and social activities. Tables 32–34
present the narratives of the trial participants mapped to 19 ICF categories (five in body functions and
structures, 12 in activities and participation, and two in environmental factors) from a previous study.15
Participants described putting off making a GP appointment until their symptoms had worsened, and
some described delays in receiving NHS care. Participants thought, in retrospect, that having a quicker
NHS care pathway in terms of diagnosis and further specialist referrals was important. Participants
also emphasised seeking early medical help and referrals from their GP:
I would say go straight to your doctor and get them to refer you. That would be the first thing because it
doesn’t just seem to go away of its own accord which I possibly thought initially and that’s why I delayed
in going to the doctor’s in the first place.
64 years, female (ESP)
Total invitations
(n = 144)
Excluded
(n = 79)
• Non-responders, n = 58
• Not willing, n = 2
• Withdrawn after consent, n = 8
    (ESP, n = 1; MUA, n = 4; ACR, n = 3)
• Non-responders after consent, n = 11
    (ESP, n = 4; MUA, n = 1; ACR, n = 6)
Consent forms returned
(n = 65)
Total interviews completed
(n = 44)
• ESP, n = 14
• MUA, n = 15
• ACR, n = 15
FIGURE 14 Flow diagram of the trial participant interviews.
TABLE 31 Characteristics of the trial participants interviewed
Treatment arm
Sex (n)
Age in years, median (IQR)
Diabetes status (n)
Male Female Diabetic Non-diabetic
ESP 5 9 58 (51–63.5) 3 11
MUA 8 7 55 (53–57.5) 5 10
ACR 7 8 59 (53–69) 5 10
IQR, interquartile range.
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TABLE 32 Participant-reported problems mapped to ICF categories: body functions and structures
Trial participants’ quotations ICF category
It was like a stabbing pain; it was very severe
73 years, male (ACR)
b280 sensation of pain
I couldn’t move my shoulder at all. So it was stuck to my side
59 years, female (ESP)
b710 mobility of joint functions
Definitely lost my strength in my arm
66 years, male (MUA)
b730 muscle power functions
I didn’t sleep at all
48 years, female (ESP)
b134 sleep functions
I was generally getting very depressed. I would have happily, towards the end,
I would happily have them amputate the arm
50 years, male (MUA)
b152 emotional functions
TABLE 33 Participant-reported problems mapped to ICF categories: activities and participation
Trial participants’ quotations ICF category
Carrying was probably a bit of a problem because I couldn’t move that arm so well
64 years, female (ESP)
d430 lifting and carrying objects
Reaching things from the tall shelves in the kitchen, reaching stuff out of the top of
the wardrobe . . . And it’s things you take for granted really
57 years, male (MUA)
d445 hand and arm use
I couldn’t drive my car even. I couldn’t change gear
55 years, male (ESP)
d475 driving
I couldn’t lift my hand up, my arm up, you know, to wash my hair or anything in the
bath. And eventually I couldn’t get into the bath properly
76 years, male (ESP)
d510 washing oneself
It was the pain and the stiffness, particularly the stiffness, and the inability to
address and attend to myself at the toilet. It was becoming a personal hygiene
issue for me
53 years, male (ACR)
d530 toileting and d520 caring
for body parts
I couldn’t get myself dressed. I couldn’t get my tops on above my head. I had to wear
slack things, so I could get my clothes on
58 years, female (ACR)
d540 dressing
I couldn’t open anything, I couldn’t use a tin opener, so I couldn’t cook neither,
I couldn’t do anything
55 years, female (ACR)
d630 preparing meals
Doing housework was nigh impossible
54 years, female (MUA)
d640 doing housework
I’m a coachbuilder by trade . . . I couldn’t work overhead, I couldn’t lift my arms up
and I couldn’t stretch my arms out, I just couldn’t do it, so I wasn’t, I didn’t go to
work, I was off for about 7 months
55 years, male (MUA)
d850 employment
Well I decorate cakes. I do novelty cakes, all kinds of decorating. That
literally stopped
64 years, female (ACR)
d920 recreation and leisure
I like gardening and I was doing the decorating on my house, all sorts of jobs like
that, sport, tennis, anything like that it sort of ruined everything really
66 years, male (MUA)
d920 recreation and leisure
I couldn’t sleep on my left side any more and if I turned over in the night and tried
to sleep on that side it instantly woke me up
57 years, male (MUA)
d410 changing basic body
position
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Just speed it up. It was, I think I went to see the GP at the beginning of November, and it wasn’t really
till the following January before I got any kind of treatment other than pain relief, by which time I’d lost
all movement.
50 years, male (MUA)
Some participants reported that they had had a range of treatments before the trial, such as painkillers,
physiotherapy, acupuncture and steroid injections, whereas others had had no treatment at all. Participants
felt that painkillers and injections used before the trial had not helped them. Similarly, participants found
that physiotherapy treatments had not helped to increase their range of movement, partly because of the
difficulty that they had exercising as a result of the pain:
I had a couple of sessions of physio before I was referred to [consultant’s name]. And I will be honest with
you; the physio basically said there was not much they could do for me at the time.
59 years, male (MUA)
Participants were concerned that they were stuck with the disability from frozen shoulder and were
eager to get it sorted. This was their main motivation for taking part in UK FROST:
Just the fact that my life would seem to be on hold because I couldn’t function properly, you know that
was my main concern, I didn’t want to be left like this permanently, I wanted something done about it,
I didn’t want to be continually taking painkillers, which I seem to be living on just to ease the pain, and
I didn’t want to be doing that. I thought, ‘I need to get something done’, that was my main concern.
59 years, female (ACR)
Improvements in outcomes and participant satisfaction following the trial
Trial participants considered pain relief and the return of shoulder movement and function to be
important treatment outcomes:
Going back to normal . . . When you had nil pain and full flexibility and movement within your shoulder.
No sleepless nights and that.
62 years, female (ESP)
Trial participants said that they had experienced significant pain relief after their treatment.
Participants in the ESP arm said that the steroid injections had reduced their pain and allowed
them to start physiotherapy:
When I went to the surgeon I was injected into my shoulder and the pain down my arm that more or less
went straight away. After that I went on that course for frozen shoulder, for therapy, and I went for
12 weeks running once a week. It seemed to go, and it’s been fine since.
76 years, male (ESP)
TABLE 34 Participant-reported problems mapped to ICF categories: environmental factors
Trial participants’ quotations ICF category
. . . my wife had to help me put my socks on, things like that, get in and out of the
shower, she had to do all the gardening, shopping, things like that. It was just really,
really sore
72 years, male (ESP)
e310 and e320 immediate
family and friends; facilitators
I had a lot of support from my work, but the household work, I couldn’t manage
because my husband had to do that for me
53 years, female (MUA)
e310 and e320 immediate
family and friends; facilitators
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So at the beginning I said the pain was 10 and now after all my physios, I’d say it was, I’d say it was
about 2 now.
56 years, female (MUA)
I mean the pain in the beginning was just horrendous, it was really, really sore, really painful but after
I’d had the physiotherapy, it was . . . I’ve got no pain at all now.
55 years, female (ACR)
Trial participants in all treatment arms reported increased shoulder movement:
Virtually full movement. My shoulder is fine as far as movement is concerned.
68 years, male (ESP)
Basically had all my full movement back.
58 years, male (MUA)
I got my life back again. I can walk my dogs. I can hold the dog leads. I can do my shopping. I can carry
things again.
58 years, female (ACR)
Trial participants described how the physiotherapy sessions (ESP and PPP) had helped to improve their
shoulder movement:
I could tell initially straightaway that my movement was starting to come, within a few days I could tell a
difference of doing the exercises and as the weeks went on, it was just got better and better and by the
time the 12 weeks was up, I virtually had full movements with no pain or anything, it was brilliant!
64 years, female (ESP)
After a few days I was doing my exercises and I was quite surprised already how much movement I had
back and then it was regular physio appointments up at the hospital just to keep moving things around
and that went really well . . . the physiotherapy was actually really, really beneficial.
45 years, female (MUA)
I felt that the physiotherapy I received was marvellous and improved the range of movements or showed
me how to keep that range of movements much quicker than they did on the right-hand side, so I felt
that everything went along fine, and I’ve got no complaints at all, none.
53 years, female (ACR)
Participants in the ACR group felt that their recovery in terms of pain and movement had been quicker
than they had expected. Some had experienced improvements as early as after 1 or 2 weeks of
physiotherapy after surgery:
It is almost like you have had a quick fix to fix your shoulder then you move on and I think personally
for me because the surgery went very well and almost after a couple of weeks I was back to normal.
44 years, male (ACR)
Participants in all treatment arms said that their ability to do routine activities had improved:
I can lift my arm above my head now, you know? I can carry stuff, and I can lift it above my waist,
and I can actually go swimming, you know? I can swim now.
54 years, male (ESP)
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My little everyday things have come back; I have come back, yes.
52 years, female (MUA)
I can do everything – there’s nothing that I can’t do; I can wash my back, I can put my bra on, fasten it at
the back, I can fasten my skirt at the side and the back now, there’s nothing I can’t do before I had the
frozen shoulder everything I could do then I can now do again.
59 years, female (ACR)
In spite of achieving pain relief and improved function, participants experienced mild and occasional
pain and restrictions during certain end-range activities:
I do get occasional pains in my arm, but it’s very mild and yeah, I’m aware that I still don’t have full
movement in my shoulder, but it is much better than it was.
45 years, female (ESP)
There’s still a wee bit of pain there, but it’s nothing. You see, I’m not concerned about it.
55 years, male (MUA)
I still get twinges now and again but it’s nothing, and that’s only when I try to put my arm right around
my back.
73 years, male (ACR)
Trial participants were satisfied with the UK FROST treatments they had received:
I’m absolutely delighted with the treatment that I was given. I feel as though it did everything that
I wanted it to do and expected it to do.
64 years, female (ESP)
I would say I’m like, 100% happy with the treatment, and the study was, like, 100%, it’s good, I didn’t
mind it.
56 years, female (MUA)
Very satisfied. I have no complaints at all.
61 years, male (ACR)
However, two participants were not satisfied with ESP. One had been treated by a private
physiotherapist before the trial and did not improve after physiotherapy during the trial. The other
was not pleased that the exercise sessions had been supervised by an unfamiliar physiotherapist:
Waste of time . . . I wouldn’t be recommending it to a friend . . . Well because by the time I got to see the
NHS physio, the private physio had already, if you like, done the hard work and they just had to, if you
like, pick up the pieces and keep it OK, and they didn’t.
50 years, female (ESP)
May I say 50%? That is mainly because when I saw the physio one to one, I was 100% happy and then
when I went to the gym and the physiotherapist sort of left you to your own devices, they didn’t really
know who I was, why I was there, and they certainly didn’t. It was basically just like going to any old gym
and being supervised by someone who didn’t know you from Adam. It was very, very disappointing.
59 years, female (ESP)
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Trial participants’ adherence to home exercises
Participants found that the exercises were difficult to begin with but eased off in subsequent sessions:
It [exercise] was difficult and painful. But I could tell week on week the pain was reducing, and my
movement was increasing. So it was obviously working quite well.
57 years, male (MUA)
However, they were aware of the benefits of exercise and persevered with doing their home
exercises regularly:
I did persevere, and I was doing what I was told, which was obviously you’ve got to have the pain to get
back to normal.
48 years, female (ESP)
Most participants said that they had not continued their home exercises after the trial because they
felt that they had regained their normal shoulder function. They shifted from doing the structured
home exercise regime to daily functional activities to keep their shoulder mobile. A few participants
did some shoulder stretches occasionally:
I’m working with my shoulder all the time so I’m not doing the exercises that the hospital gave me,
because I’m working my, I’m swimming, I’m doing . . . I go on long walks, I take the dog out and what
have you, so I’m using my arm.
54 years, male (ESP)
Trial participants’ treatment preferences before and after the trial
Participants had various treatment preferences before the trial. Some of the participants allocated to MUA
and ACR felt that physiotherapy would be ineffective because it had not worked for them previously or
they felt that physiotherapy would be difficult with their painful shoulder. MUA was perceived as less
invasive and ACR was perceived as an effective treatment. A few preferred physiotherapy so that they
could avoid the risks of surgery. Some did not have a particular preference at all. Three participants with
diabetes felt that it would take longer to recover after ACR because of their diabetes:
I’m not really too sure why I wouldn’t choose physiotherapy. I just think surgery seems a more final option.
Physiotherapy, it might work, it may help, it may not. But to me, if I was given surgery, the surgery would
work. I had more faith in the surgery working than the physiotherapy itself.
53 years, male (ACR)
Well the first option would have been more intense physiotherapy which I didn’t find would have been
successful because I’d already had physiotherapy. The second option was to have been invasive surgery
which means cutting open, an actual surgical procedure which I wasn’t that keen on to be honest
with you.
55 years, female (MUA)
Well I didn’t want to go to surgery or anything like that, so I just had the needle in my shoulder. I don’t
think I’d have wanted to go surgery at my age.
76 years, male (ESP)
Just I didn’t think, as I said, I didn’t know if any was better than the other, I just went along with what
was there.
55 years, male (MUA)
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Despite preferences at the outset, at the end of the trial there was a sense from participants that
they would choose the same treatment that they had been allocated, particularly those who had
received ACR:
Oh no I would have the same treatment. As I say I was only there for 10 weeks and I mean, on my
11th week I was still hell of a lot better.
61 years, female (ESP)
Probably the same, because I had to get it moving to start with, it just felt as though it was never going
to move. So again, the manipulation, it kind of kick-started it and got it moving, because I honestly
thought it was never, ever going to move.
53 years, female (MUA)
I think if it happened to me again, I would be looking to be referred for keyhole surgery again. I think it
was an excellent course of treatment and if it had to happen again, that’s the treatment I would want.
53 years, male (ACR)
A few participants in the ESP and MUA arms wanted to choose ACR for a permanent and quicker
solution for their shoulder problem:
If I had a recurrence of the frozen shoulder in the same joint, I would obviously look for alternative
treatment for the simple reason because obviously that treatment, although it alleviated the symptoms,
hasn’t completely got rid of the symptoms then because if it recurs. So you would look for a permanent
solution . . . I would think if it came back again, I would prefer to have the keyhole surgery, yes.
68 years, male (ESP)
Trial participants’ experience of participating in the trial
Trial participants had altruistic and personal reasons for participating in the trial. They desired to
help other people and contribute to research, and some expected to have their shoulder problem
treated quickly:
Because I’m all in favour, if you can do something to help other people not go through the misery that
you’ve been through, and gone through, then I would do it.
62 years, female (ESP)
That I would be seen to sooner than if I didn’t do it. And I would have the opportunity to have any
treatments much sooner than being on the waiting list. It’s not a very nice reason for you to hear, but
that’s what I did it for.
53 years, female (ACR)
Trial participants found the trial questionnaires relevant and simple to complete. A few felt that the
questions were lengthy and repetitive. Some had difficulties answering the questions about comparing
their health status with that of the previous month:
It was quite easy, they were simple questions, and I just sort of flew through the questionnaire with
no problem.
64 years, female (ESP)
Very repetitive [laughter]. Very repetitive. It went on and on and on. Just when you thought you’d finished
there would be another page added on. They are a bit of a pain really.
57 years, male (MUA)
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Trial participants said that the physiotherapists who delivered the physiotherapy sessions (ESP and PPP)
were supportive and helpful:
My physiotherapist was very nice and he didn’t push me to do anything that wasn’t in my ability and
yeah, we just took it at a nice, steady pace.
41 years, female (ESP)
The physiotherapist really knew what she was doing and straight away assessed exactly where I was at
and what I needed to be doing, and that worked really well.
50 years, male (MUA)
They also liked seeing the same physiotherapist so that good connections and rapport could be
developed throughout the programme:
I think seeing the same person is always helpful because otherwise it must be time saving as well because
you haven’t got to read up on the case every time and you get a good rapport like that.
53 years, male (MUA)
Participants in the MUA and ACR arms said that the surgical procedures were explained and went well:
The day in the surgery, I was told everything, how long I would be off work for, and I had targeted
physiotherapy immediately after, I knew that was part of it. I attended on the day of my operation;
everything went very, very smoothly.
58 years, female (MUA)
It was just a case of just sitting around, reading books, talking with other people, some people had been
there two to three times and had various operations, everyone was just chatting and making everyone
feel at ease with you know their own experiences . . . And then it was a case of get in, swabbed up and
on the trolley through to the operating theatre, operation I believe obviously went fantastic, went really
well. It was just a case of waking up, recovery.
44 years, male (ACR)
Trial participants felt that their treatment packages were well co-ordinated and did not require major
modifications. Two MUA participants with diabetes suggested providing more information on the
effects of pain block and steroid injections on blood sugar levels. A few participants in the ESP and
ACR arms felt that the exercises were time-consuming:
Well personally I found it quite difficult to make sure I had them that many times in the day. I’m not too
sure how somebody working or having a family could actually manage to fit it in because as I say, by the
time going towards the middle to the end of the programme . . .
64 years, female (ESP)
Yeah that was quite difficult because it takes up quite a bit of time and it is quite tiring. I’m not the
fittest person and I did find it quite tiring to do all the exercises required.
53 years, male (ACR)
Interviews with surgeons and physiotherapists
The flow diagram of the surgeons’ and physiotherapists’ interviews is presented in Figure 15. The
characteristics of surgeons and physiotherapists are presented in Table 35.
The four themes from the interviews with surgeons and physiotherapists are described in the
following sections.
QUALITATIVE STUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
A stage-based approach in routine treatment of frozen shoulder
Surgeons and physiotherapists described a stage-based treatment approach (from conservative to
surgical interventions depending on the severity and duration of symptoms) in their routine practice.
During the early painful phase, surgeons and physiotherapists thought that pain control with steroids
would be the priority so that exercises could be initiated. Physiotherapists also provided patients with
education as part of their treatment plan:
A humeral steroid injection is beneficial for pain relief. It allows them to do the physiotherapy. So, I do use
that a lot.
Surgeon 6
I would always tend to go down the glenohumeral joint injection first to see if that settled things down
and to give me a window where I could then push them with regards to their exercises.
Physiotherapist 1
And then it’s education; tell them all about the condition, what we know about the condition, let them
know that it is going to get better over time, and it may not resolve fully and so on. So we’ll basically
educate them, reassure them.
Physiotherapist 5
Total invitations
Reasons for exclusion
  Consent forms returned
• Surgeons, n = 8
• Physiotherapists, n = 9
  Interviews completed
• Surgeons, n = 8
• Physiotherapists, n = 8
Surgeons
• Non-responders, n = 3
• Not willing, n = 1
Physiotherapists
• Non-responders, n = 4
• Not willing, n = 1
• Non-responders after consent, n = 1
• Surgeons, n = 12
• Physiotherapists, n = 14
FIGURE 15 Flow diagram of surgeons’ and physiotherapists’ interviews.
TABLE 35 Characteristics of the surgeons and physiotherapists interviewed
Health professional
Sex
Median (IQR) years of experience
in treating shoulder conditionsMale Female
Surgeons 7 1 11 (7–16.25)
Physiotherapists 0 8 13.5 (12–15.75)
IQR, interquartile range.
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Surgeons felt that exercises during the early, painful, phase may aggravate the pain but that exercises
after surgery are important for recovery:
Physiotherapy in isolation without an injection I’ve found most patients present having had really pain
that’s not manageable because they’re trying to stretch and rehab a painful shoulder from frozen shoulder
just increases their pain.
Surgeon 2
We do believe in physiotherapy afterwards. One is to have specialised physiotherapists who can allay
their fears and talk about their fitness, talk about their recovery, talk about the time scales and the pain.
That’s one compliment of the physiotherapies is some health professionals who can talk to them on a
regular basis.
Surgeon 3
During the stiffness-dominant and postoperative phases, physiotherapists focused on improving shoulder
movements, strength and function. They prescribed an intensive exercise regimen that included vigorous
shoulder stretches, joint manipulation/mobilisation and home or gym-based exercises:
I know that pain is not a problem then I can push them, I can do the more vigorous stretches, I can
manipulate their joints or mobilise their joints and I put them on a more gym-based or exercise-based
programme . . . I will go and more push them towards reaching their more functional goals and more
towards achieving their return to work and that kind of thing task.
Physiotherapist 4
For people with severe or longstanding symptoms and those resistant to conservative treatments, both
surgeons and physiotherapists considered surgery as the final treatment option. For most surgeons,
ACR was the default procedure as it resulted in faster recovery and low risk of humeral fractures, and
they were familiar with the procedure:
So, if a shoulder is extremely stiff, tight and quite painful I would probably avoid doing a manipulation on
these patients and my preference would be ACR if the longevity of the stiffness and the symptoms is quite
prolonged again my preference would be an ACR.
Surgeon 6
Generally, the people that don’t respond to physio often will end up seeing a surgeon at some point. So
the tricky more longer-term frozen shoulder patients are the ones with diabetes that tend to have more
problems and end up requiring intervention.
Physiotherapist 2
Physiotherapists felt that the UK FROST physiotherapy programmes and the exercise booklet gave
them flexibility to choose exercises that were compatible with their routine practice. A few suggestions
were made, for example structuring the treatment components to suit the stages of frozen shoulder,
spreading out the 12 weekly sessions over 6 months and having group sessions:
I think the interventions that were on the booklet were what I would use generally. There was always an
option there for me to tick off what I would do so I was in agreement with the options that were there
and in agreement with the options that they actually, didn’t want you to use.
Physiotherapist 2
I think group sessions would be really useful because patients get a lot from each other, and having
experience group sessions with other clients with different pathologies, you know, they find that really
reassuring . . .
Physiotherapist 5
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Physiotherapists also commented on the feasibility of the UK FROST physiotherapy programmes in the
NHS, and there was a sense that it would be difficult to deliver the number of UK FROST physiotherapy
sessions in their routine practice:
We don’t normally get the luxury of being able to see patients as often as the FROST trial was letting us.
I think it was 12 treatments we could have overall.
Physiotherapist 2
. . . they [trial participants] were seen with the 24 hours post surgery and they had 12 sessions which is a
luxury because in our trust, that is never, not going to happen and that never used to happen.
Physiotherapist 4
In general practice, well if somebody is improving and they’re self-managing, then we don’t need
to be seeing these patients every week and our service would not allow us to be able to see them
every week.
Physiotherapist 7
Treatment expectations and preferences
Surgeons and physiotherapists had mixed treatment expectations. Although surgeons said that they
maintained equipoise, they also said that ESP would not be as effective as surgery:
They usually come to me and say, ‘What would you do doctor?’ I just be honest with them that so far,
I have done this, and my results are reasonable, but I wouldn’t say that this is the only answer. There are
other answers that are equally valid and have to be tested . . . It is an ethical thing to do because all three
of the treatments are valid and accepted treatment for frozen shoulder.
Surgeon 3
My expectation is that physio won’t work. My expectation is that the other two are probably equivocal.
Surgeon 7
Some surgeons and physiotherapists expected similar outcomes across treatment arms. A few
physiotherapists felt that the surgical arms, especially the ACR arm, would perform better than the
ESP arm. Although some considered MUA an outdated intervention with a risk of injury, some felt
that it would be comparable with ACR. Some physiotherapists mentioned that post-surgical soreness
is common with ACR:
I expected my patients to get better on whichever arm they chose.
Surgeon 3
I’m expecting the MUAs to be surprisingly better than I would expect. I think the arthrolysis do great
anyway and the physio is an unfair one, because if we’re seeing them over such a long time the natural
history of the frozen shoulder is it will get better. Going against my own profession here; is it the physio
that made it better or is it just time.
Physiotherapist 6
I’ve had experience of patients doing well in them in them all and equally patients not doing well in
them all. I thought they were; I don’t think they were randomised equally. I thought there were more
randomised to surgery. It was more for surgery than physio. So no, I didn’t have any predisposed feelings
about it at all.
Physiotherapist 8
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Surgeons and physiotherapists would have preferred that hydrodilatation had been one of the UK
FROST trial arms. Hydrodilatation was described as an easy-to-use, less invasive and inexpensive
procedure and an alternative for reducing NHS waiting lists for surgery:
I’d definitely have a hydrodilatation group because part of your trial is trying to work out if the cheaper
operation is better than the more expensive operation and hydrodilatations probably gained quite
popularity since we started the trial design and it reflects current practice.
Surgeon 5
It needs hydrodilatation in it. I personally think it gets really good results on a big bulk of patients and it’s
a wasted opportunity to have done this study and not have that as one of the arms.
Physiotherapist 6
Factors that influence treatment outcomes
Similar to trial participants, surgeons and physiotherapists perceived that pain relief and improved
movements and function were important outcomes. Pain relief was the priority outcome
for physiotherapists:
Better in a sentence? That their pain is resolved, and their movements improve, and they return to full
function within their daily living, both at work and for recreation and home. That’s what I expected to
achieve in any of the arm of the trial.
Surgeon 3
So yeah, pain relief first and foremost and then everything else after that; increasing their range of
movement, function, return to activities, whether it be sport or work or hobbies and so on. But yeah,
definitely pain is the number one.
Physiotherapist 5
I think pain is always the predominant thing with these patients. They just want someone to do something
to help with the pain.
Physiotherapist 7
Surgeons and physiotherapists felt that diabetes negatively affects treatment outcomes:
Well my experience with diabetics they have been very bad for a hell of a long time, OK, and that’s again
maybe just my experience, I haven’t measured that experience, but I’ve seen plenty of them of male
diabetics that say, ‘Well, I’ve been stiff for three years’, or two-and-a-half years, that’s not uncommon.
Surgeon 8
I think my understanding is diabetic patients are slightly more prone to developing a frozen shoulder. It
seems to be potentially more complications, slightly more resistant to treatment. And the chances of them
maybe developing it again are slightly higher, I think.
Physiotherapist 2
They also felt that participants engaging with treatments and having positive expectations leads to
better outcomes:
With any treatment they do they have to engage, and that is something that I emphasise to my patients.
So I spent a lot of time in the initial consultations giving them the knowledge. So what makes them better,
it’s the patient themselves and their knowledge.
Surgeon 3
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I think the expectations and belief is probably the most noticeable factor that affects people’s outcome;
if they believe something is the right thing, the best thing for them, they seem to do well.
Physiotherapist 5
Perceptions about trial participants’ experience
Surgeons and physiotherapists felt that the trial participants were happy to be involved in UK FROST.
At the same time, participants came to the trial with fixed ideas about the treatment they wanted:
Once they had consented to be part of the study, and they had no problems because they were equally
welcome on what treatment they would get . . . all those who once we enrolled them on to the study,
were OK with that.
Surgeon 6
So, we saw a lot of frozen shoulders coming in, but a lot of them had fixed ideas of what treatment they
wanted. They didn’t want surgery yet, or they didn’t want to take time off work was the other one, but
less so. The standout one was they didn’t want an operation, or they wanted to try physiotherapy and
injection and then they would opt for surgery. They wanted it to be continuum like that, not a one or
the other.
Physiotherapist 8
Surgeons and physiotherapists said that some people declined to take part in the trial because their
previous physiotherapy had not worked and so they did not want to be randomised to receive ESP:
Many of them they say, ‘Look, I would love to contribute to the greater good and be involved in clinical
trials, but I’ve come to the point that I will not consent for physiotherapy if I was randomised to that’.
Surgeon 8
Like I say, if patients have already had physiotherapy, some of those patients have not wanted to be
recruited at risk of repeating what’s already not worked. So that was quite awkward to do.
Physiotherapist 6
Physiotherapists said that the UK FROST interventions were well received. Surgeons and physiotherapists
said that participants were surprised with the number of PPP sessions they received during the trial.
Surgeons and physiotherapists described how a few participants randomised to ESP felt that they were
not improving:
They seem to be quite happy with the intervention [ESP] generally. If they had had an injection they were
happier because their pain level was better and they were able to tolerate the exercises a bit better.
Physiotherapist 2
I think most of them were with my experience, the patients were really, really very happy, the ones who
went to the manipulation as well as arthroscopy capsular release.
Physiotherapist 4
Discussion
Principal findings
An embedded qualitative interview study was conducted within UK FROST to explore the experiences of
the trial participants and health professionals (surgeons and physiotherapists) of the trial interventions.
The key findings were as follows.
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Trial participants described that frozen shoulder had a major impact on all aspects of their life. They were
keen to get their shoulder problem sorted, which motivated them to participate in the trial. They also
insisted on seeking early medical help and a quicker NHS care pathway. In general, trial participants were
satisfied with the UK FROST interventions and found them acceptable. They reported improvements in
pain, movement and function. Participants who had received ACR described quicker recovery than they
had expected.
Surgeons and physiotherapists followed a stage-based treatment approach in their routine practice.
Both felt that people with diabetes tend to have poorer outcomes. They suggested that hydrodilatation
could have been a treatment arm of the trial. Both described that some people who had received
previously ineffective physiotherapy did not want to take part in the trial.
The common perceptions among trial participants, surgeons and physiotherapists were that (1) trial
participants were happy to be part of UK FROST; (2) pain relief and regaining shoulder movements and
function are important outcomes; (3) steroids help pain relief and to initiate shoulder exercises; (4) a
progressive physiotherapy programme would improve shoulder movements and function; (5) adherence
to prescribed exercises is important for better outcomes; and (6) all had their personal preferences
among UK FROST treatments.
Frozen shoulder has a negative impact on all areas of life
Although frozen shoulder has a self-resolving natural history, our findings indicate that it is a painful
and debilitating condition causing a considerable level of disability and reduced quality of life. This
resonates with the results of previously published studies on this topic.18,99,100 The problems due to
frozen shoulder, as described in our participants’ interviews, were mapped to the ICF biopsychosocial
framework of disability.96,97 This is the first time, to our knowledge, that the ICF has been used
specifically to describe functioning and disability due to frozen shoulder. Our findings support the
range of problems reported in previous studies by people living with chronic shoulder pain.18,98–101
Our results on participants’ concerns in seeking early diagnosis and referrals are comparable with
those of a previous qualitative study in people with frozen shoulder.18 However, in the context of
variable prognosis (from self-resolving to resistant/chronic cases) of frozen shoulder, a screening tool
to identify the subgroup of patients who might benefit from early referral would be helpful. Factors
such as chronicity, severity, diabetes, inability to cope with functional restriction and pain tolerance
could be incorporated to predict the need for further treatment.
Pain relief and regaining shoulder movements and function are important
treatment outcomes
Trial participants and health professionals described pain relief and improvements in function and
range of motion as the main outcomes to be achieved from the treatment of frozen shoulder. Their
priorities resonate with similar results from a previous survey of 225 health-care professionals102
and from other studies.13,18,103,104
Steroids help with pain relief and with initiating exercises
Our interviews with trial participants and health professionals support the existing evidence on the use
of corticosteroid injections for pain relief. Pain relief is important as it enables physiotherapy exercises
to be undertaken to maintain the range of movement and to avoid long-term symptoms. There is
moderate evidence to support the efficacy of steroids for pain, function and disability when compared
with placebo21,105 and additional benefit with shoulder exercises.106 Steroids are also reported to be a
potentially cost-effective option.13
Commitment to adhering to prescribed exercises is important for better outcomes
Participants and health professionals had similar views that continued patient engagement with the
prescribed exercise is important for better outcomes.107–109 During the early recovery phase, UK FROST
participants were motivated by treatment benefits109 and had self-determination110 to cope with the
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pain associated with exercise. However, during the recovery phase, participants prioritised daily
functional activities and did not seem to mind about the minor residual deficits they still had. They
aimed for pain relief and enough movement to allow adequate daily function. These findings are in
line with a previous study which conceptualised participants’ views on ‘ideal’ (no symptoms at all)
and ‘adequate’ (return to function with residual deficits) recovery from musculoskeletal complaints.111
Trial participants, surgeons, and physiotherapists had their personal preferences
among UK FROST treatments
Our interview findings suggest that treatment choices did exist among trial participants112,113 and
health professionals.114–116 The preferences of surgeons and physiotherapists were mainly based on
their clinical experience in routine practice.114–116 It would be highly unlikely for experts not to acquire
personal preferences, especially when treatment decisions are expertise based because of a lack of
strong evidence. The trial participants also had a range of preferences before participating in the trial.
This is evident from both the main trial data and the interviews. In spite of having personal treatment
preferences before the trial, the trial participant interviews indicated that all UK FROST interventions
were well received and accepted. This also supports the main trial findings, which indicated that patient
preferences did not influence the treatment outcomes.
Frozen shoulder and diabetes
Frozen shoulder is a common complaint in people with diabetes, with an incidence ranging between 10%
and 36%.117 Our interview findings indicate that the presence or absence of diabetes did not influence
trial participants’ experiences of the trial interventions. These support the main trial findings, which
indicate no significant between-group differences in the mean OSS between diabetic and non-diabetic
participants across the treatment arms. The perceptions of surgeons and physiotherapists were that
people with diabetes tend to have poorer outcomes (prolonged/severe symptoms, or resistant to
conservative management). These are supported by the existing literature,118,119 and findings from
the main trial found diabetes as a significant predictor of outcome in people with frozen shoulder.
Hydrodilatation as one of the UK FROST treatments
Hydrodilatation involves stretching the capsule of the shoulder joint and reducing the inflammation
within it by injecting a mixture of sterile saline, local anaesthetic and steroid. The UK FROST surgeons
and physiotherapists suggested that hydrodilatation should have been one of the treatment arms of the
trial. They perceived it as an easy-to-administer, less invasive and cost-effective alternative to combat
the NHS waiting lists for surgery. However, the available evidence on the effects of hydrodilatation
is inconclusive.25,120,121 A meta-analysis120 of seven small RCTs concluded that hydrodilatation combined
with corticosteroid has no significant clinical effect on pain, disability and shoulder movements compared
with corticosteroid alone. A further RCTs25 in 50 participants with severe frozen shoulder found ACR
compared with hydrodilatation improved OSS at 6 months. Despite the lack of sufficient evidence,
hydrodilatation appears to be growing in popularity and is being increasingly used by shoulder surgeons.122
This resonates with the views of the UK FROST surgeons. More large-scale and high-quality RCTs
evaluating the clinical effectiveness and safety of hydrodilatation compared with those of other
treatments are essential to make recommendations and to guide evidence-based practice.123
Surgery preferred for prolonged or resistant frozen shoulder cases
Following conservative management, people with frozen shoulder might continue to have persistent pain
and poorer outcomes.123,124 Often, people with prolonged symptoms and those resistant to conservative
treatments of at least 6 months are seen in secondary care and recommended for surgery as the final
treatment option.26,124,125 Of the two surgical procedures used in UK FROST, evidence shows that surgeons
commonly perform ACR123 for the controlled procedure of capsular release126 and improved clinical
outcomes.127 This reflects the views of surgeons and physiotherapists who indicated that people with
prolonged frozen shoulder symptoms or not improving with conservative treatment might need ACR.
This aligns with the main trial findings, which confirmed that participants who received ACR were least
likely to require further treatment.
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Study limitations
First, the interviews were conducted with participants who took part in UK FROST and therefore may
not be relevant outside this context. Second, the qualitative study only included two trial participants
who did not receive their allocated treatments, which could have influenced the predominantly positive
experiences towards the trial interventions. Third, given the geographical spread of trial participants
and health professionals interviewed, 93% of interviews were conducted via the telephone. Therefore,
we are uncertain if participants would have expressed their views differently if face-to-face interviews
were conducted. Last, the response rate to participate was low across all arms. Those who did not
participate might have reported different experiences.
Strengths
To our knowledge, UK FROST is the first clinical trial to explore the perspectives of both trial
participants and health professionals involved in the trial. Interviews were conducted by a researcher
not involved in the trial and by using open-ended questions that allowed trial participants and health
professionals to express their opinions freely. The interview codes and themes were reviewed by
another qualitative researcher to ensure rigour of analysis and interpretation of data.
Implications for clinical practice
Our findings indicate the following implications for clinical practice:
1. Frozen shoulder has a major impact on all aspects of an individual’s life. A better understanding of
patients’ problems and identifying ways to address their concerns during clinical assessments would
optimise holistic and patient-centred care.
2. Trial participants had their own treatment preferences. Some preferred surgery as a quick solution
to their shoulder problem and some perceived physiotherapy to be a low-risk intervention. These
personal treatment preferences should be well understood by health professionals and patients
should be provided with opportunities to address their preferences during shared decision-making.
3. Health professionals should also consider their own preferences for treatment and how these affect
their treatment decisions. They should carefully consider the evidence available for the treatments
they provide. All UK FROST treatments were perceived as acceptable, beneficial and satisfactory.
Steroids play an important role in reducing pain and helping people begin their physiotherapy
exercises. The evidence on the benefits and anticipated risks of these treatments must be
considered in treatment decision-making and clearly communicated to participants.
Conclusion
This qualitative study has provided a fuller understanding of the perspectives of UK FROST trial
participants and health professionals and has complemented some of the key findings of the main trial.
Our findings indicate that although the content of the physiotherapy interventions was acceptable to
trial participants and health professionals, they also highlight concerns about delivering this intensity
of treatment within the constraints of the NHS. Future trial designs would usefully include qualitative
research as part of intervention development to ensure the feasibility of the interventions in the NHS.
More primary qualitative studies on people with frozen shoulder are needed to integrate patient
perspectives into informing patient-centred care and shared decision-making.
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Chapter 6 Discussion and conclusion
To our knowledge, UK FROST is the largest RCT to date that evaluates three commonly used optionsto treat frozen shoulder. The trial was sufficiently powered to allow strong conclusions to be drawn
about the effectiveness of these treatments. Crucially, all arms of UK FROST involved physiotherapy
protocols that were designed to provide pathways to reduce variations in usual NHS care and to
optimise clinical practice. It is therefore important to emphasise that, although physiotherapy is a
common treatment in NHS practice, the ESP intervention was a specifically designed, standardised,
new physiotherapy pathway for UK FROST that was based on the best available evidence and on expert
consensus. The pragmatic, multicentre design focused on delivering good standards of practice for all
treatment options. Importantly, unlike previous RCTs, a thorough and detailed economic evaluation was
undertaken to assess the relative cost-effectiveness of the three treatments during the trial follow-up
period. The primary analysis perspective is the NHS and this will have direct applicability to informing
future policy and commissioning decisions in the UK. In this chapter, we begin by summarising the main
results, before going on to explore the potential risks of bias that might challenge the trial’s validity and
applicability. We conclude by discussing the application of the trial’s findings to clinical practice and our
recommendations for future research.
Principal findings of clinical effectiveness
Primary outcome
At the 12-month primary end point, participants randomised to ACR had, on average, a statistically
significantly higher (better) OSS than MUA (2.01 points, 95% CI 0.10 to 3.91 points) and ESP (3.06 points,
95% CI 0.71 to 5.41 points), based on ITT analysis. Although statistically significant, mean estimates
were short of the minimal clinically important effect size of 4–5 OSS points (the trial was powered
for differences of 4 points for comparing MUA with ACR, and 5 points for comparisons with ESP).
Differences of clinically important magnitude, however, were included in the 95% CIs for the benefit of
MUA and ESP compared with ACR at 3 months, and of ACR compared with ESP at 12 months. Clinically
meaningful group differences may, therefore, exist for these comparisons in the wider population.
Additionally collected OSS scores to assess the impact of waiting times revealed little change between
baseline and the start of any of the treatments. Six months following treatment, scores improved more in
the surgical arms than in the ESP arm and were similar to final follow-up scores across all arms by 8 months.
Analyses of the data incorporating all available time points for each participant (day of treatment, 6 months
post treatment, and 3, 6 and 12 months post randomisation) found that, compared with the primary
analysis, group differences at the different follow-up points tended to be of smaller magnitude, except
between ACR and ESP at 12 months (3.26 points in favour of ACR, 95% CI 1.18 to 5.35 points). The 95% CI
still included the minimal clinically important difference for this comparison of 5 OSS points.
There was no statistically significant effect of treatment group for interactions with participants’
diabetes status, receipt of previous physiotherapy, baseline treatment preference or duration of frozen
shoulder symptoms at baseline.
Secondary outcomes
Of the secondary outcomes, QuickDASH and shoulder pain followed a similar pattern to the OSS, in that
significantly poorer outcomes were observed for ACR patients at 3 months but better outcomes were
observed at 12 months post randomisation than for MUA or ESP patients. There were no statistically
significant differences between the treatment arms for reduction in frozen shoulder symptoms as measured
by the extent of recovery. In terms of pain or stiffness at the end of physiotherapy, participants in the ESP
arm had relatively lower levels of predominant pain by the end of physiotherapy, whereas participants in
the ACR arm had relatively lower levels of predominant stiffness, than those in the other arms.
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Fidelity of treatment
Of the participants randomised to their allocated treatment, 82% completed MUA, 80% completed
ACR and 81% completed ESP. Only 16 participants (3%) crossed over to a different trial treatment, and
17 (3%) received an alternative, non-trial, treatment. As part of the surgical treatments, optimal release
was reported as achieved in 92% of MUA procedures and 98% of ACR procedures. Steroid injection
was delivered for all completed MUAs and 28% of ACRs. Steroid injection was also given to 80% of
patients randomised to ESP. Participants who completed the ESP intervention attended a median of
9 sessions, whereas PPP following surgical procedures had slightly fewer sessions (median of 7 for
MUA and 8 for ACR).
Further treatment
Following completion of their randomised treatment, a number of participants received further
treatment. There were no specific criteria to inform this decision, which was at the discretion of the
treating surgeon. Most commonly, this was ACR for participants allocated to MUA (seven participants);
and further physiotherapy (six participants) or ACR (four participants) for participants allocated to ESP.
Participants in the ACR arm received fewest further treatments.
Safety
In total, only 10 SAEs were reported for nine participants, of whom eight were randomised to ACR
and two were randomised to MUA. The events mainly related to serious medical complications such
as chest infection or stroke, some of which may be related to comorbidities or surgery in general,
rather than being specifically related to the trial procedures. As an example, a stroke was diagnosed
3 months after ACR. Furthermore, of the eight SAEs in participants randomised to ACR there were
two participants who did not have ACR (one had MUA and the other had a non-trial physiotherapy
treatment). Only one of the two participants allocated to MUA who experienced a SAE actually
received MUA, and the other participant had no treatment for their frozen shoulder. There was,
therefore, only a marginal difference in the safety profile between MUA and ESP for which in
the latter group there were half of the participants. There were 33 non-serious AEs reported for
31 participants, with comparable rates in the three arms.
Systematic review update of the currently available evidence
To place the trial findings in the context of current evidence, the HTA systematic review about
management of frozen shoulder was updated.13 The updated review focused only on evidence from
RCTs and the interventions and outcomes collected in UK FROST. Hydrodilatation, however, was
also included as its popularity has increased since a survey was undertaken to inform the design of UK
FROST.22 Moreover, during the qualitative interviews with health-care professionals in the nested study,
some surgeons and physiotherapists commented that this could have been a treatment option in the trial.
Nine trials were identified, including UK FROST. The number of participants in the other trials ranged
from 26 to 136; therefore, UK FROST was substantially larger. All trials, including UK FROST, were
rated as being at high risk of bias in terms of blinding of participants and clinicians and outcome
assessment.23–25,128–132 Three trials were rated as being at high risk of bias for incomplete outcome
reporting,24,128,130 two trials were rated as being at high risk of bias for selective reporting129,130 and
two trials were rated as being at high risk of bias for ‘other’ biases.23,128 Owing to the considerable
heterogeneity of the interventions and the generally limited evidence for many of the comparisons,
only two trials, UK FROST and one other trial,129 were pooled in a meta-analysis, which compared
long-term shoulder functioning between ACR and physiotherapy plus steroid injection. The pooled
effect favoured ACR, but was smaller in magnitude than the clinical threshold of the standard effect
size used in UK FROST. The second trial provided little additional weighted evidence. Overall, most
of the comparisons between treatments were informed by single trials, based in single centres, with
considerable variation in the interventions used and timing of outcome assessments. UK FROST
provides the strongest evidence with broad generalisability of the three treatments it evaluated.
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Although UK FROST did not include hydrodilatation, evidence of hydrodilatation’s effectiveness from
four trials was inconclusive.23,25,130,132
Cost-effectiveness
The base-case economic analysis showed that at 12 months MUA was, on average, £276 more costly
per participant (95% CI £65.67 to £487.35) than ESP. MUA was slightly more beneficial in terms
of utilities than ESP (on average 0.0396 more QALYs per participant than ESP, 95% CI –0.0008 to
0.0800). The ICER for the ITT approach in the imputed data set between MUA and ESP was £6984 per
additional QALY. ACR was more costly than ESP (on average £1733.78 more expensive per participant,
95% CI 1529.48 to 1938.06). Despite the QALY gain accrued by ACR participants (on average 0.0103
more QALYs per participant than ESP, 95% CI –0.0304 to 0.0510), the ICER was over £100,000 per
additional QALY. ACR was more expensive than MUA and resulted in slightly fewer QALYs. Therefore,
given the limited differences in outcomes observed in the ACR arm compared with the other two
treatment options, along with the much higher costs, it is difficult to justify ACR as a first-line treatment
option on evidence of cost-effectiveness. MUA was the intervention most likely to be cost-effective at a
£20,000 per QALY threshold (MUA 86% > ESP 14% > ACR 0%).
The results of the base-case analysis remained robust to several sensitivity analyses that assessed
the impact of areas of uncertainty around a number of study components. This included our analyses
being robust to missing data and the assumptions around missing data. However, the cost-effectiveness
of MUA compared with ESP was sensitive to the addition of non-shoulder costs and the broader
perspective that included private treatment costs and days off work. A key cost driver in these analyses
was days off work, at £113.80 per day. During the 12-month follow-up, participants allocated to the ESP
arm had a median of no days off work, participants allocated to the MUA arm had a median of 6 days
off work, and participants allocated to the ACR arm had a median of 2 weeks off work. This potentially
could be related to quicker access to treatment for ESP participants, and may be important in patient
decision-making. The analysis was also limited to a 12-month follow-up. However, as the results of
the OSS at 12 months show that 50% of the participants were only 5 points away from regaining
full function, this suggests it is unlikely that an important difference in QALYs would emerge during
longer-term follow-up. Regarding costs, the important costs of treatment, and complications, were
expected to have been captured during the 12-month follow-up.
Qualitative study findings
Trial participants described how frozen shoulder had a major impact on all aspects of their life.
They were keen to get their shoulder problem resolved, which motivated them to participate in the trial.
They thought that seeking early medical help and having a quicker NHS care pathway were important.
In general, trial participants were satisfied with the UK FROST interventions and found them acceptable.
They reported improvements in pain, shoulder movements and function. Participants who received ACR
described recovering more quickly than they had expected. Surgeons and physiotherapists followed a
stage-based treatment approach in their routine practice. Both groups of professionals felt that people
with diabetes tend to have poorer outcomes. They suggested that hydrodilatation could have been a
treatment arm of the trial. Both groups of professionals commented that some people who had received
previously ineffective physiotherapy had not wanted to take part in the trial.
Trial validity and minimising bias
Various measures were taken to ensure trial validity and minimise bias, or to explore the potential for
bias, of which some are discussed here.
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The secure randomisation method helped to ensure comparability in the characteristics of the
participants in the three treatment arms. A greater number of participants in the MUA arm were
currently in paid work, and there was some arm imbalance in having had a similar shoulder problem
on the opposite side from the reference shoulder. A sensitivity analysis of the primary outcome, which
included employment status as an additional covariate, found that the results were similar to those
observed in the primary analysis. The use of unequal random allocation reflected differential treatment
effect expectations. The greater number of participants allocated to the surgery arms than allocated to
physiotherapy allowed for a larger effect size to justify the higher costs of and potential risks associated
with surgery.27
To help ensure a good standard of care, surgeons were advised to use techniques with which they
were familiar, which also helped to avoid learning curve problems. Most operations were carried out
by consultant surgeons for both surgical procedures, and most operating surgeons routinely performed
both procedures up to once per month. Both ESP and PPP were delivered by qualified physiotherapists
who were predominantly band 6 and treated two or three frozen shoulder patients per month. It is
unlikely that not including students or assistants in delivering physiotherapy introduced bias, as this
was applied consistently across all treatment arms. The number of physiotherapy sessions across the
three trial arms was similar. All participants were provided with standardised, written physiotherapy
advice detailing the home exercises they needed to perform.
There were low levels of attrition in the completion of the primary outcome and there was no evidence
of differential dropout in any of the treatment arms. There were no systematic differences in baseline
characteristics compared between those included in the primary analyses and all randomised participants.
The use of a mixed-effect, repeated measures analysis model that included data from any participants
with at least one valid follow-up meant that only 6% of participants were not included in the primary
analysis. This also increased the statistical power of the analyses compared with the single time point
comparison used for the sample size calculation.27 There was a ceiling effect at 12-month follow-up,
in that 24% of participants had regained full function (top OSS score). Although it is encouraging that
participants across all three treatment arms were recovering well, it could be argued that this limited
the potential to find clinically meaningful differences at the primary end point.
Given the nature of the trial treatments, blinding participants and clinicians to treatment allocation
was not possible or desirable in this pragmatic trial. The statistician and health economist were blinded
to group allocation until after the data had been hard locked and no further changes could be made.
The lack of any subgroup effect of participant baseline preferences on treatment outcome (using the
OSS) may in part mitigate concerns about introducing bias from a lack of blinding in the participant
self-reported primary outcome.
It could be argued that a potential bias of the primary analyses concerned the different waiting times
for treatment delivery, with ESP starting at around 14 days, and MUA and ACR starting at around
57 days and 72 days post randomisation, respectively. This could have benefited those in the ESP arm at
the 3-month follow-up when compared with participants who had not yet received a trial intervention
or who were recovering from a surgical procedure. To account for different waiting times, participants
also completed the OSS on the day of treatment and 6 months later. Reassuringly, the OSS appeared
to stay stable between baseline and the start of any of the treatments. Analyses incorporating all data
were largely consistent with the primary analysis findings. This analysis is limited, however, as it reflects
treatment effects at pragmatic follow-up times accounting for the different outcome trajectories, rather
than observing what would have happened had all three trial arms been delivered at similar times.
A further potential threat to study validity is non-compliance because the treatments were not delivered
as planned to all participants. This could dilute the treatment effect observed in the ITT primary analysis.
Only 16 participants (3%) crossed over to a different trial treatment, and 17 (3%) received an alternative
treatment that was not a trial intervention (e.g. steroid injection only). However, around 20% of
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participants across all three trial arms did not complete their treatment, according to our defined
criteria. This was expected, as the natural history is for frozen shoulder to resolve,133–135 particularly for
participants awaiting MUA or ACR, who did not receive their allocated treatment because the waiting
time was 57 and 72 days, respectively. For ESP patients, although up to 12 sessions of physiotherapy
were encouraged, based on existing evidence,38,39 we used strict criteria to define ‘compliers’ as having
to complete eight or more sessions, or fewer if the participant and/or physiotherapist were satisfied
with their progress. To explore the effect of non-compliance on the OSS at the primary end point of
12 months, an instrumental variable regression was undertaken comparing ESP compliers and those
who would have complied in the two surgery groups. ESP outcomes were lower at 12 months, as in the
primary analysis, but this was neither statistically significant nor clinically important, with a difference of
< 2 points on the OSS. Interestingly, unadjusted OSS at 12 months found that participants who complied
with ESP scored, on average, 5 points higher on the OSS than those who did not, which is potentially
clinically important. Finally, a steroid injection was delivered for all who received completed MUA and
for 80% of patients randomised to ESP, compared with 28% of those who received ACR, who had a
steroid injection at the surgeon’s discretion. This could be argued to be a bias against ACR, but it is
consistent with our finding from a survey of 53 surgeons, carried out when developing the trial protocol,
that only 30% routinely provide a steroid injection alongside ACR.27 Therefore, this result reflects
clinical practice.
Applicability of results
Characteristics of the trial population
Among the 914 patients screened who met the inclusion criteria, the application of the eligibility criteria
meant that only 95 patients were excluded for genuine clinical reasons, the frequency of which was
similar across the eligibility criteria. A further 21 patients were excluded for other reasons, 295 eligible
patients did not consent and the recruitment target was met with 503 participants randomised into
the trial. Review of the baseline characteristics confirmed the inclusion of appropriate trial participants
who were in their sixth decade of life and slightly more women.133,135 Characteristics were comparable
between patients who did and patients who did not consent to take part.
The consent rate among eligible patients was 63%. Nearly one-third of patients did not consent
because they ‘wanted surgery’ or ‘did not want physiotherapy’. There were 41% who did not take
part because they preferred ‘keyhole surgery’ (ACR), where over half thought it would be a ‘fairly’ or
‘very’ effective treatment. Among patients who did take part, around half had no treatment preference,
but the majority of the remainding patients preferred surgery. This preference for surgery could be
explained by the fact that trial participants had already had symptoms for around 8–9 months at the time
of enrolment. Moreover, nearly two-thirds of trial participants had previously received physiotherapy for
their affected shoulder. Although it is recognised that the trial was not powered to detect statistically
significant effects between treatment allocation and subgroups, none was found when exploring the
effect on treatment outcome of whether or not participants had previously had physiotherapy, their
treatment preferences, or the duration of their symptoms.
Finally, 30% of trial participants had diabetes, a common complaint in people with frozen shoulder,
ranging between 10% and 36%.117 Participants with diabetes tended to have poorer outcomes at all
time points, which is why we stratified for this at randomisation.62 The subgroup analyses, however,
showed that whether or not participants were diabetic did not have a statistically significant effect on
treatment comparisons.
Applicability of the trial findings
The pragmatic design and setting of UK FROST helps to ensure that the findings have immediate
applicability to the NHS. The criteria used to enrol participants were minimised, and exclusions
were kept to a minimum. Nor were there stringent criteria as to which surgeons could operate on
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participants. Most of those surgeons who did operate were consultants, as would be expected. Although
trial physiotherapy had to be delivered by qualified physiotherapists (i.e. not by students or assistants),
in routine clinical practice students or assistants would be supervised by qualified physiotherapists.
The provision of standardised, written physiotherapy advice detailing the home exercises participants
needed to perform may not have been entirely reflective of all NHS practice, but it ensured that a good
standard of care was applied across all groups.
The trial protocol stipulated that the surgical procedures should be performed within 18 weeks of
randomisation, in keeping with NHS waiting list targets at the time, and MUA and ACR were delivered,
on average, at around 57 days and 72 days post randomisation. Encouragement was given to deliver
both ESP and PPP as soon as possible, particularly PPP within 24 hours of surgery.
It is important to emphasise that, although physiotherapy is a common treatment in NHS practice,
the ESP intervention was a specifically designed, standardised and new physiotherapy pathway to test
the optimal delivery of physiotherapy in the NHS. Both of the physiotherapy groups were developed
using evidence from various sources6,13,18,33,34 and consensus from an expert Delphi study,35 which
encouraged the delivery of up to 12 treatment sessions. In the case of ESP a steroid injection was
to be offered at the first opportunity, whereas with PPP it was not anticipated that a steroid injection
would normally be given. Current NHS pressures and waiting times, however, may compromise early
access to physiotherapy and timely access to the surgical procedures. The seven or eight sessions
of physiotherapy delivered across the three trial arms, along with 80% of participants allocated to
ESP receiving a steroid injection, could also have been more than what is routinely provided in the
NHS. For example, at baseline, randomised participants reported that they had received only five
sessions of physiotherapy and 53% had received a steroid injection. Physiotherapy services may
also vary substantially across the UK.28 In the context of the trial, standardised and structured
physiotherapy protocols were applied to ensure the rigorous and optimal delivery across all three
treatment groups.
During the design of UK FROST, a national survey of health-care professionals found that only 5%
used hydrodilatation to treat a frozen shoulder.22 Therefore, UK FROST focused on the more urgent
comparisons of ESP with the more costly, invasive surgical interventions. Since then, hydrodilatation
appears to have increased in popularity. When the trial team undertook an informal survey with
surgeons and physiotherapists who have collaborated with us on UK FROST and on another upper limb
orthopaedic surgical trial (ProFHER-2), we found that 52 out of 78 respondents used hydrodilatation to
treat a frozen shoulder in a hospital setting. The qualitative interviews, from our nested study, found
that some physiotherapists and surgeons thought that hydrodilatation was a treatment option for
consideration. The systematic review we have undertaken presents inconclusive evidence of the
effectiveness of hydrodilatation from two trials, both small and rated as at high risk of bias, that
compared MUA with hydrodilatation,23,130 and two further trials that compared hydrodilatation with
physiotherapy and steroid injection132 and ACR.25 Although the applicability of the UK FROST findings
needs to be considered in the context of hydrodilatation’s increasing popularity, there is a paucity of
rigorous evidence to support its use.
Most trials in the systematic review that compared the treatments included in UK FROST appeared to
involve a single centre. By contrast, in UK FROST participants were recruited across a range of urban
and rural areas that included 28 hospitals in England, six hospitals in Scotland and one hospital in Wales.
The large number of participating hospitals and health-care professionals improves generalisability of
findings. There could be concerns about the influence on patient outcome of the small number of
participants to whom surgeons and physiotherapists delivered treatment. This effect was statistically
controlled for by including the adjustment of hospital site in the primary model.
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Application of the trial results to clinical practice
The characteristics of the trial participants and duration of their symptoms were as expected.
Therefore, at the primary end point of 12 months for the primary outcome, it was encouraging to find
that participants in all three treatment arms had improved considerably since they had been enrolled
into the trial. Although participants in the ACR arm did a little better, the mean differences between
the treatment options were not of the magnitude of the minimally clinically importance difference that
we sought. By contrast, at the earlier time point of 3-month follow-up, participants in the MUA arm did
a little better than participants in the ACR arm, and a clinically important difference was approached
between participants in the ESP and ACR arms in favour of the former. The timing of delivery of
these interventions could explain these findings. However, the analyses that attempted to account for
variation in waiting times illustrated that the differences between treatment options were smaller than
those from the primary analyses, except for a further benefit in favour of ACR compared with ESP, and
smaller still than the minimally clinically important difference. The findings for the secondary outcomes
showed a similar pattern. Therefore, there is evidence that ESP has potential early benefits compared
with ACR. Although it could be argued that these benefits are confounded by waiting times and the
surgical procedures being performed in more carefully selected participants whose frozen shoulder
had not resolved naturally, pragmatically, this reflects the quicker access to this intervention in clinical
practice, with waiting times for surgery likely to be longer than those during the trial. Importantly,
participants in the nested qualitative study commented on the need for their frozen shoulder to
be resolved and so ESP offers quick access to an effective treatment. Otherwise, the evidence is
inconclusive on whether any of the three treatment options is superior in terms of primary and
secondary outcomes. For these findings to be replicated in clinical practice, ESP with a steroid injection
would need to be delivered as rigorously as it was in UK FROST. Although this might be potentially
challenging in routine care in the NHS, the effective delivery of ESP could prevent the ‘opportunity
cost’ of using theatre resources for MUA or ACR, and avoid the need for PPP.
These findings also apply to people with diabetes, as the presence or absence of diabetes in
participants did not have a statistically significant effect on treatment comparisons.
All three treatments had similar completion rates, at around 80%. There was an optimal release in
92% and 98% of participants who had MUA or ACR, respectively. Overall, among those allocated
to ACR, this treatment was more definitive, with further treatment required for 4% of participants.
Nearly twice as many participants in the MUA arm (7%) required further treatment and even more
in the ESP arm (15%) required further treatment. Serious complications were rare, although the
ACR arm was relatively less safe (4%). Only two participants allocated to MUA experienced a serious
complication (1%). One of the participants in the ACR arm who was diagnosed with a deep-vein
thrombosis actually received non-trial physiotherapy. Therefore, only a marginal difference was seen
in the safety profiles of MUA and ESP, with the latter arm having half the participants. The systematic
review that was undertaken in an attempt to further underpin UK FROST findings found that most
of the comparisons between treatments were limited by the availability of single trials, often in a
single centre with small sample sizes, and the considerable presence of bias and the heterogeneity of
treatment interventions. None of the included trials helped to produce conclusive findings about the
effectiveness of the interventions evaluated in UK FROST. Although hydrodilatation has increased in
popularity in clinical practice, and although research in this area has also increased, evidence of its
effectiveness was inconclusive in the systematic review. In this context, hydrodilatation will need
to be considered carefully as a treatment option for patients with a frozen shoulder.
Finally, ESP was the least expensive intervention, as most participants in this arm did not require
a surgical procedure. MUA was the second most expensive treatment option, with participants
spending one-third of the time in theatre compared with ACR, for which the latter was by far the
most expensive option. MUA, however, resulted in more QALYs over the duration of the study than
either ESP or ACR. This meant that MUA had an 86% probability of being a cost-effective intervention
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at the threshold of £20,000 per QALY threshold if commissioners of services would be willing to pay
£6984 per additional QALY.
Conclusion
UK FROST has provided robust clinically relevant evidence that none of the three treatments was clearly
superior in improving patient-reported shoulder pain and functioning at 12 months. Our specifically
designed ESP pathway can be accessed quickly in the NHS and has lower costs. However, the likelihood
of further treatment being required is higher with ESP than with the other two interventions. MUA
produced the most QALYs overall. At a modest additional cost, MUA is the most cost-effective option
to the NHS, with an ICER of £6984 per additional QALY. Patients who receive ACR are the least likely
to need further treatment, but ACR is associated with relatively higher risks and costs. These findings
should help inform treatment decisions by patients, providers and commissioners of care.
The conclusions should be interpreted with some caution given the potential confounding effect of waiting
times to surgery, which have also lengthened since the trial. This may have meant that participants with
a more resistant frozen shoulder were those who received an operation. It also could be challenging to
implement the ESP pathway in clinical practice with the same optimal timing of access and to the same
standard of delivery as in UK FROST.
Recommendations for research
To address the increasing popularity of hydrodilatation, and the paucity of rigorous evidence for
hydrodilatation’s effectiveness and cost-effectiveness, we recommend the inclusion of hydrodilatation
in a high-quality RCT with an economic evaluation. Trial participants had their own treatment
preferences in the nested qualitative study; some perceived a surgical procedure to be a quick
solution to their shoulder problem, whereas physiotherapy was perceived as a low-risk alternative.
Given patient preferences for different treatment options and the trial findings, we propose the
RCT be a three-arm trial that compares hydrodilatation versus ESP with steroid injection versus MUA
with a steroid injection followed with PPP, as MUA was the more cost-effective of the two surgical
interventions. When designing this RCT, including an outcome measure that is not limited by a ceiling
effect should be considered and rigorously assessed for stiffness. Finally, in clinical practice it could be
complex for patients and surgeons to discuss the risks and benefits of the three treatment options
evaluated in UK FROST, along with the inconclusive evidence for hydrodilatation. Therefore, it could be
of value to undertake research on how to integrate patient and clinician perspectives on the evidence
to inform patient-centred care and shared decision-making.
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Appendix 1 Participating trusts
l Basildon and Thurrock University Hospitals NHS Foundation Trust.
l Bedfordshire Hospital NHS Foundation Trust.
l Blackpool Teaching Hospitals NHS Foundation Trust.
l Cardiff & Vale University Health Board (University Hospital of Wales).
l Dorset County Hospital NHS Foundation Trust.
l East and North Hertfordshire NHS Trust.
l East Kent Hospitals University NHS Foundation Trust.
l Frimley Health NHS Foundation Trust.
l Hampshire Hospitals NHS Foundation Trust.
l James Paget University Hospitals NHS Foundation Trust.
l Manchester University NHS Foundation Trust.
l NHS Forth Valley (Forth Valley Royal Hospital).
l NHS Grampian (Aberdeen Woodend Hospital).
l NHS Greater Glasgow and Clyde (Glasgow Royal Infirmary, Royal Alexandra Hospital, West Glasgow
Ambulatory Care Hospital).
l NHS Tayside (Perth Royal Infirmary).
l North Bristol NHS Trust.
l North Tees and Hartlepool NHS Foundation Trust.
l Northern Devon Healthcare NHS Trust.
l Northumbria Healthcare NHS Foundation Trust.
l Oxford University Hospitals NHS Foundation Trust.
l Royal Free London NHS Foundation Trust.
l Royal Liverpool and Broadgreen University Hospitals NHS Trust.
l Sandwell and West Birmingham Hospitals NHS Trust.
l Sherwood Forest Hospitals NHS Foundation Trust.
l South Tees Hospitals NHS Foundation Trust.
l Southport and Ormskirk Hospital NHS Trust.
l Taunton and Somerset NHS Foundation Trust.
l The Dudley Group NHS Foundation Trust.
l The Mid Yorkshire Hospitals NHS Trust.
l The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust.
l Torbay and South Devon NHS Foundation Trust.
l United Lincolnshire Hospitals NHS Trust.
l University Hospitals Coventry and Warwickshire NHS Trust.
l University Hospitals of Leicester NHS Trust.
l University Hospitals of North Midlands NHS Trust.
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Appendix 2 Table of amendments
Type (non-substantial
or substantial) Approved date Documents amended Brief description of amendment
Substantial
amendment 1
12 January 2015 Update to trial protocol
(V2.0_12/01/15)
Update to trial
participant information
sheet (V2.0_12/01/15)
Addition of shoulder
home exercise leaflet
(V1.0_01/12/14)
1. Clarification in the trial participant
information sheet about the possible
need for further treatment after all three
treatments. Also clarification that the £5
unconditional payment at 12 months is for
all treatment arms
2. Addition of home exercise leaflet
3. Change to trial protocol to be explicit the
analysis that will adjust for age, sex and
diabetes and that an exploratory subgroup
analysis will be done for the presence
of diabetes
Substantial
amendment 2
24 May 2016 Update to trial protocol
(V3.0_20/04/16)
Update to pre-treatment
form (V2.0_20/04/2016)
Clinic staff poster
(V1.0_04/12/2014)
1. Change to allow trial poster to be available
in a public part of the hospital
2. Permission for hospitals to publicise the
trial through initiatives such as the ‘OK to
ask’ campaign
3. Amended the protocol with additional
subgroup analysis as proposed by DMEC
4. Amended the protocol to update sites on
what treatment the participant will have
while awaiting surgery
5. Amended protocol for pre-treatment form
in the ESP arm to complete either on first
day of physiotherapy or before steroid
injection, whichever is first
6. Inclusion of text messaging SWAT at
3-month time point
7. Updated protocol with amended protocol
regarding feedback comments at the
funder’s request
8. Added a list of amendment changes to the
protocol since original REC approval at the
funder’s request
Non-substantial
amendment 1
17 August 2016 N/A Addition of new participating sites
Substantial
amendment 3
21 December 2016 UK FROST tissue and
blood approach letter
(V1.0_15/11/2016)
UK FROST tissue and
blood consent form
(V1.0_15/11/2016)
UK FROST tissue and
blood PIL (V1.0_15/11/
2016)
UK FROST trial protocol
(V4.0_15/11/2016)
The protocol was updated, and accompanying
materials were provided, to allow us to
undertake a nested shoulder capsular tissue
and blood study within the host trial
Non-substantial
amendment 2
13 October 2017 N/A Change in principal investigator at Forth Valley
and Basildon sites
N/A, not applicable; REC, Research Ethics Committee; SWAT, study within a trial.
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Appendix 3 Recruitment
TABLE 36 Recruitment by site
Site Screened (n) Randomised, n (% of screened) Withdrawn, n (% of randomised)
1 58 12 (21) 0 (0)
2 9 6 (67) 0 (0)
3 12 7 (58) 0 (0)
4 8 6 (75) 0 (0)
5 45 11 (24) 0 (0)
6 8 5 (63) 0 (0)
7 49 17 (35) 1 (6)
8 8 4 (50) 0 (0)
9 11 9 (82) 2 (22)
10 12 12 (100) 1 (8)
11 20 18 (90) 1 (6)
12 4 0 (0) N/A
13 79 34 (43) 1 (3)
14 17 11 (65) 4 (36)
15 7 7 (100) 0 (0)
16 15 1 (7) 0 (0)
17 48 45 (94) 1 (2)
18 15 7 (47) 0 (0)
19 48 22 (46) 0 (0)
20 2 1 (50) 0 (0)
21 16 14 (88) 0 (0)
22 18 11 (61) 0 (0)
23 10 3 (30) 0 (0)
24 58 26 (45) 0 (0)
25 12 5 (42) 0 (0)
26 26 18 (69) 0 (0)
27 3 0 (0) N/A
28 10 9 (90) 0 (0)
29 69 49 (71) 2 (4)
30 13 5 (38) 0 (0)
31 52 27 (52) 2 (7)
32 35 16 (46) 1 (6)
33 11 5 (45) 0 (0)
continued
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TABLE 36 Recruitment by site (continued )
Site Screened (n) Randomised, n (% of screened) Withdrawn, n (% of randomised)
34 32 23 (72) 1 (4)
35 34 32 (94) 0 (0)
36 32 22 (69) 2 (9)
37 8 3 (38) 0 (0)
Total 914 503 (55) 19 (4)
N/A, not applicable.
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Appendix 4 Practitioner characteristics
TABLE 37 Practitioner characteristics
Characteristic MUA ACR ESP Total
Surgeons N = 58 N = 65 – N = 90
Operating surgeon grade, n (%)
Consultant 36 (62) 42 (65) – 49 (54)
Registrar 5 (9) 3 (5) – 7 (8)
Unknown 17 (29) 20 (31) – 34 (38)
Number of operations of this type performed per month by operating surgeon, n (%)
0–1 28 (48) 30 (46) – 38 (42)
2–3 8 (14) 9 (14) – 11 (12)
≥ 4 3 (5) 4 (6) – 4 (4)
Missing 19 (33) 22 (34) – 37 (41)
Physiotherapists N = 148 N = 175 N = 78 N = 285
Physiotherapist band, n (%)
Band 5 18 (12) 28 (16) 9 (12) 47 (16)
Band 6 71 (48) 87 (50) 36 (46) 139 (49)
Band 7 43 (29) 47 (27) 23 (29) 73 (26)
Band ≥ 8 15 (10) 12 (7) 10 (13) 24 (8)
Missing 1 (< 1) 1 (1) – 2 (1)
Physiotherapist experience, n (%)
Treating 0–1 frozen shoulders per month 44 (30) 58 (33) 18 (23) 94 (33)
Treating 2–3 frozen shoulders per month 65 (44) 75 (43) 34 (44) 127 (45)
Treating ≥ 4 frozen shoulders per month 35 (24) 38 (22) 24 (31) 59 (21)
Missing 4 (3) 4 (2) 2 (3) 5 (2)
DOI: 10.3310/hta24710 Health Technology Assessment 2020 Vol. 24 No. 71
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Brealey et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
117

Appendix 5 Elements of physiotherapy
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TABLE 38 Physiotherapy elements received (common treatments)
Treatment given
ESP (N= 80; average number of
sessions, n= 8.7)
MUA (N= 158; average number of
sessions, n= 7.9)
ACR (N= 156; average number of
sessions, n= 8.3)
Predominant paina
(average sessions,
n= 4.9)
Predominant
stiffness (average
sessions, n= 3.8)
Predominant pain
(average sessions,
n= 4.0)
Predominant
stiffness (average
sessions, n= 3.8)
Predominant pain
(average sessions,
n= 5.1)
Predominant
stiffness (average
sessions, n= 3.2)
Patients recording problem at least once 72 63 140 134 146 120
Advice and education
Patients, n (%) 71 (99) 63 (100) 139 (99) 134 (100) 146 (100) 118 (98)
Number of sessions, mean (SD) 5.3 (3.4) 4.6 (2.4) 4.5 (3.5) 4.2 (3.3) 5.3 (3.5) 4.0 (2.8)
Median (minimum, maximum) 5 (1, 12) 4 (1, 12) 4 (1, 17) 3 (1, 17) 4 (1, 15) 3 (1, 12)
% of total sessionsb 96 (378/395) 96 (288/300) 97 (621/639) 94 (568/602) 97 (778/802) 95 (468/492)
Home exercises (instruction/review)
Patients, n (%) 64 (89) 55 (87) 139 (99) 134 (100) 146 (100) 119 (99)
Number of sessions, mean (SD) 4.6 (3.4) 4.3 (2.8) 4.4 (3.5) 4.3 (3.3) 5.3 (3.5) 4.0 (2.7)
Median (minimum, maximum) 4 (1, 12) 4 (1, 12) 3 (1, 17) 3 (1, 17) 4 (1, 15) 4 (1, 12)
% of total sessionsb 75 (295/395) 80 (239/300) 97 (617/639) 95 (572/602) 96 (772/802) 96 (473/492)
Supervised exercises (gentle active/self-assisted)
Patients, n (%) 71 (99) 61 (97) 132 (94) 123 (92) 142 (97) 108 (90)
Number of sessions, mean (SD) 5.3 (3.4) 4.6 (2.5) 4.2 (3.4) 3.8 (3.1) 5.0 (3.6) 3.8 (2.6)
Median (minimum, maximum) 5 (1, 12) 4 (1, 12) 3 (1, 17) 3 (1, 17) 4 (1, 15) 3 (1, 12)
% of total sessionsb 95 (374/395) 93 (280/300) 86 (552/639) 78 (471/602) 89 (711/802) 83 (406/492)
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Treatment given
ESP (N= 80; average number of
sessions, n= 8.7)
MUA (N= 158; average number of
sessions, n= 7.9)
ACR (N= 156; average number of
sessions, n= 8.3)
Predominant paina
(average sessions,
n= 4.9)
Predominant
stiffness (average
sessions, n= 3.8)
Predominant pain
(average sessions,
n= 4.0)
Predominant
stiffness (average
sessions, n= 3.8)
Predominant pain
(average sessions,
n= 5.1)
Predominant
stiffness (average
sessions, n= 3.2)
Supervised exercises (function based)
Patients, n (%) 12 (17) 60 (95) 64 (46) 109 (81) 77 (53) 99 (83)
Number of sessions, mean (SD) 3.2 (2.8) 3.5 (2.3) 3.3 (3.2) 3.5 (3.1) 3.3 (2.8) 3.3 (2.6)
Median (minimum, maximum) 2 (1, 9) 3 (1, 11) 2 (1, 13) 2 (1, 17) 2 (1, 13) 3 (1, 12)
% of total sessionsb 10 (38/395) 70 (211/300) 33 (214/639) 64 (386/602) 31 (251/802) 66 (326/492)
Manual shoulder mobilisation
Patients, n (%) 8 (11) 17 (27) 82 (59) 82 (61) 90 (62) 71 (59)
Number of sessions, mean (SD) 1.9 (1.8) 2.1 (1.1) 3.2 (2.1) 3.4 (2.9) 3.3 (2.6) 2.9 (2,2)
Median (minimum, maximum) 1 (1, 6) 2 (1, 4) 3 (1, 10) 2 (1, 15) 2 (1, 11) 2 (1, 11)
% of total sessionsb 4 (15/395) 12 (36/300) 41 (264/639) 47 (280/602) 37 (293/802) 41 (204/492)
Posture correction
Patients, n (%) 32 (44) 23 (27) 57 (41) 47 (35) 68 (47) 51 (43)
Number of sessions, mean (SD) 3.2 (2.5) 2.3 (1.5) 2.6 (2.1) 2.9 (2.6) 3.1 (2.4) 2.5 (2.2)
Median (minimum, maximum) 2 (1, 10) 2 (1, 6) 2 (1, 9) 2 (1, 11) 2 (1, 13) 2 (1, 11)
% of total sessionsb 26 (101/395) 18 (54/300) 23 (149/639) 22 (135/602) 26 (208/802) 26 (128/492)
Other
Patients, n (%) 27 (38) 22 (35) 61 (44) 34 (25) 50 (34) 29 (24)
Number of sessions, mean (SD) 2.6 (2.7) 2.9 (2.5) 2.6 (2.5) 2.6 (2.2) 3.2 (3.4) 2.8 (2.6)
Median (minimum, maximum) 1 (1, 12) 2 (1, 10) 2 (1, 12) 2 (1, 9) 1.5 (1, 15) 2 (1, 11)
% of total sessionsb 17 (69/395) 21 (64/300) 25 (158/639) 15 (89/602) 20 (158/802) 16 (81/492)
a Columns relating to predominant pain also include sessions during which patients indicated pain and stiffness equally, as the applicable treatments were the same.
b Percentage out of the total sessions for predominant pain (or stiffness), including sessions during which the particular treatment was not given.
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TABLE 39 Physiotherapy elements received (pain-specific treatments)
Treatment given
ESP MUA ACR
Predominant paina
(average sessions, n= 4.9)
Predominant pain
(average sessions, n= 4.0)
Predominant pain
(average sessions, n= 5.1)
Patients recording problem at
least once
72 140 146
Hydrotherapy
Patients, n (%) 5 (7) 8 (6) 8 (5)
Number of sessions, mean (SD) 3.6 (2.6) 4.0 (3.1) 4.8 (2.1)
Median (minimum, maximum) 4 (1, 7) 3.5 (1, 8) 5 (1, 7)
% of total sessionsb 5 (18/395) 5 (32/639) 5 (38/802)
Relaxation techniques
Patients, n (%) 32 (44) 17 (12) 25 (17)
Number of sessions, mean (SD) 2.3 (1.8) 2.1 (1) 1.8 (1.4)
Median (minimum, maximum) 1 (1, 8) 2 (1, 4) 1 (1, 6)
% of total sessions 18 (72/395) 5 (35/639) 6 (45/802)
Superficial cold
Patients, n (%) 15 (21) 7 (5) 6 (4)
Mean (SD) sessions 2.3 (1.4) 1.6 (1.1) 2.8 (2.6)
Median (minimum, maximum) 2 (1, 6) 1 (1, 4) 1.5 (1, 7)
% of total sessions 9 (35/395) 2 (11/639) 2 (17/802)
TENS
Patients, n (%) 9 (13) 4 (3) 2 (1)
Number of sessions, mean (SD) 2 (1) 2.5 (1.7) 1.5 (0.7)
Median (minimum, maximum) 2 (1, 4) 2 (1, 5) 1.5 (1, 2)
% of total sessions 5 (18/395) 2 (10/639) 0.4 (3/802)
Trigger-point therapy
Patients, n (%) 21 (29) 16 (11) 19 (13)
Number of sessions, mean (SD) 3.2 (2.5) 2.1 (1.5) 1.7 (1.1)
Median (minimum, maximum) 2 (1, 10) 2 (1, 6) 1 (1, 4)
% of total sessions 17 (67/395) 5 (34/639) 4 (33/802)
TENS, transcutaneous electrical nerve stimulation.
a Columns relating to predominant pain also include sessions during which patients indicated pain and stiffness
equally, as the applicable treatments were the same.
b Percentage out of the total sessions for predominant pain, including sessions during which the particular treatment
was not given.
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TABLE 40 Physiotherapy elements received (stiffness-specific treatments)
Treatment given
ESP MUA ACR
Predominant stiffness
(average sessions, n= 3.8)
Predominant stiffness
(average sessions, n= 3.8)
Predominant stiffness
(average sessions, n= 3.2)
Patients recording problem at
least once
63 134 120
Supervised exercises (stretching)
Patients, n (%) 1 (2%) 75 (56%) 67 (56%)
Number of sessions, mean (SD) 4.0 (–) 3.0 (2.7) 2.7 (2.4)
Median (minimum, maximum) 4 (4, 4) 2 (1, 15) 2 (1, 11)
% of total sessionsa 1 (4/300) 37 (223/602) 36 (178/492)
Supervised exercises (strengthening)
Patients, n (%) 20 (32%) 59 (44%) 52 (43%)
Number of sessions, mean (SD) 2.0 (1.3) 3.1 (2.6) 2.4 (2)
Median (minimum, maximum) 1.5 (1, 5) 2 (1, 11) 2 (1, 8)
% of total sessionsa 13 (40/300) 30 (182/602) 26 (126/492)
Soft-tissue techniques
Patients, n (%) 9 (14%) 36 (27%) 34 (28%)
Number of sessions, mean (SD) 2.6 (1.4) 2.6 (2.1) 2.3 (1.8)
Median (minimum, maximum) 3 (1, 5) 2 (1, 8) 2 (1, 8)
% of total sessionsa 8 (23/300) 15 (92/602) 16 (77/492)
PNF
Patients, n (%) 22 (35%) 16 (12%) 22 (18%)
Number of sessions, mean (SD) 2.3 (2) 2.6 (1.8) 2.4 (1.9)
Median (minimum, maximum) 1 (1, 8) 2 (1, 6) 2 (1, 9)
% of total sessionsa 17 (50/300) 7 (42/602) 11 (53/492)
Spinal/scapulothoracic manual therapy
Patients, n (%) 22 (35%) 21 (16%) 16 (13%)
Number of sessions, mean (SD) 2.0 (1.3) 2.8 (1.8) 2.1 (1.7)
Median (minimum, maximum) 2 (1, 5) 2 (1, 7) 1 (1, 7)
% of total sessionsa 15 (45/300) 10 (59/602) 7 (33/492)
PNF, proprioceptive neuromuscular facilitation.
a Percentage out of the total sessions for predominant stiffness, including sessions during which the particular
treatment was not given.
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Appendix 6 Oxford Shoulder Score subdomains
TABLE 41 Unadjusted OSS pain subdomain by treatment arm
Time point
Treatment arm
TotalMUA ACR ESP
Baseline
n 200 202 99 501
Mean (SD) 3.7 (2.59) 3.3 (2.11) 3.6 (2.38) 3.5 (2.37)
Median 3 3 3 3
Minimum, maximum 0, 16 0, 12 0, 11 0, 16
3 months
n 178 179 90 447
Mean (SD) 7.8 (3.68) 6.7 (3.57) 8.8 (4.00) 7.6 (3.78)
Median 8 7 9 8
Minimum, maximum 0, 16 0, 16 0, 16 0, 16
6 months
n 177 170 83 430
Mean (SD) 10.7 (3.97) 10.2 (3.75) 10.5 (4.36) 10.5 (3.96)
Median 11 11 11 11
Minimum, maximum 0, 16 1, 16 0, 16 0, 16
12 months
n 183 175 88 446
Mean (SD) 11.3 (4.22) 12.2 (3.84) 11.3 (4.20) 11.7 (4.09)
Median 12 13 12 12
Minimum, maximum 1, 16 1, 16 1, 16 1, 16
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FIGURE 16 Unadjusted mean OSS pain items and 95% CIs by treatment arm.
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TABLE 42 Unadjusted OSS function subdomain by treatment arm
Time point
Treatment arm
TotalMUA ACR ESP
Baseline
n 200 202 99 501
Mean (SD) 16.7 (6.92) 15.9 (6.21) 16.7 (6.41) 16.4 (6.54)
Median 17 16 17 16
Minimum, maximum 2, 32 1, 29 2, 31 1, 32
3 months
n 178 179 90 447
Mean (SD) 23.8 (7.24) 20.7 (7.99) 23.9 (7.41) 22.6 (7.72)
Median 26 22 26 25
Minimum, maximum 4, 32 2, 32 1, 32 1, 32
6 months
n 177 170 83 430
Mean (SD) 27.9 (6.25) 26.2 (6.73) 26.0 (7.07) 26.9 (6.64)
Median 30 29 28 29
Minimum, maximum 2, 32 4, 32 4, 32 2, 32
12 months
n 183 175 88 446
Mean (SD) 28.0 (6.19) 28.5 (6.50) 27.5 (6.68) 28.1 (6.41)
Median 31 32 30 31
Minimum, maximum 3, 32 1, 32 3, 32 1, 32
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FIGURE 17 Unadjusted mean OSS function items and 95% CIs by treatment arm.
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Appendix 7 Illustration of treatment effects
12 months
6 months
3 months
ESP vs. ACR
12 months
6 months
3 months
ESP vs. MUA
Comparison and time point
Favours ESP Favours surgery
–8 –6 –4 –2 0 2 4 6 8
3.06 (0.71 to 5.41)
0.98 (–1.31 to 3.26)
–4.72 (–7.06 to –2.39)
1.05 (–1.28 to 3.39)
2.15 (–0.12 to 4.42)
–1.36 (–3.70 to 0.98)
Effect (95% CI)
FIGURE 18 Estimated mean OSS differences from primary analysis model by treatment arm (ESP vs. surgery). Grey lines
indicate sought minimal clinically important difference.
12 months
6 months
3 months
MUA vs. ACR
2.01 (0.10 to 3.91)
–1.17 (–3.02 to 0.67)
–3.36 (–5.27 to –1.45)
Comparison and time point
Favours MUA Favours ACR
–8 –6 –4 –2 0 2 4 6 8
Effect (95% CI)
FIGURE 19 Estimated mean OSS differences from primary analysis model by treatment arm (MUA vs. ACR). Grey lines
indicate sought minimal clinically important difference.
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Appendix 8 Oxford Shoulder Score by
treatment completion at start and end of trial
TABLE 43 Unadjusted OSS scores at 12 months by treatment completion
Characteristic
MUA ACR ESP
Completed
treatment
Did not
complete
treatment
Completed
treatment
Did not
complete
treatment
Completed
treatment
Did not
complete
treatment
Baseline
n 163 37 161 41 80 19
Mean (SD) 20.4 (8.9) 20.8 (8.9) 19.0 (7.6) 19.9 (8.4) 20.7 (7.8) 18.3 (8.4)
Median (minimum, maximum) 20 (2, 48) 20 (3, 36) 19 (1, 37) 19 (4, 35) 20 (2, 42) 18 (4, 34)
12 months
n 157 26 147 28 77 11
Mean (SD) 39.8 (9.3) 36.5 (12.4) 41.1 (9.5) 38.8 (12.3) 39.5 (10.2) 34.2 (11.8)
Median (minimum, maximum) 43 (4, 48) 39 (7, 48) 45 (2, 48) 44.5 (7, 48) 43 (4, 48) 39 (10, 46)
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Appendix 9 Other secondary analyses
Analysis excluding questionnaire responses received more than 6 weeks
beyond the intended follow-up
As > 5% of responses were received beyond the intended follow-up (6% at 3 months, 10% at 6 months,
9% at 12 months), these data were excluded from the primary analysis model in a secondary analysis.
Overall, the results remained similar to those observed in the primary analysis (Table 44). The magnitude
of differences between MUA and ESP was slightly reduced at all time points, and treatment differences
were shown to be less in favour of ACR at all time points when compared with ESP and MUA.
Analysis adjusting for baseline imbalances
As employment status was found to be slightly imbalanced between treatment arms and associated
with OSS scores (participants in paid work having better outcomes), it was included as an additional
covariate in the analysis model as a sensitivity analysis. The results were similar to those observed in
the primary analysis (Table 45).
TABLE 44 Estimated mean OSS differences by treatment arm (estimates from analysis, excluding data received after
6 weeks)
Time point Mean (95% CI) Mean (95% CI) Mean (95% CI) p-value
MUA ESP Difference
3 months 30.6 (29.2 to 32.0) 31.8 (29.8 to 33.9) –1.24 (–3.65 to 1.18) 0.32
6 months 37.3 (35.9 to 38.6) 35.5 (33.5 to 37.5) 1.74 (–0.60 to 4.09) 0.15
12 months 38.5 (37.1 to 40.0) 37.5 (35.5 to 39.6) 0.98 (–1.45 to 3.40) 0.43
ACR ESP Difference
3 months 26.7 (25.3 to 28.1) 31.8 (29.8 to 33.9) –5.11 (–7.53 to –2.68) < 0.01
6 months 35.8 (34.4 to 37.2) 35.5 (33.5 to 37.5) 0.28 (–2.07 to 2.64) 0.81
12 months 40.0 (38.6 to 41.5) 37.5 (35.5 to 39.6) 2.50 (0.05 to 4.94) 0.05
ACR MUA Difference
3 months 26.7 (25.3 to 28.1) 30.6 (29.2 to 32.0) –3.87 (–5.80 to –1.95) < 0.01
6 months 35.8 (34.4 to 37.2) 37.3 (35.9 to 38.6) –1.46 (–3.32 to 0.40) 0.12
12 months 40.0 (38.6 to 41.5) 38.5 (37.1 to 40.0) 1.52 (–0.44 to 3.47) 0.13
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TABLE 45 Estimated mean OSS differences by treatment arm (estimates from analysis, adjusted for employment status)
Time point Mean (95% CI) Mean (95% CI) Mean (95% CI) p-value
MUA ESP Difference
3 months 29.9 (28.5 to 31.3) 31.5 (29.6 to 33.5) –1.63 (–3.97 to 0.71) 0.17
6 months 36.7 (35.3 to 38.1) 34.9 (33.0 to 36.8) 1.82 (–0.46 to 4.11) 0.12
12 months 37.9 (36.5 to 39.3) 37.2 (35.2 to 39.1) 0.78 (–1.56 to 3.11) 0.51
ACR ESP Difference
3 months 26.7 (25.3 to 28.1) 31.5 (29.6 to 33.5) –4.84 (–7.17 to –2.50) < 0.01
6 months 35.6 (34.3 to 37.0) 34.9 (33.0 to 36.8) 0.77 (–1.51 to 3.06) 0.51
12 months 40.1 (38.7 to 41.5) 37.2 (35.2 to 39.1) 2.89 (0.55 to 5.24) 0.02
ACR MUA Difference
3 months 26.7 (25.3 to 28.1) 29.9 (28.5 to 31.3) –3.21 (–5.13 to –1.29) < 0.01
6 months 35.6 (34.3 to 37.0) 36.7 (35.3 to 38.1) –1.05 (–2.91 to 0.81) 0.27
12 months 40.1 (38.7 to 41.5) 37.9 (36.5 to 39.3) 2.12 (0.21 to 4.03) 0.03
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
132
Appendix 10 Subgroup descriptive
statistics (Oxford Shoulder Score)
TABLE 46 Unadjusted OSS by treatment arm and diabetes status
Time point
Diabetic (N= 150, 30%) Non-diabetic (N= 353, 70%)
MUA ACR ESP MUA ACR ESP
Baseline
n 141 142 69 12 12 5
Mean (SD) 20.1 (8.43) 19.3 (7.27) 20.8 (8.48) 24.8 (8.55) 20.5 (9.26) 20.8 (8.04)
Median 20 19.5 20 23 22.5 21
Minimum, maximum 2, 40 4, 37 2, 42 15, 48 6, 35 9, 30
3 months
n 127 128 64 12 11 5
Mean (SD) 32.6 (10.05) 28.9 (10.39) 34.1 (9.75) 33.9 (7.77) 28.3 (11.46) 35 (14.32)
Median 34 31 36 35 32 40
Minimum, maximum 7, 48 5, 48 7, 48 20, 46 9, 43 14, 48
6 months
n 125 123 60 12 9 3
Mean (SD) 39.9 (8.24) 37.7 (9.26) 38.2 (9.37) 36.6 (9.23) 34.3 (11.74) 33.3 (20.43)
Median 42 40 40 38.5 36 42
Minimum, maximum 5, 48 9, 48 6, 48 15, 48 7, 46 10, 48
12 months
n 126 122 62 12 10 5
Mean (SD) 40.4 (8.94) 42.0 (8.43) 40.8 (7.79) 39.5 (6.67) 39.2 (13.65) 34.6 (11.78)
Median 43 45 43 38.5 43 35
Minimum, maximum 7, 48 8, 48 10, 48 27, 48 3, 48 20, 48
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TABLE 47 Unadjusted OSS by treatment arm and previous physiotherapy
Time point
Had previous physiotherapy for affected
shoulder (N= 308, 61%)
Did not have previous physiotherapy for
affected shoulder (N= 192, 38%)
MUA ACR ESP MUA ACR ESP
Baseline
n 125 123 59 75 77 39
Mean (SD) 20.9 (8.25) 19.3 (7.64) 20.3 (8.54) 19.8 (9.85) 19.1 (7.78) 20 (7.11)
Median 21 19 19 20 20 20
Minimum, maximum 2, 40 2, 37 2, 42 2, 48 1, 37 6, 39
3 months
n 111 112 58 67 66 32
Mean (SD) 31.4 (10.13) 27.1 (11.40) 32.3 (11.41) 32.1 (10.93) 28.2 (10.50) 33.3 (10.20)
Median 34 27 34.5 34 31 35.5
Minimum, maximum 7, 48 2, 47 4, 46 5, 48 8, 48 8, 48
6 months
n 108 105 53 69 64 30
Mean (SD) 39.4 (9.01) 36.4 (10.41) 35.4 (11.95) 37.4 (10.65) 36.9 (9.12) 38.5 (9.19)
Median 42 39 39 40 39.5 40
Minimum, maximum 5, 48 7, 48 6, 48 3, 48 10, 48 7, 48
12 months
n 115 109 54 68 65 34
Mean (SD) 40.4 (8.67) 40.4 (10.18) 38.8 (10.53) 37.7 (11.49) 41.51 (9.48) 39 (10.59)
Median 43 44 42.5 42 45 42.5
Minimum, maximum 4, 48 2, 48 4, 48 5, 48 6, 48 10, 48
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TABLE 48 Unadjusted OSS by treatment arm and patient preference
Time point
Randomised to preferred treatment
(N= 131, 26%)
Randomised to non-preferred treatment
(N= 105, 21%)
Had no preference at baseline
(N= 263, 52%)
MUA ACR ESP MUA ACR ESP MUA ACR ESP
Baseline
n 56 64 11 39 27 38 103 110 49
Mean (SD) 18.8 (9.52) 16.6 (7.30) 25 (5.76) 21.8 (8.73) 20.2 (8.04) 16.6 (8.08) 20.9 (8.33) 20.4 (7.62) 21.8 (7.22)
Median 18 15 25 22 20 16.5 21 21 21
Minimum, maximum 2, 38 1, 31 16, 39 2, 48 4, 37 2, 42 2, 40 2, 37 6, 37
3 months
n 47 54 9 36 24 37 94 100 43
Mean (SD) 31.7 (11.31) 26.0 (11.60) 37.9 (5.49) 29.6 (9.18) 26.3 (10.79) 28.6 (11.48) 32.4 (10.44) 28.3 (10.96) 35.3 (10.35)
Median 35 25.5 37 30 27 32 35 30 38
Minimum, maximum 5, 48 3, 47 31, 45 7, 47 8, 44 6, 45 8, 48 2, 48 4, 48
6 months
n 47 53 9 34 24 32 95 92 42
Mean (SD) 37.6 (11.29) 35.4 (9.82) 41.6 (5.36) 38.68 (6.83) 36.3 (9.72) 33.19 (11.87) 39.0 (9.82) 37.1 (10.21) 37.9 (10.81)
Median 40 38 43 40 40 37 42 40 41
Minimum, maximum 4, 48 10, 48 32, 48 15, 48 14, 48 6, 48 3, 48 7, 48 6, 48
12 months
n 50 53 10 36 24 34 95 97 43
Mean (SD) 39.2 (9.47) 39.4 (9.84) 42.7 (4.27) 38.5 (8.57) 41.0 (8.92) 38.2 (10.19) 40.0 (10.10) 41.4 (10.39) 38.8 (11.60)
Median 42.5 42 44 40.5 45.5 40.5 44 45 43
Minimum, maximum 4, 48 6, 48 35, 48 10, 48 21, 48 10, 48 5, 48 2, 48 4, 48
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TABLE 49 Unadjusted OSS by treatment arm and duration of symptoms at baseline
Time point
Duration of symptoms:
< 9 months (N= 249, 61%)
Duration of symptoms:
≥ 9 months (N= 245, 49%)
MUA ACR ESP MUA ACR ESP
Baseline
n 103 95 51 93 105 47
Mean (SD) 18.3 (8.33) 18.8 (7.53) 19.6 (7.53) 22.7 (9.04) 19.6 (7.90) 21.0 (8.51)
Median 18 19 18 24 19 21
Minimum, maximum 2, 36 2, 34 2, 39 1, 48 1, 37 4, 42
3 months
n 88 83 46 86 95 43
Mean (SD) 31.4 (10.21) 28.2 (11.61) 30.7 (10.89) 32.0 (10.76) 26.9 (10.60) 34.5 (10.72)
Median 34 31 32 34 27 36
Minimum, maximum 8, 46 2, 48 6, 48 5, 48 3, 47 4, 48
6 months
n 89 81 42 84 88 40
Mean (SD) 38.2 (10.42) 37.2 (9.63) 37.6 (8.35) 39.0 (9.07) 36.0 (10.05) 35.1 (13.3)
Median 40 41 40 42 39 40
Minimum, maximum 3, 48 7, 48 12, 48 5, 48 10, 48 6, 48
12 months
n 94 84 44 86 90 43
Mean (SD) 39.0 (11.35) 40.9 (10.45) 39.1 (10.02) 40.0 (8.00) 40.7 (9.60) 38.5 (8.00)
Median 43 45 43.5 43 44 43
Minimum, maximum 4, 48 2, 48 10, 48 10, 48 6, 48 10, 48
TABLE 50 Unadjusted OSS for patients who completed treatment by receipt of steroid injection
Time point
MUA ACR ESP
Received
steroid
injection
Did not
receive steroid
injection
Received
steroid
injection
Did not
receive steroid
injection
Received
steroid
injection
Did not
receive steroid
injection
Baseline
n 163 – 45 – 64 10
Mean (SD) 20.4 (8.89) 18.1 (7.51) 20.7 (6.83) 18.1 (10.04)
Median 20 18 20 17
Minimum,
maximum
2, 48 2, 33 6, 39 4, 34
12 months
n 157 – 40 – 61 4
Mean (SD) 39.8 (9.33) 42.1 (9.76) 39.8 (10.21) 28.5 (16.82)
Median 43 45.5 44 29
Minimum,
maximum
4, 48 2, 48 10, 48 10, 46
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Appendix 11 Secondary outcomes descriptives
TABLE 51 Unadjusted QuickDASH by treatment arm
Time point
Treatment arm
TotalMUA ACR ESP
Baseline
n 192 197 96 485
Mean (SD) 57.0 (20.97) 61.7 (18.51) 59.4 (19.69) 59.4 (19.82)
Median 59 64 60 61
Minimum, maximum 0, 100 14, 100 14, 98 0, 100
3 months
n 173 178 86 437
Mean (SD) 34.5 (23.95) 43.2 (24.01) 34.0 (23.98) 38.0 (24.32)
Median 30 41 32 34
Minimum, maximum 0, 91 0, 93 0, 96 0, 96
6 months
n 171 169 75 415
Mean (SD) 21.98 (21.98) 26.1 (21.21) 25.9 (25.07) 24.36 (22.30)
Median 16 21 18 18
Minimum, maximum 0, 98 0, 91 0, 91 0, 98
12 months
n 175 167 81 423
Mean (SD) 20.0 (23.16) 17.3 (21.39) 20.9 (22.77) 19.1 (22.40)
Median 11 9 14 11
Minimum, maximum 0, 98 0, 93 0, 89 0, 98
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TABLE 52 Unadjusted Numeric Rating Scale for Pain by treatment arm
Time point
Treatment arm
TotalMUA ACR ESP
Baseline
n 199 201 99 499
Mean (SD) 6.8 (2.23) 7 (1.89) 6.9 (2.37) 6.9 (2.13)
Median 7 7 7 7
Minimum, maximum 0, 10 0, 10 0, 10 0, 10
3 months
n 178 178 88 444
Mean (SD) 3.8 (2.61) 4.5 (2.64) 3.5 (2.69) 4.0 (2.67)
Median 3 4 3 4
Minimum, maximum 0, 10 0, 10 0, 10 0, 10
6 months
n 175 169 77 421
Mean (SD) 2.48 (2.43) 2.7 (2.34) 2.6 (2.76) 2.6 (2.46)
Median 2 2 2 2
Minimum, maximum 0, 10 0, 9 0, 9 0, 10
12 months
n 179 174 86 439
Mean (SD) 2.2 (2.62) 1.6 (2.10) 2.2 (2.55) 2.0 (2.43)
Median 1 1 1.5 1
Minimum, maximum 0, 9 0, 9 0, 10 0, 10
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TABLE 53 Unadjusted extent of recovery by treatment arm
Time point
Treatment arm
TotalMUA ACR ESP
Baseline
n 198 201 99 498
Mean (SD) 83.8 (21.79) 86.2 (20.11) 89.2 (15.35) 85.9 (20.03)
Median 90 95 100 95
Minimum, maximum 0, 100 0, 100 50, 100 0, 100
3 months
n 176 176 89 441
Mean (SD) 48.3 (36.35) 51.4 (35.94) 52.0 (36.54) 50.3 (36.18)
Median 50 55 55 50
Minimum, maximum 0, 100 0, 100 0, 100 0, 100
6 months
n 174 171 78 423
Mean (SD) 29.6 (35.51) 32.3 (33.97) 35 (37.25) 31.7 (35.20)
Median 10 20 20 20
Minimum, maximum 0, 100 0, 100 0, 100 0, 100
12 months
n 179 175 88 442
Mean (SD) 25.5 (33.99) 18.9 (31.00) 24.6 (31.71) 22.7 (32.5)
Median 5 0 10 4.5
Minimum, maximum 0, 100 0, 100 0, 100 0, 100
TABLE 54 Predominant shoulder problem (among patients who received their allocated treatment)
Problem
Treatment arm, n (%)
MUA (N= 164) ACR (N= 162) ESP (N= 99)
At the start of physiotherapy N = 156 N = 152 N = 80
Pain 60 (38) 59 (39) 34 (43)
Stiffness 45 (29) 39 (26) 16 (20)
Pain and stiffness equally 51 (33) 54 (36) 30 (38)
At the end of physiotherapya N = 150 N = 150 N = 78
Pain 37 (25) 39 (26) 15 (19)
Stiffness 98 (65) 82 (55) 52 (67)
Pain and stiffness equally 15 (10) 29 (19) 11 (14)
a For patients who attended two or more physiotherapy sessions.
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Appendix 12 Adverse events
TABLE 55 Serious adverse events (summary by treament arm)
Number of events MUA (N= 2) ACR (N= 8) ESP (N= 0)
Type (n)
Prolonged hospitalisation 0 2 0
Required hospitalisation 0 0 0
Other medically important condition 1 1 0
Not reported on SAE form 1 5 0
Relationship to trial treatments (n)
Not related 1 2 0
Unlikely to be related 0 2 0
Possibly related 0 0 0
Probably related 0 1 0
Definitely related 1 3 0
Expectedness (n)
Expected 0 2 0
Unexpected 1 2 0
Not reported on SAE form 1 4 0
Number of patients MUA (N= 201) ACR (N= 203) ESP (N= 99)
Number of patients with one or more SAE 2 (1%) 7 (3%) 0 (0%)
Number of patients with one SAE 2 6 0
Number of patients with two SAEs 0 1 0
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TABLE 56 Non-serious AEs (summary by treatment arm)
Number of events MUA (N= 15) ACR (N= 13) ESP (N= 5)
Relationship to trial treatments (n)
Not related 4 0 3
Unlikely to be related 2 2 0
Possibly related 4 5 1
Probably related 1 0 0
Definitely related 1 3 0
Not reported on AE form 3 3 1
Expectedness (n)
Expected 9 7 3
Unexpected 3 3 1
Not reported through AE form 3 3 1
Severity (n)
Mild 3 6 2
Moderate 5 2 1
Severe 2 2 0
Missing/not reported on AE form 5 3 2
Number of patients MUA (N= 201) ACR (N= 203) ESP (N= 99)
Number of patients with one or more AE 14 (7%) 12 (6%) 5 (5%)
Number of patients with one AE 13 11 5
Number of patients with two AEs 1 1 0
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Appendix 13 Treatment preferences
Among non-consenting patients (n = 295), ACR was the most popular treatment, followed by ESP(Table 57). Few patients gave MUA as their preferred treatment. Although clinicians did not have
a preferred treatment for nearly half of these patients (45%), the agreed treatment was often ACR in
line with patient preferences (43%). Average strength of any treatment preference was high for MUA,
ACR and ESP (mean of 9 out of 10), but lower for individuals who wanted surgery but did not mind
what surgery might be performed (Table 58).
In line with the above results, non-consenting patients thought that ACR was more likely to be
effective than other treatments. More than half of these patients expected ESP to be fairly or very
ineffective. Randomised patients, on the other hand, were more likely to evaluate trial treatments
neutrally (i.e. as neither effective nor ineffective), although ACR was expected to be the most
effective (Table 59).
Baseline preferences among randomised patients are shown in Table 60. Approximately half of
participants had no treatment preference, and among those who did have a preference this was
predominantly for surgery or for ACR in particular. Participants who had received physiotherapy
prior to entering the trial only marginally preferred other treatments more and physiotherapy less.
After 12 months’ follow-up, there was a trend for patients to change their preference to the treatment
they had been allocated to (Table 61). Preference for ACR was much more common among patients
who had received their preferred treatment than among those who initially preferred another
treatment (50% vs. 31%), whereas the opposite was true for physiotherapy (13% vs. 23%).
TABLE 57 Treatment preferences of non-consenting patients
Preference
Patient preference
(consent status CRF)
(N= 281), n (%)
Detailed patient
preference (optional
preferences CRF)
(N= 158), n (%)
Clinician advice
(consent status CRF)
(N= 271), n (%)
Agreed treatment
(consent status CRF)
(N= 270), n (%)
Any surgery – 20 (13) – –
MUA 26 (9) 11 (7) 27 (10) 32 (12)
ACR 116 (41) 58 (37) 91 (34) 117 (43)
ESP 82 (29) 48 (30) 32 (12) 80 (30)
No preference 49 (17) 21 (13) 121 (45) –
Other 8 (3) – – 41 (15)
TABLE 58 Strength of treatment preference of non-randomised patients (scale 1–10)
Any surgery MUA ACR ESP
n 14 11 54 34
Mean (SD) 5.1 (4.41) 9.0 (1.10) 9.0 (1.69) 9.0 (1.34)
Median (minimum, maximum) 3 (1, 10) 9 (7, 10) 10 (1, 10) 10 (6, 10)
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TABLE 59 Treatment expectations
Treatment arm, n (%)
MUA ACR ESP
Non-consenting patients
Very ineffective 4 (3) 2 (1) 38 (26)
Fairly ineffective 12 (8) 4 (3) 43 (29)
Cannot decide 81 (56) 52 (36) 29 (20)
Fairly effective 24 (17) 35 (24) 26 (18)
Very effective 24 (17) 53 (36) 10 (7)
Randomised patients
Very ineffective 22 (5) 29 (6) 42 (9)
Fairly ineffective 22 (5) 13 (3) 86 (18)
Cannot decide 231 (47) 208 (43) 252 (52)
Fairly effective 121 (25) 85 (17) 73 (15)
Very effective 90 (18) 151 (31) 35 (7)
TABLE 60 Treatment preferences for randomised patients at baseline
N
Baseline preference, n (%)
MUA ACR Either surgery ESP No preference
Total
All patients 499 35 (7) 76 (15) 86 (17) 39 (8) 263 (53)
Allocation
MUA 199 20 (10) 28 (14) 36 (18) 12 (6) 103 (52)
ACR 202 8 (4) 38 (19) 29 (14) 16 (8) 111 (56)
ESP 98 7 (7) 10 (10) 21 (21) 11 (11) 49 (50)
Previous physiotherapy
Had previous physiotherapy 306 25 (8) 48 (16) 57 (19) 20 (7) 156 (51)
Did not have previous physiotherapy 190 10 (5) 28 (15) 27 (14) 19 (10) 106 (56)
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TABLE 61 Treatment preferences for randomised patients at 12 months
N
Preference at 12-month follow-up, n (%)
MUA ACR Either surgery ESP No preference
Total
All patients 416 102 (25) 150 (36) 40 (10) 76 (18) 48 (12)
Allocation
MUA 166 81 (49) 31 (19) 25 (15) 10 (6) 19 (11)
ACR 166 16 (10) 102 (61) 11 (7) 22 (13) 15 (9)
ESP 84 5 (6) 17 (20) 4 (5) 44 (52) 14 (17)
Baseline preference
MUA 29 9 (31) 7 (24) 4 (14) 6 (21) 3 (10)
ACR 63 16 (25) 31 (49) 5 (8) 7 (11) 4 (6)
Either surgery 70 17 (24) 33 (47) 6 (9) 9 (13) 5 (7)
ESP 31 5 (16) 8 (26) 0 (0) 12 (39) 6 (19)
No preference 220 54 (25) 70 (32) 24 (11) 42 (19) 30 (14)
Receipt of baseline preferred treatmenta
Received preferred treatment 103 23 (22) 51 (50) 9 (9) 13 (13) 7 (7)
Did not receive preferred treatment 90 24 (27) 28 (31) 6 (7) 21 (23) 11 (12)
a Excludes patients who had no baseline preference.
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Appendix 14 Oxford Shoulder Score
change scores
Patients’ assessment of how their shoulder was by the end of the trial compared with 1 yearpreviously revealed that the vast majority of patients felt ‘much better’ (i.e. data on other response
categories were limited). ‘Much better’ was associated with a median OSS score change of 23, whereas
‘slightly better’ was associated with a median score change of 10 (Table 62). The trial effect size on
which UK FROST was powered was half of this (4–5 OSS points).
TABLE 62 Anchoring of OSS change scores
Difference in OSS score between
baseline and 12 months
How is your shoulder compared with 1 year ago?
Much better Slightly better About the same Slightly worse Much worse
n 359 42 20 9 6
Mean (SD) 22.7 (8.0) 9.4 (9.3) 3.4 (7.0) 4.9 (11.8) –3.7 (6.56)
Median 23 10 0.5 1 –2
Minimum, maximum –3, 42 –13, 34 –5, 18 –6, 26 –14, 5
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Appendix 15 Outcomes for patients
receiving no treatment
TABLE 63 Unadjusted trial outcomes by receipt of treatment
OSS QuickDASH
Received any
treatment (N= 441)
Did not receive any
treatment (N= 62)
Received any
treatment (N= 441)
Did not receive any
treatment (N= 62)
Baseline
n 439 62 428 57
Mean (SD) 19.7 (8.2) 21.1 (8.3) 59.8 (19.7) 56.3 (20.7)
Median 20 20.5 61 58
Minimum, maximum 1, 48 3, 36 0, 100 23, 100
3 months
n 409 38 400 37
Mean (SD) 30.3 (11.0) 29.0 (11.6) 37.9 (24.2) 38.9 (26.3)
Median 32 33 34 32
Minimum, maximum 2, 48 5, 47 0, 96 0, 91
6 months
n 395 35 381 34
Mean (SD) 37.5 (10.0) 35.3 (11.1) 24.0 (22.0) 27.9 (25.1)
Median 40 39 18 20.5
Minimum, maximum 3, 48 6, 48 0, 98 0, 89
12 months
n 405 41 385 38
Mean (SD) 40.1 (9.6) 36.3 (13.5) 18.3 (21.5) 27.0 (29.2)
Median 43 43 11 14
Minimum, maximum 2, 48 7, 48 0, 98 0, 93
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Appendix 16 Health-related quality of life
and quality-adjusted life-years
TABLE 64 Health-related quality of life: number of questionnaires returned and completed EQ-5D-5L scores
Treatment arm
Baseline, n (%) 3 months, n (%) 6 months, n (%) 12 months, n (%)
Complete Missing Complete Missing Complete Missing Complete Missing
MUA (N= 201) 199 (99) 2 (1) 173 (86) 28 (14) 172 (85) 29 (15) 178 (88) 23 (12)
ACR (N= 203) 200 (98) 3 (2) 175 (86) 28 (14) 165 (81) 38 (19) 175 (86) 28 (14)
ESP (N = 99) 95 (96) 4 (4) 88 (89) 11 (11) 75 (76) 24 (24) 86 (87) 13 (13)
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TABLE 65 Health-related quality of life: proportion reporting EQ-5D-5L levels 1–5 by dimension, treatment arm and time point (complete cases)
Dimension
Baseline, n (%) 3 months, n (%) 6 months, n (%) 12 months, n (%)
MUA ACR ESP MUA ACR ESP MUA ACR ESP MUA ACR ESP
Mobility
Level 1 159 (79.1) 146 (71.9) 69 (69.7) 148 (73.6) 130 (64.0) 67 (67.7) 145 (72.1) 128 (63.1) 55 (55.6) 144 (71.6) 129 (63.6) 66 (66.7)
Level 2 14 (7.0) 18 (8.9) 10 (10.1) 12 (6.0) 15 (7.4) 8 (8.1) 13 (6.5) 14 (6.9) 7 (7.1) 14 (7.0) 17 (8.4) 10 (10.1)
Level 3 18 (9.0) 28 (13.8) 10 (10.1) 10 (5.0) 20 (9.9) 9 (9.1) 10 (5.0) 14 (6.9) 8 (8.1) 14 (7.0) 17 (8.4) 4 (4.0)
Level 4 8 (4.0) 9 (4.4) 7 (7.1) 5 (2.5) 9 (4.4) 5 (5.1) 5 (2.5) 10 (4.9) 5 (5.1) 8 (4.0) 13 (6.4) 7 (7.1)
Level 5 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0) 2 (1.0) 1 (1.0) 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 2 (1.0) 1 (0.5) 3 (3.0) 26 (12.9) 27 (13.3) 9 (9.1) 28 (13.9) 36 (17.7) 24 (24.2) 21 (10.5) 27 (13.3) 12 (12.1)
Reporting probability 40 (20.1) 56 (27.7) 27 (28.1) 27 (15.4) 46 (26.1) 23 (25.6) 28 (16.2) 39 (23.4) 20 (26.7) 36 (20.0) 47 (26.7) 21 (24.1)
Self-care
Level 1 17 (8.5) 12 (5.9) 10 (10.1) 65 (32.3) 39 (19.2) 28 (28.3) 95 (47.3) 75 (37.0) 35 (35.4) 106 (52.7) 116 (57.1) 51 (51.5)
Level 2 66 (32.8) 52 (25.6) 26 (26.3) 67 (33.3) 70 (34.5) 36 (36.4) 54 (26.9) 60 (29.6) 25 (25.3) 52 (25.9) 32 (15.8) 21 (21.2)
Level 3 80 (39.8) 94 (46.3) 45 (45.5) 29 (14.4) 47 (23.2) 15 (15.2) 14 (7.0) 27 (13.3) 10 (10.1) 13 (6.5) 21 (10.3) 9 (9.1)
Level 4 34 (16.9) 42 (20.7) 17 (17.2) 15 (7.5) 19 (9.4) 8 (8.1) 8 (4.0) 5 (2.5) 5 (5.1) 6 (3.0) 6 (3.0) 5 (5.1)
Level 5 3 (1.5) 2 (1.0) 1 (1.0) 0 (0.0) 2 (1.0) 3 (3.0) 1 (0.5) 1 (0.5) 0 (0.0) 3 (1.5) 1 (0.5) 2 (2.0)
Missing 1 (0.5) 1 (0.5) 0 (0.0) 25 (12.4) 26 (12.8) 9 (9.1) 29 (14.4) 35 (17.2) 24 (24.2) 21 (10.5) 27 (13.3) 11 (11.1)
Reporting probability 183 (91.5) 190 (94.1) 89 (89.9) 111 (63.1) 138 (78.0) 62 (68.9) 77 (44.8) 93 (55.4) 40 (53.3) 74 (41.1) 60 (34.1) 37 (42.1)
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Dimension
Baseline, n (%) 3 months, n (%) 6 months, n (%) 12 months, n (%)
MUA ACR ESP MUA ACR ESP MUA ACR ESP MUA ACR ESP
Usual activities
Level 1 12 (6.0) 7 (3.5) 7 (7.1) 47 (23.4) 26 (12.8) 22 (22.2) 74 (36.8) 64 (31.5) 31 (31.3) 92 (45.8) 94 (46.3) 46 (46.5)
Level 2 58 (28.9) 35 (17.2) 19 (19.2) 70 (34.8) 67 (33.0) 35 (35.4) 67 (33.3) 60 (29.6) 25 (25.3) 53 (26.4) 48 (23.7) 22 (22.2)
Level 3 70 (34.8) 97 (47.8) 43 (43.4) 38 (18.9) 58 (28.6) 20 (20.2) 22 (11.0) 27 (13.3) 13 (13.1) 22 (11.0) 21 (10.3) 12 (12.1)
Level 4 41 (20.4) 53 (26.1) 24 (24.2) 19 (9.5) 22 (10.8) 10 (10.1) 10 (5.0) 14 (6.9) 4 (4.0) 9 (4.5) 10 (4.9) 6 (6.1)
Level 5 19 (9.5) 9 (4.4) 6 (6.1) 2 (1.0) 5 (2.5) 3 (3.0) 0 (0.0) 2 (1.0) 2 (2.0) 3 (1.5) 3 (1.5) 2 (2.0)
Missing 1 (0.5) 2 (1.0) 0 (0.0) 25 (12.4) 25 (12.3) 9 (9.1) 28 (13.9) 36 (17.7) 24 (24.2) 22 (11.0) 27 (13.3) 11 (11.1)
Reporting probability 188 (94.0) 194 (96.5) 92 (92.9) 129 (73.3) 152 (85.4) 68 (75.6) 99 (57.2) 103 (61.7) 44 (58.7) 87 (48.6) 82 (46.6) 42 (47.7)
Pain/discomfort
Level 1 3 (1.5) 3 (1.5) 1 (1.0) 16 (8.0) 6 (3.0) 11 (11.1) 37 (18.4) 24 (11.8) 18 (18.2) 60 (29.9) 57 (28.1) 22 (22.2)
Level 2 22 (11.0) 11 (5.4) 9 (9.1) 83 (41.3) 61 (30.1) 39 (39.4) 85 (42.3) 87 (42.9) 34 (34.3) 69 (34.3) 73 (36.0) 43 (43.4)
Level 3 88 (43.8) 87 (42.9) 37 (37.4) 48 (23.9) 74 (36.5) 23 (23.2) 37 (18.4) 43 (21.2) 11 (11.1) 31 (15.4) 28 (13.8) 11 (11.1)
Level 4 66 (32.8) 83 (40.9) 35 (35.4) 27 (13.4) 28 (13.8) 11 (11.1) 12 (6.0) 12 (5.9) 7 (7.1) 14 (7.0) 14 (6.9) 7 (7.1)
Level 5 21 (10.5) 17 (8.4) 16 (16.2) 3 (1.5) 9 (4.4) 5 (5.1) 1 (0.5) 2 (1.0) 5 (5.1) 5 (2.5) 3 (1.5) 4 (4.0)
Missing 1 (0.5) 2 (1.0) 1 (1.0) 24 (11.9) 25 (12.3) 10 (10.1) 29 (14.4) 35 (17.2) 24 (24.2) 22 (11.0) 28 (13.8) 12 (12.1)
Reporting probability 197 (98.5) 198 (98.5) 97 (99.0) 161 (91.0) 172 (96.6) 78 (87.6) 135 (78.5) 144 (85.7) 57 (76.0) 119 (66.5) 118 (67.4) 65 (74.7)
Anxiety/depression
Level 1 97 (48.3) 84 (41.4) 40 (40.4) 110 (54.7) 100 (49.3) 50 (50.5) 117 (58.2) 108 (53.2) 49 (49.5) 120 (59.7) 126 (62.1) 57 (57.6)
Level 2 47 (23.4) 64 (31.5) 25 (25.3) 35 (17.4) 38 (18.7) 18 (18.2) 33 (16.4) 33 (16.3) 13 (13.1) 31 (15.4) 20 (9.9) 15 (15.2)
Level 3 40 (19.9) 41 (20.2) 20 (20.2) 21 (10.5) 27 (13.3) 11 (11.1) 20 (10.0) 15 (7.4) 7 (7.1) 26 (12.9) 21 (10.3) 7 (7.1)
Level 4 10 (5.0) 7 (3.5) 6 (6.1) 8 (4.0) 7 (3.5) 5 (5.1) 3 (1.5) 9 (4.4) 2 (2.0) 3 (1.5) 5 (2.5) 6 (6.1)
Level 5 6 (3.0) 6 (3.0) 8 (8.1) 1 (0.5) 6 (3.0) 5 (5.1) 0 (0.0) 2 (1.0) 4 (4.0) 0 (0.0) 4 (2.0) 3 (3.0)
Missing 1 (0.5) 1 (0.5) 0 (0.0) 26 (12.9) 25 (12.3) 10 (10.1) 28 (13.9) 36 (17.7) 24 (24.2) 21 (10.5) 27 (13.3) 11 (11.1)
Reporting probability 103 (51.5) 118 (58.4) 59 (59.6) 65 (37.1) 78 (43.8) 39 (43.8) 56 (32.4) 59 (35.3) 26 (34.7) 60 (33.3) 50 (28.4) 31 (35.2)
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economics analysis
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TABLE 66 Description of economic variables in UK FROST
Variable Description
Missing values (%)
Range Mean SDTotal ESP MUA ACR
Baseline variables
age Age at trial entry 0 0 0 0 30 to 70 54.25 7.72
sex Male or female 0 0 0 0 1, 2 63% female
eq5d_B EQ-5D-5L at baseline 1.79 4.04 0.99 1.48 –0.37 to 1.00 0.43 0.26
OSS_B OSS score at baseline 0.40 0 0.50 0.49 1 to 48 19.89 8.25
Diabetes Diabetic yes/no at baseline 0 0 0 0 1, 3 70% not diabetic
alloc Treatment allocation 0 0 0 0 1, 3
Outcome variables for HRQoL
eq5d_3m EQ-5D-5L at 3 months 13.32 11.1 13.9 13.8 –0.245 to 1.00 0.60 0.26
eq5d_6m EQ-5D-5L at 6 months 18.09 24.2 14.4 18.7 –0.257 to 1.00 0.70 0.23
eq5d_12m EQ-5D-5L at 12 months 12.72 13.1 11.4 13.8 –0.328 to 1.00 0.73 0.26
Outcome variables for costs (£)
Cost_ESP Costs of ESPa 0 0 0 0 59.80 to 768.40 279.46 148.8
Cost_MUA Costs of MUAa 0 0 0 0 259.20 to 972.00 424.81 115.5
Cost_ACR Costs of ACRa 0 0 0 0 877.30 to 3082.30 2170.46 431.1
Cost_PPP Costs of physiotherapyb 0 0 0 0 0 to 975.20 209.65 152.9
Cost_add Additional treatmentsc 0 0 0 0 0 to 167.97 2.83 21.0
Cost_further Further treatmentsd 0 0 0 0 0 to 1521.87 41.41 204.2
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Variable Description
Missing values (%)
Range Mean SDTotal ESP MUA ACR
Cost_other Other treatmentse 0 0 0 0 0 to 668 7.18 49.42
Cost_crossovers Treatment after crossoverf 0 0 0 0 0 to 125.01 0.50 7.87
Cost_Hosp_INP Inpatient costs regarding complicationsg 0 0 0 0 0 to 4926.24 32.85 312.1
Cost_Hosp_OUP Outpatient costs regarding complicationsh 0 0 0 0 0 to 875.07 19.37 82.71
Cost_GP_pr Costs of GP visits (surgery) 33.00 37.40 31.80 32.00 0 to 822.80 57.26 110.6
Cost GP_phone Costs of GP visits (telephone) 34.20 38.30 32.30 34.00 0 to 197.60 6.33 23.01
Cost Nurse_pr Costs of practice nurse 36.40 40.40 34.30 36.40 0 to 75.95 2.10 6.54
Cost_Nure_dis Costs of district nurse 33.80 37.40 32.80 33.00 0 to 380 1.94 21.69
Cost_Physio_c Costs of district physiotherapist 33.40 35.30 32.80 33.00 0 to 1214.40 56.27 183.1
Cost_OT_c Costs of occupational therapist 16.90 16.20 16.40 17.70 0 to 282 0.67 13.79
Outcomes for cost-effectiveness
Total_QALYs Total QALYs over 1 year 26.6 35.3 22.4 26.6 –0.225 to 0.979 0.66 0.207
Total Costs Total costs over 1 year 40.50 44.40 38.80 40.40 0 to 5732.54 1372.36 1095.99
OT, occupational therapist.
a For those who had ESP/surgery (MUA/ACR).
b Costs of PPP for those who had surgery (MUA/ACR).
c Any treatments the patient received before/during receiving randomised treatment.
d Any treatments the patient received after completing randomised treatment.
e Any non-trial treatments the patient had if they did not start/complete their randomised treatment.
f Cost of further treatments following crossover.
g Hospital inpatient stay costs related to complications.
h Hospital outpatient costs related to complications.
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TABLE 67 Number and proportion of patients with complete data by treatment arm
Time point
Treatment arm, n (%)
ESP (N= 99) MUA (N= 201) ACR (N= 203)
Complete: HRQoL
Baseline 95 (95.96) 199 (99.00) 200 (98.52)
3 months 88 (88.89) 173 (86.07) 175 (86.21)
6 months 75 (75.76) 172 (85.57) 165 (81.28)
12 months 86 (86.87) 178 (88.56) 175 (86.21)
Overall 64 (64.65) 156 (77.61) 149 (73.40)
Complete: costs
3 months 78 (78.79) 164 (81.59) 158 (77.83)
6 months 71 (71.72) 155 (77.11) 150 (73.89)
12 months 77 (77.78) 161 (80.10) 158 (77.83)
Overall 55 (55.56) 123 (61.19) 121 (59.61)
Complete: both HRQoL and costs
3 months 76 (76.77) 161 (80.10) 154 (75.86)
6 months 68 (68.69) 152 (75.62) 144 (70.94)
12 months 75 (75.76) 159 (79.10) 157 (77.34)
Overall 46 (46.46) 117 (58.21) 116 (57.14)
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EQ-5D-5L baseline
EQ-5D-5L 3 months
EQ-5D-5L 6 months
EQ-5D-5L 12 months
(a)
503 individuals at entry to trial
Observed data
Missing data
cost_gp_prac_3m_bc
cost_nume_prac_3m_bc
cost_of_community_3m_bc
cost_gp_prac_6m_bc
cost_nume_prac_6m_bc
cost_of_community_6m_bc
cost_gp_prac_12m_bc
cost_nume_prac_12m_bc
cost_of_community_12m_bc
(b)
503 individuals at entry to trial
Observed data
Missing data
FIGURE 20 Pattern of missing data in UK FROST data set. (a) EQ-5D-5L data; and (b) cost data.
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TABLE 68 Logistic regression for (1) missingness of costs and QALYs on baseline variables and (2) missingness between
missing costs and QALYs and observed outcomes
Odds ratio in logistic regression for missing data (95% CI)
Missing data on costs Missing data on QALYs
Treatment allocation (MUA vs. ESP) 0.80 (0.48 to 1.32) 0.60 (0.34 to 1.05)
Treatment allocation (ACR vs. ESP) 0.85 (0.52 to 1.41) 0.71 (0.41 to 1.23)
Sex 1.26 (0.85 to 1.88) 0.87 (0.55 to 1.37)
Age 0.99 (0.97 to 1.01) 0.95 (0.93 to 0.98)a
Diabetes 1.11 (0.89 to 1.38) 1.06 (0.82 to 1.35)
EQ-5D-5L at baseline 0.28 (0.14 to 0.57)a 0.31 (0.14 to 0.67)a
QALYs at 3 months 0.003 (0.00 to 0.09)a 0.00 (0.00 to 0.50)a
QALYs at 6 months 0.007 (0.00 to 0.306)a 0.15 (0.0001 to 1.15)
Costs at 3 months 1.00 (0.99 to 1.00) 0.99 (0.99 to 1.00)
Costs at 6 months 1.00 (0.99 to 1.00) 1.00 (0.99 to 1.00)
a Statistically significant at 5% level.
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FIGURE 21 Comparison of the distribution of imputed values (imputations 1–10) with the observed data (imputation
number 0) for (a) costs; and (b) QALYs. Individual values are represented by dots; the width of a row of dots represents
the frequency of values in the distribution.
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TABLE 69 Sensitivity analysis (scenario 6): summary for incremental analysis (ITT), cost-effectiveness results and uncertainty of different methods for handling missing data (MUA vs. ESP)
Incremental cost (£) (95% CI) Incremental QALYs (95% CI)
ICER
(£ per QALY)
Probability cost-effective
at £20,000/QALY (%)
MAR 276.507 (65.67 to 487.35) 0.0396 (–0.0008 to 0.0800) 6984 88
228.605 (0.94 to 456.27) 0.0339 (–0.0138 to 0.0816) 6750 81
Same MNAR parameters in MUA and ESP
–10% quality of life in both arms 228.605 (0.94 to 456.27) 0.0414 (–0.0041 to 0.0868) 5227 89
+10% cost in both arms 234.7271 (–6.91 to 476.36) 0.0339 (–0.0138 to 0.0816) 6935 80
–50% quality of life in both arms 228.605 (0.94 to 456.27) 0.0713 (0.0221 to 0.1206) 3204 99
+50% cost in both arms 259.2152 (–52.66 to 571.09) 0.0339 (–0.0138 to 0.0816) 7665 78
–10% quality of life and + 10% costs in both arms 234.7271 (–6.91 to 476.36) 0.0413277 (–0.004 to 0.087) 5680 88
–50% quality of life and +50% costs in both arms 259.2152 (–52.66 to 571.09) 0.0710225 (0.0217 to 0.1203) 3650 98
Different MNAR parameters in MUA and ESP
–10% quality of life in ESP 228.605 (0.94 to 456.27) 0.0559849 (0.010 to 0.102) 4083 96
–10% quality of life in MUA 228.605 (0.94 to 456.27) 0.0192851 (–0.0281 to 0.0667) 11,854 62
+10% cost in ESP 199.748 (–32.80 to 432.29) 0.0338503 (–0.0139 to 0.0816) 5901 82
+10% cost in MUA 261.540 (28.02 to 495.06) 0.0338673 (–0.0138 to 0.0816) 7722 79
–50% quality of life in ESP 228.605 (0.94 to 456.27) 0.144459 (0.101 to 0.188) 1582 99
–50% quality of life in MUA 228.605 (0.94 to 456.27) –0.0390401 (–0.0895 to 0.0114) –5856 3
+50% cost in ESP 84.318 (–171.7 to 340.42) 0.0337907 (–0.0139 to 0.0815) 2495 87
+50% cost in MUA 393.28 (130.9 to 655.60) 0.0338787 (–0.014 to 0.082) 11,608 71
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